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NURSE/ALLIED HEALTH LUNG CANCER
WORKSHOP
AUSTRALIA – NURSING PRACTICE & ENVIRONMENTS
M. Duffy, Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA
This presentation presents an overview of the role of dedicated lung cancer
nurses within the Australian context. It outlines the incidence of lung cancer,
and draws attention to burden of symptoms, mortality and survival rates. The
role of the lung cancer nurse in the multidisciplinary team is a key focus of
the presentation. A case study from clinical practice is used to demonstrate
how this is achieved with a particular emphasis on the importance of meeting
the supportive care needs of the lung cancer population.
Disclosure: The author has declared no conflicts of interest.
NEWZEALAND – NURSING PRACTICE&ENVIRONMENTS
L. O’Grady, Northland District Health Board, Whangarei/NEW ZEALAND
There is a significantly higher incidence and mortality rate for Maori
compared to non-Maori with lung cancer. Four regional cancer networks
have been established in New Zealand to improve delivery of cancer care.
These regional cancer networks support cancer service planning, facilitate
clinical cancer practice improvement and systems performance improvement
throughout the country. They also facilitate workforce development, service
review and monitoring. The networks have been particularly focussed on
improving the quality of care for lung cancer patients. Lung cancer is one of
the priority cancers for service improvement in New Zealand. There has been
a particular focus on reducing inequities for Maori. A national lung cancer
work group has been formed to promote a nationally coordinated and
consistent approach to the delivery of care to patients with lung cancer. Lung
cancer clinical nurse specialist (CNS) roles are being established in New
Zealand and have been part of our lung cancer workforce for about five
years; our numbers are small with less than ten across the country presently.
These positions provide specialist care and coordination of care to patients
with suspected or confirmed lung cancer. The challenges for lung cancer
nursing in New Zealand are achieving to key performance indicators in the
face of resource constraints, the disproportionate numbers of Maori with lung
cancer, developing nurse-led clinics and acceptance of the role by other
health care professionals.
Disclosure: The author has declared no conflicts of interest.
UNITED STATES OF AMERICA – NURSING PRACTICE &
ENVIRONMENTS
M. O’Brien,Minnesota Oncology in Edina, Minnesota/UNITED STATES OF
AMERICA
In the US nurses are the single largest group of health professionals
comprised 2.9 million registered nurses. The US is experiencing a significant
nursing shortage, which is expected to peak by 2020. The shortage is due to
an increase in demand, aging nursing population, lack of nursing faculty,
clinical sites, and clinical preceptors for education. The national nursing
shortage will affect all aspects from direct patient care, hospitals, clinics,
insurance companies, etc. Cancer is a major public health problem in the
United States. More than 80 percent of cancer treatment is delivered in
community based practices. Economic, technologic, and social forces have
combined to create an environment which increasingly complex cancer
therapies are administered in the ambulatory care setting. This has created
new roles, responsibilities, and challenges for oncology nurses. Lung cancer
is the least funded in dollars even though lung cancer kills more people than
all other cancers combined. In 2010, $1,386 dollars per death was spent on
lung cancer research. Additional research funding is being advocated in a
newly established pipeline within the Department of Defense. On January 27,
2009 the Lung Cancer Mortality Reduction Act (LCMRA) was again
introduced and is gaining co-sponsorship. This is the first ever authorizing
legislation to fund a comprehensive, multi-agency plan to reduce lung
cancer’s mortality by 2016. The US Food and Drug Administration (FDA)
are now authorized to regulate the manufacturing, marketing and sale of
tobacco products. There are many US states that have smoke free law in
public places. The US Environmental Protection Agency (EPA) estimates
that each year 21,000 people die of lung cancer as a result of being exposed
to elevated levels of radon. The US Surgeon General, the EPA recommends
that every home be tested for radon.
Disclosure: M. O’Brien: Speaker: Genentech Bayer.
UNITED KINGDOM – NURSING PRACTICE &
ENVIRONMENTS
S. Moore, Royal Marsden NHS Foundation Trust, Surrey/UNITED
KINGDOM
This presentation presents an overview of lung cancer within the UK context
including incidence, mortality and survival rates. It briefly describes the
management of patients with lung cancer and environments of care. Finally,
it focuses on nursing practice in relation to lung cancer care, and in particular
models of specialist nursing in the UK. Examples of current practice
intiatives are described.
Disclosure: The author has declared no conflicts of interest.
PATIENT – FAMILY – MEDICAL – LAWYER: WORKING
TOGETHER FOR BETTER OUTCOMES FOR THE PATIENT
P. Gianoutsos, Department of Thoracic Medicine, Royal Prince Alfred
Hospital, Camperdown, New South Wales/AUSTRALIA
Thoracic malignancies, principally carcinoma of the lung and mesothelioma, of
necessity require, where legal recourse may be sought, a very careful history of
exposure to potentially causative factors. Independent of direct and passive
smoking other occupational exposures need be considered including asbestos,
radon, mustard gas, polycyclic hydrocarbons, chloromethyl ether, nickel and
inorganic arsenic have been associated with increased lung cancer risk. Rolah
McCabe in 2001 brought a case for her carcinoma of the lung against British
American Tobacco in the Victorian Courts initially being awarded $700,00.00
but having the judgement overturned on appeal. To this day the case remains on
the books of the courts, an index of how tenaciously the lawyers will fight for the
Tobacco companies emphasizing how taking action is fraught with legal hurdles.
Asbestos as the cause of mesothelioma is associated with an average 40 year
hiatus between first exposure and disease with all periods of exposure being
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materially contributory. Because of the long duration patients may have diffi-
culty in recalling precise times and circumstances of contact. When writing the
medico legal report be very cautious in marshalling the factual material gathered,
particularly the exposure history being careful to include both work and domes-
tic scene contact of the alleged incriminating factors. As the doctor with the
expertise you need to encompass a broad field which caters for the needs of the
patient, the family, yourself and your fellow medical colleagues involved in the
case as well as the lawyers and the courts.
Disclosure: The author has declared no conflicts of interest.
NURSING MANAGEMENT & SYMPTOMS OF DISEASE
PROGRESSION
M. Collins, Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA
There has been increased length of survival of lung cancer patients with
metastatic disease. Improved survival in the palliative phase requires clini-
cians to have improved expertise in symptom management. A high preva-
lence of symptoms was found in most patients not just those patients who are
closer to death. As part of comprehensive cancer care high quality manage-
ment of cancer pain depends on the utilisation of evidence based standards
for screening, assessment, treatment, and follow-up for general cancer pain
and specific pain syndromes. Management should focus on the routine
screening for the presence or absence and intensity of pain. Patients with a
positive screen should undergo a more detailed assessment. This includes
descriptive pain assessment, investigation of likely etiology and measure of
functional impairment. When managing pain clinicians should provide pain
education, a comprehensive management plan that includes rescue medica-
tions and offer bowel regimens in patients receiving opioids chronically.
Effective and timely communication is important to maintain continuity of
opioid doses and consistency of management across health care settings.
Disclosure: The author has declared no conflicts of interest.
MAINTAINING NUTRITION
T. Martin1, N. Kiss1, S. Muir1 1Peter MacCallum Cancer Centre, Mel-
bourne, Victoria/AUSTRALIA
Up to 60% of lung cancer patients have nutrition impact symptoms and
greater than 50% are malnourished on presentation. Weight loss may result
from metabolic abnormalities, treatment side-effects, mechanical issues, or
dietary restrictions. The development of an evidence based care pathway
aimed to standardise the nutritional management of lung cancer patients
during and post treatment. A comprehensive review of the literature includ-
ing evidenced based guidelines (EBG) was completed followed by consul-
tation with the multidisciplinary team (MDT). Evidence for each component
of the nutrition care process was reviewed. Where no evidence was found,
professional consensus was obtained. Limited evidence exists specifically for
the nutritional management of lung cancer patients. However, the Dietitians
Association of Australia (DAA) cachexia and radiotherapy EBG informed
the foundation of interventions in the care pathway. The goals of manage-
ment include weight stabilisation, optimising nutritional intake and hydra-
tion, managing treatment-related side-effects, and optimising QOL. Patients
will be screened at diagnosis using the Malnutrition Screening Tool (MST)
and referred to the dietitian if at risk of malnutrition. Patients receiving high
nutritional risk radiotherapy /- chemotherapy will be routinely seen by the
dietitian in week one of treatment. Patient-Generated Subject Global Assess-
ment (PG-SGA) category will be used to determine frequency of reviews
during and following treatment. The pathway prompts the dietitian to closely
collaborate with the MDT for symptom management and decisions regarding
enteral feeding. The development of the lung care pathway has implemented
best practice and ensured a consistent and standard provision of nutritional
management for lung cancer patients.
Disclosure: The author has declared no conflicts of interest.
MESOTHELIOMA IN UNITED KINGDOM
S. Moore, Royal Marsden NHS Foundation Trust, Surrey/UNITED
KINGDOM
Currently over 2000 people are diagnosed with mesothelioma in the UK. In
the past, service provision for mesothelioma has suffered because of the
relative rarity of the disease. Until recently, distinct mesothelioma services
have not existed and the level of care throughout the country is recognised
as variable (Department of Health (DH) 2007). However, in the last few
years, with the launch of the Mesothelioma Framework in 2007 (DH 2007),
services have improved significantly. This presentation describes mesothe-
lioma within the UK context including incidence, mortality and survival
rates, patient management and care environments. It then focuses on current
nursing and support initiatives, including face-to-face and online support
forums, Mesothelioma UK (a national nurse led resource centre for patients,
family members and professionals) and M-NAT (the Mesothelioma Nurses
Action Team).
References
Department of Health (DH) (2007a) Mesothelioma Framework. Department
of Health, London.
Disclosure: The author has declared no conflicts of interest.
MESOTHELIOMA IN THE UNITED STATES OF AMERICA
M. O’Brien,Minnesota Oncology in Edina, Minnesota/UNITED STATES OF
AMERICA
The number of mesothelioma cases in the US has reached its peak and has
begun to drop. The annual incidence of mesothelioma in the United States is
estimated to be approximately 3300 cases per year. Asbestos no longer
mined in the US but is still imported. The Environmental Protection Agency
banned all new use of asbestos. The Occupational Safety and Heath Admin-
istration (OSHA) has established acceptable exposure standards and man-
dated worker protection guidelines. There is still a substantial amount of
asbestos in buildings that will be removed with remodeling or demolition. It
is unknown the future impact of events such as the World Trade Center
disaster on September 11, 2001, when millions of New Yorkers were
potentially exposed to air filled with carcinogenic asbestos particles. Single
modality therapy has failed to improved survival. Multimodality treatments
that combine several complementary approaches, i.e. surgery together with
either radiation or a combination of chemotherapy agents are complicated
treatments and should only be pursued at a mesothelioma center of excel-
lence. Chemotherapy options include the FDA-approved combination of
Alimta and Cisplatin, as well as other drugs which are currently in active
clinical trials. Other drugs showing positive results in trial include Gemcit-
abine and Navelbine. Recent novel approaches are gene therapy, immuno-
therapy, photodynamic therapy and multimodality therapy and are still in
their experimental stages. Cooperative group trials are sponsored by National
Cancer Institute (NCI) and include researchers, cancer centers and commu-
nity physicians in the US, Canada and Europe. They identify areas that need
to be investigated and design trials to generate data. The National Cancer
Institute maintains an up-to-date website with current clinical trials both in
the US and abroad. The Mesothelioma Applied Research Foundation pro-
vides individualized referrals for patients to clinical trials and mesothelioma
specialists.
Disclosure: M. O’Brien: Speaker: Genentech Bayer.
LUNG CANCER BIOMARKERS WORKSHOP
TECHNIQUES – HOW TO MEASURE BIOMARKERS
A. Dobrovic, The University of Melbourne; Peter MacCallum Cancer
Centre, Melbourne, Victoria/AUSTRALIA
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Molecular pathology is the analysis of DNA and RNA information from both
normal and diseased tissues. Molecular pathology enables medicine to
become personalised and an understanding of the basic methodology, in-
cluding its limitations, is desirable for the oncologist. In lung cancer, EGFR
mutation testing has entered routine practice in order to identify an important
group of patients that are responsive to EGFR inhibitors. The clinical benefit
of KRAS mutation testing is more controversial but it can play a role in
confirming that an EGFR mutation is absent. Tissue remains the issue and its
availability and quality can place severe constraints on the testing that can be
performed.
Disclosure: A. Dobrovic: Kras Advisory Board: Merck; Research funding:
Pfizer; Sponsored attendance (accommodation) at national conference: No-
vartis, Roche.
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TESTING FOR BIOMARKERS – SESSION 1
LOSS OF SATB l EXPRESSION IS A MARKER OF POOR
SURVIVAL IN LUNG CANCER
M.R.J. Kohonen-Corish1,5, C.I. Selinger1, W.A. Cooper2, S. Al-Sohaily1,
D.N. Mladenova1, L. Pangon1, C.W. Kennedy4, B.C. McCaughan3, C.
Stirzaker
1 1
Cancer Research Program, Garvan Institute of Medical Research,
Sydney, New South Wales/AUSTRALIA; 2Tissue Pathology and Diagnostic
Oncology; 3Department of Cardiothoracic Surgery, Royal Prince Alfred
Hospital, Camperdown, New South Wales/AUSTRALIA; 4Department of
Surgery, Strathfield Private Hospital, Strathfield, New South Wales/AUS-
TRALIA; 5St Vincent’s Clinical School, Faculty of Medicine, The University
of New South Wales, Sydney, New South Wales/AUSTRALIA
Background: Lung cancer is the leading cause of cancer-related mortality
and requires more effective molecular markers of prognosis and therapeutic
responsiveness. Special AT-rich binding protein 1 (SATB1) is a global
genome organiser that recruits chromatin remodelling proteins to epigeneti-
cally regulate hundreds of genes in a tissue-specific manner. SATB1 over-
expression is a powerful predictor of poor prognosis in breast cancer, but the
significance of SATB1 expression has not been previously evaluated in lung
cancer.
Methods: A cohort of 285 lung cancers was evaluated by immunohisto-
chemistry. Epigenetic silencing of SATB1 was examined in cell lines by
5-Aza 2-deoxycytidine and trichostatin A (TSA) treatment, and chromatin
immunoprecipitation.
Results: Significant loss of SATB1 expression was found in squamous
preinvasive lesions (P0.042) and in non-small cell lung cancers
(NSCLC, P0.001) compared with matched normal bronchial epithe-
lium. Loss of SATB1 independently predicted poor cancer-specific sur-
vival in squamous cell carcinomas (SCC; HR 2.06, 95% CI 1.1-3.7,
P0.016). Treatment of lung cancer cell lines with the histone deacety-
lase inhibitor TSA resulted in up-regulation of SATB1. SATB1 was
associated with a decrease in the active chromatin mark acetylated
histone H3K9 and an increase in the repressive polycomb mark trimethy-
lated H3K27 in a SCC cell line relative to a normal bronchial epithelial
cell line.
Conclusions: This is the first study showing that SATB1 expression is lost
in early preinvasive squamous lesions and that loss of SATB1 is associ-
ated with poor prognosis in lung SCC. Loss of SATB1 expression may be
a result of epigenetic silencing caused by histone modifications.
Disclosure:M.R.J. Kohonen-Corish has declared no conflicts of interest. All
other authors have not declared conflicts of interest.
TESTING FOR BIOMARKERS – SESSION 2
MESOTHELIOMA BIOMARKERS – NOW AND THE
FUTURE
J. Creaney1,2, A. Segal3, A.W. Musk1,4, S.J. Skates5, B.W.S. Robinson1,2,4.
1National Research Centre for Asbestos Related Diseases, Perth, Western
Australia/AUSTRALIA; 2The Australian Mesothelioma Tissue Bank, Sir
Charles Gairdner Hospital, Nedlands, Western Australia/AUSTRALIA;
3PathWest Laboratory Medicine, Western Australia/AUSTRALIA; 4Depart-
ment of Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands,
Western Australia/AUSTRALIA; 5Biostatistics Center, Massachusetts Gen-
eral Hospital/UNITED STATES OF AMERICA
The asbestos-related tumour malignant mesothelioma represents a significant
clinical challenge. Not only can this tumour be difficult to diagnose but
treatment options are limited. Recently there has been increased interest in
the role of biomarkers in mesothelioma; for screening of asbestos-exposed
individuals, as an aid for diagnosis, and as an alternative to radiological
methods of monitoring patients’ response to therapy. The aim of the current
presentation is to provide a summary of the current status of biomarkers for
mesothelioma. A resurgence of interest in mesothelioma biomarkers fol-
lowed the finding in 2003 that soluble mesothelin was elevated in these
patients. Follow-up studies have demonstrated that mesothelin is elevated in
over 80% of patients with advanced disease, in approximately 50% at
diagnosis and 15% before diagnosis. Whilst mesothelin has a strong positive
predictive value for mesothelioma, the lack of sensitivity at diagnosis has
fuelled the search for complementary markers. However, studies world-wide
on a range of soluble markers including osteopontin, MPF, hyaluronic acid,
CA125, CA15-3 and others have failed to improve upon diagnostic accuracy.
Therefore the search is on to discover novel biomarker(s) for this disease
using a variety of genomic, proteomic and immunologic approaches.
Disclosure: J. Creaney: Consultanty fees from Fujirebio Diagnostic Incor-
porated (FDI) Malvern, PA, USA; B.W.S. Robinson: Consultancy fees from
Fujirebio Diagnostic Incorporated (FDI) Malvern, PA, USA. All other
authors have declared no conflicts of interest. Work by these authors was
funded in part by grants from the National Health and Medical Research
Council and the Insurance Commission of Western Australia.
TISSUE: HOW MUCH DO WE NEED FOR MORPHOLOGY
AND MOLECULAR
E. Duhig, Department of Anatomical Pathology, Pathology Queensland, The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA
How long is a piece of string? Following histological/cytological diagnosis,
potential assessment can be made of EGFR mutations and EGFR copy
number, KRAS mutations and EML4-ALK mutations. Some other proposed
predictive tests include ERCC1, RRM1, BRCA1 and Serpin B3. Several
factors influence successful diagnosis including molecular testing. These
include the tumour itself, the form of biopsy and the test. These parameters
will be discussed.
Disclosure: The author has declared no conflicts of interest.
EARLY STAGE
USE OF PET/CT IN RADIOTHERAPY PLANNING IN LUNG
CANCER
M. MacManus, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA
Aims: PET and PET/CT imaging represent major advances in the imaging of
lung cancer. PET has had a particularly high impact on the selection of
patients who are candidates for potentially curative or “radical” radiotherapy
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(RT). Because of their superior accuracy compared to CT alone, 18F-
fluorodeoxyglucose (FDG)-PET/CT images are invaluable for RT target
volume definition in non-small cell lung cancer (NSCLC). The use of PET in
patient selection for RT and its role in RT planning are considered.
Methods: Published data on the staging patients with NSCLC are reviewed
with particular emphasis on the small number of studies performed in
candidates for potentially curative radical RT or chemoRT. Additionally,
studies where PET or PET/CT were directly used in RT target volume
definition are discussed.
Results: In the two large studies where PET or PET/CT were used to select
patients with NSCLC for radical RT a remarkably consistent proportion of
patients were found to be unsuitable for aggressive treatment because of
upstaging by PET (30% and 25% in Australian and Polish studies respec-
tively). In all studies where target volumes defined with the assistance of
PET were compared to volumes defined using CT alone, there were clinically
significant differences between them. PET often prevented geographic miss
of tumour. Patients actually treated with radical RT or chemoRT after PET
based selection and RT planning had better outcomes than comparable
patients treated without the assistance of PET.
Conclusion: PET/CT is recommended for patient selection and RT planning
in patients with NSCLC.
Disclosure: The author has declared no conflicts of interest.
THE FUTURE OF RADIOTHERAPY FOR LUNG CANCER –
TECHNICAL OR BIOLOGICAL
D. Ball, Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
Victoria/AUSTRALIA
The computer revolution has led to an avalanche of technological innovation
in radiotherapy treatment planning and delivery over the last decade. This
has resulted in more accurate dose calculation and greater precision of
treatment delivery allowing for better conformality and tighter margins on
the target volume and greater sparing of surrounding normal tissues. The
corollary is that it should be possible to dose escalate to levels beyond what
was previously thought safe, the hypothesis being that higher doses will
eradicate more tumour clonogens. Dose escalation, a relatively simple idea,
has become a pervasive theme in radiation oncology research in lung cancer,
especially in the application of hypofractionated image guided treatment
schedules for early stage disease. Further, there is a mistaken belief among
the public at large and possibly among some clinicians that treatments
delivered using new technology are somehow biologically more effective
than treatment delivered using older equipment even though the tumouricidal
agent – megavoltage photons – is the same, and the fundamental aim is to
give higher doses. Unfortunately our understanding of the radiobiology of
lung cancer has not kept pace with these technical developments, for
example there is limited understanding of the role of molecular biomarkers
in predicting which cancers will or will not respond to radiotherapy, or which
patients are more at risk of serious normal tissue injury. There is considerable
scope for research in personalising radiotherapy for patients as is happening
with the newer targeted pharmacologic agents. There is some emerging
information for example on the potential of EGFR mutations to predict
outcomes; and the detection by FLT PET scanning of accelerated repopula-
tion which may be best managed by altered fractionation. There has also
been relative neglect of hypoxia as a potential target for enhancing radiation
cytotoxicity. The solutions for achieving greater conformality and dose
escalation will be achieved by physicists and engineers and technical
progress is likely to peak in the near future. The challenge for the radiation
oncologists treating lung cancer on the other hand is to improve their
understanding of the biology of the disease and to learn how to modify the
way in which x-rays can be used to improve and personalise patient
treatments and outcomes.
Disclosure: The author has declared no conflicts of interest.
LYMPH NODE DISSECTION AFTER ACOSOG-Z30: WHAT
SHOULD SURGEONS DO NOW?
G. Wright, Surgical Oncology, St Vincent’s Hospital, Fitzroy, Victoria/
AUSTRALIA
Background: Lymph node dissection practice varies significantly, ranging
from no sampling to systematic mediastinal lymph node dissection
(SMLND). Prior to 2002 no statistically significant survival benefit had been
demonstrated for SMLND. Hence the only benefit appeared to be accurate
staging. From 1999-2004, the American College of Surgeons Oncology
Group accrued 1111 patients for the ACOSOG-Z30 trial, which compared
node sampling to SMLND in proven N0 and non-hilar N1 disease. The trial
demonstrated no survival advantage of SMLND, seeming to contradict a
2006 meta-analysis, which demonstrated a significant advantage in stage
I-IIIA.
Aim: To interpret and update current evidence for lymph node dissection for
incorporation into intra-operative strategy.
Methods: Results from ACOSOG-Z30 were analysed in conjunction with
the meta-analysis of three randomized trials comparing node sampling to
SMLND.
Results: For proven node negative patients, SMLND does not confer a
survival advantage. For all other situations, there remains a significant
survival advantage for SMLND.
Discussion: The standard of care for resectable lung cancer includes sys-
tematic node sampling. This ensures accurate staging and appropriate ad-
ministration of adjuvant chemotherapy. It should be noted that ACOSOG-
Z30 closed prior to the advent of routine adjuvant chemotherapy, so overall
survival must be interpreted in that setting. Patients should have sampling of
all mediastinal node stations and any suspicious hilar station, either by
endobronchial ultrasound, mediastinoscopy and/or intra-operative frozen
section. If any nodes are found to be positive then SMLND is indicated. The
cost implications may result in thoracic surgeons continuing to perform
routine SMLND, as there were no significant deleterious effects in
ACOSOG-Z30.
Disclosure: G. Wright: Investigator on the ACOSOG-Z30 trial. The author
has declared no conflicts of interest in relation to this work.
YOUNG INVESTIGATOR/FELLOW ABSTRACT
ORALS
OPTICAL DIFFERENTIATION OF MALIGNANT AND BE-
NIGN LYMPHADENOPATHY BY GREY SCALE TEXTURE
ANALYSIS OF ENDOBRONCIAL ULTRASOUND COVEX
PROBE IMAGES
P. Nguyen1, F. Bashirzadeh, IB. Masters2, O. Salvado3, N. Dowson3, D.
Fielding
1 1
The Department of Thoracic Medicine, The Royal Brisbane and
Women’s Hospital, Herston, Queensland/AUSTRALIA; 2The Department of
Respiratory Medicine, The Royal Children’s Hospital, Herston, Queensland/
AUSTRALIA; 3Australian eHealth Research Centre, CSIRO Information &
Communication Technologies Centre, Herston, Queensland/AUSTRALIA
Real time transbronchial needle aspiration using the Endobronchial Ultra-
sound Convex Probe (EBUS-CP) bronchoscope is used for tissue diagnosis
of mediastinal lymphadenopathy. We investigated whether grey scale texture
analysis of EBUS-CP derived images could differentiate malignant from
benign pathology thereby adding to procedural data.
Methods: 50 patients with lymph node metastases from primary lung or
other cancers, and 41 patients with benign lymphadenopathy were included.
Using MATLAB (v7.8.0.347 (R2009a), The Mathworks, Natwick, MA),
lymph node area and width to height ratios (W:H) were measured. Texture
classification based on first and second order grey scale features were also
analysed.
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Results: Malignant nodes compared to benign nodes were significantly
larger (mean area 22918 pixels2 vs. 10704 pixels2, P0.0001) and had a
smaller W:H (mean 1.04 vs. 1.28, P0.0001). Texture classification showed
that malignant nodes compared to benign nodes had a higher grey scale
standard deviation (mean 26.83 vs. 20.30, P0.0001), a higher entropy
(mean 6.48 vs. 6.0201, P0.0001), a lower correlation (mean 0.67 vs. 0.74,
P0.0001) and lower energy (mean 0.19 vs. 0.34, P0.0001). The areas
under the receiver operator curves for sensitivity vs. specificity were: 0.81 for
area, 0.79 for W:H, 0.81 for standard deviation, 0.80 for entropy, 0.76 for
correlation and 0.82 for energy. A validation set correctly classified 25/33
(0.76) lymph nodes.
Conclusions: These novel data suggest grey scale texture analysis of
EBUS-CP images could be used to differentiate benign from malignant
lymphadenopathy.
Disclosure: Funding: The Royal Brisbane and Women’s Hospital Founda-
tion, The Australian Lung Foundation, The Cancer Council of Queensland.
A RETROSPECTIVE ANALYSIS OF SURVIVAL OUTCOMES
FOR TWODIFFERENT RADIOTHERAPY FRACTIONATION
SCHEDULES GIVEN IN THE SAME OVERALL TIME FOR
LIMITED STAGE SMALL CELL LUNG CANCER
C. Bettington1, L. Tripcony2, B. Hickey1, G. Bryant1, G. Pratt2and M. Fay2
1Mater Radiation Oncology, South Brisbane, Queensland/AUSTRALIA; 2The
Royal Brisbane and Women’s Hospital, Herston, Queensland/AUSTRALIA
Purpose: To compare survival outcomes for two fractionation schedules of
thoracic radiotherapy, both given over 3 weeks, in patients with limited stage
small cell lung cancer (LS-SCLC).
Methods and Materials: At Radiation Oncology Mater Centre (ROMC) and
the Royal Brisbane & Women’s Hospital (RBWH), patients with LS-SCLC
treated with curative intent are given radiotherapy (with concurrent chemo-
therapy) to a dose of either 40Gy in 15 fractions (“the 40Gy/15# group”) or
45Gy in 30 fractions (“the 45Gy/30# group”). The choice largely depends on
institutional preference. Both these schedules are given over 3 weeks, using
daily and twice-daily fractionation respectively. The records of all such
patients treated from January 2000 to July 2009 were retrospectively re-
viewed and survival outcomes between the two groups compared.
Results: Of 118 eligible patients, there were 38 patients in the 40Gy/15#
group and 41 patients in the 45Gy/30# group. The median relapse-free
survival time was 12 months in both groups. Median overall survival was 21
months (95%CI 2-37 months) in the 40Gy/15# group and 26 months (95%CI
1-48 months) in the 45Gy/30# group. The 5-year overall survival rates were
20% and 25%, respectively (P0.24). On multivariate analysis, factors
influencing overall survival were: whether prophylactic cranial irradiation
(PCI) was given (P0.01) and whether salvage chemotherapy was given at
the time of relapse (P0.057).
Conclusions: These results suggest it is the acceleration rather than the
hyperfractionation of thoracic radiotherapy that optimises outcomes when
concurrent chemoradiotherapy is given for LS-SCLC.
Disclosure: C. Bettington: has declared no conflicts of interest. All other
authors have not declared conflicts of interest.
QUEENSLAND LUNG CANCER SCREENING STUDY:
INTERIUM RESULTS
H. Marshall1, RV. Bowman1, J. Crossin2, M. Fuentes2, R. Slaughter2,
L. Passmore1, L. McCaul1, D. Courtenay1, M. Webb2, M. Windsor3, IA.
Yang1, P.V. Zimmerman1, T. Hayes2, S. Redmond2, K.M. Fong1 1Depart-
ments of Thoracic Medicine, 2Medical Imaging and 3Thoracic Surgery, The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA
Introduction: Effectiveness of LDCT screening is not yet known. The
Queensland Lung Cancer Screening Study screens volunteers based on the
NLST/ACRIN protocol.
Aims: Observational cohort study to assess: disease detection rate; lung
nodule work-up; cost; quality of life issues; smoking cessation; biomarker
collection feasibility.
Methods: Recruitment is via advertisement and press release. Major inclu-
sion criteria: age 60-74 years; smoking history 30 pack years; fit for
surgery. Volunteers receive one prevalence and two incidence scans with
follow-up for three further years. LDCT parameters: Phillips Brilliance 64
slice multidetector scanner; 0.9 mm slice width. Scan reporting: two radiol-
ogists independently and independent CAD reading (Phillips Brilliance
software); final report is agreed by consensus. A positive result is defined by
any nodule 4 mm diameter. Nodules 10 mm diameter are followed with
interval scans, larger nodules undergo further investigation.
Results (median, range unless stated): Between December 2007 and May
2010, 242 volunteers were screened (66% men). Age 64 years (59-74); 46%
current smokers; smoking history 55 pack-years (29-184); FEV1 %predicted
95 (47-155). 289 indeterminate nodules 4 mm diameter were detected
(mean 1.2 per participant, range 0-11), 60% were in the right lung. Median
nodule diameter was 4.2 mm (4-34). Four cases of stage I-II lung cancer were
diagnosed. Three had surgery, one had radical chemoradiotherapy. Another
participant died of non-cancer causes.
Conclusions: A high prevalence of indeterminate nodules has been found in
this high-risk cohort. Cancer prevalence is 1.4%. Curative intent treatment
has been possible for all participants with lung cancer.
Disclosure: Supported by a Queensland Smart State Grant and NCARD.
MAINTENANCE CHEMOTHERAPY IN EXTENSIVE
SMALL CELL LUNG CANCER (ESCLC): A META ANAL-
YSIS OF RANDOMISED TRIALS
M. Bagia1, B. Houghton, C. Brown, M. Boyer2, M. Millward3, M.Stockler1
1Clinical Trials Centre, University of Sydney, Sydney, New South Wales/
AUSTRALIA; 2Sydney Cancer Centre, Camperdown, New South Wales/
AUSTRALIA; 3Universtiry of Western Australia, Crawley, Western Austra-
lia/AUSTRALIA
Background: Chemotherapy is the principal treatment for extensive small
cell lung cancer (ESCLC), but its optimal duration is ill-defined. The purpose
of this study was to locate and summarise published randomised trials of
maintenance chemotherapy to help plan future research.
Methods: Our main objectives were to determine the effects of maintenance
chemotherapy on progression free survival (PFS) and overall survival (OS)
in patients with ED SCLC. Randomised trials were identified by searching
Medline, EMBASE and Cochrane data bases. The HR and p-values from
individual trials were extracted from a recently published meta analysis that
included trials of maintenance therapy in ESCLC, but did not separate them
from trials of limited stage disease (Rossi et al. Lung Cancer 2010; online
24th Feb). Pooling of data and subgroup analysis were performed with Rev
Man v5.0.
Results: We identified 4 eligible trials, all of maintenance chemotherapy,
including 498 patients. The median number of patients per arm was 27
(range18-112). Induction chemotherapy lasted 6-8 cycles in 3 trials, and 4
cycles in 2 trials. Induction chemotherapy included cisplatin in 3 trials with
either etoposide, irinotecan or ifosphamide. Maintenance chemotherapy was
associated with a significantly longer PFS (HR 0.77, 95% CI 0.60 to 0.99; p
0.04), but not OS (HR 0.80, 95% CI 0.59 to 1.08; p 0.7). There were trends
towards the effects on PFS being greater in trials using a platinum-based
induction regimen (HR 0.64 v1.00, interaction p 0.09) and trials using 4 or
fewer cycles of induction chemotherapy versus more than 4 cycles (HR 0.61
v0.99, interaction p 0.07).
Conclusion: Trials of maintenance chemotherapy were small, heteroge-
neous, and showed improved PFS, but not OS, in patients with ESCLC.
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Future trials of maintenance therapy are warranted, and should be powered
to detect moderate effects on survival.
Disclosure: M. Boyer: Sponsored attendance at international meeting:
Boehringer Ingelhiem; M. Millward: Advisory Board Member: Roche,
Eli-Lilly, Boehringer Ingelheim; Travel Support: Roche; M. Stockler: Our
groups are currently doing trials partly supported by AZ, Bionomics, Bayer,
Roche, Pfizer, Novartis, MSD. I have received honoraria for educational
presentations from Novartis, Pfizer, MSD, Roche. All other authors have not
declared conflicts of interest.
EVALUATION OF EGFR MUTATIONS IN NSCLC USING
ME-PCR AND HRM
K.B. Sriram1,2, M.E. Tan1, S.M. Savarimuthu Francis1,2, C.M.Wright1,2, V.
Relan1,2, M.U. Martins1, R.V. Bowman1,2, I.A. Yang1,2 and K.M. Fong1,21
The Prince Charles Hospital, Chermside, Queensland/AUSTRALIA; 2The
University of Queensland, St Lucia, Queensland/AUSTRALIA
NSCLC patients with EGFR mutations have improved survival when treated
with tyrosine kinase inhibitors (TKI). Many methods are able to detect EGFR
mutations in patient samples, but most are technically difficult and resource
intensive. Mutant enriched PCR (ME-PCR) assay and high resolution melt
analysis (HRM) are easy to perform and inexpensive. The current study was
designed to assess ME-PCR and HRM in screening for EGFR mutations in
NSCLC tissue and matched serum samples.
Methods: We examined EGFR mutation status (exon 19 DEL and exon 21
L858R) in DNA obtained from 522 primary NSCLC frozen tumour (surgi-
cally resected) and 64 matched serums using ME-PCR and HRM. In
addition, DNA sequencing was performed on 134/522 tissues to validate
ME-PCR and HRM findings.
Results: EGFR mutations were detected in 5.2% (27/522) by ME-PCR and
HRM. ME-PCR detected 11 DEL and 16 L858R mutations and HRM
detected 9 DEL and 18 L858R mutations. The sensitivity of ME-PCR and
HRM were 100% and 96%, while the specificities were 96% and 98%
respectively. Matched serum DNA was available for 6 EGFR mutation
patients (2 DEL and 4 L858R) and 58 EGFR wild-type patients. ME-PCR
detected mutations in 3 serums (2-DEL and 1-L858R) and HRM detected
mutations in 2 serums (1-DEL and 1-L858R).
Conclusion: ME-PCR and HRM have comparable diagnostic accuracy in
detecting EGFR mutations in tumour tissue. Both ME-PCR and HRM are
able to detect EGFR mutations in serum of NSCLC patients. These findings
will need to be validated in a large scale prospective study. Supported by
NHMRC Medical Postgraduate Scholarship 569762 & TPCH Foundation.
Disclosure: All authors have declared no conflicts of interest.
SYMPTOMS AND SUPPORTIVE CARE
NON-PHARMALOGICAL MANAGEMENT OF DYSPNOEA
C. Sheehan, The Cunningham Centre for Palliative Care, Sacred Heart
Centre, Darlinghurst, New South Wales/AUSTRALIA
Dyspnoea affects up to 65% of lung cancer patients during their illness
trajectory. The multi-dimensional nature of this distressing symptom dictates
that a multimodality approach to the management is often required. Treat-
ment of underlying reversible causes can be effective but often disease
progression and other mechanisms can not be easily reversed. The symp-
tomatic treatment relies on pharmacological management including opiates
and benzodiazepines and non pharmacological interventions. Non pharma-
cological management often draws on various members of a multidisci-
plinary team. Nursing staff, physiotherapists and psychologists play an
integral role in teachingJI and delivery of interventions. There is are varying
levels of evidence in the literature surrounding a for the wide number of
approaches that exist for non-pharmacological interventions for dyspnoea in
the setting of lung cancer, such interventions including, among others,
oxygen therapy and structured nurse-led clinic interactions. There is a larger
body of evidence for the non pharmacological management of dyspnoea
from the in the setting of non-malignant conditions such as chronic obstruc-
tive pulmonary disease and motor neurone disease. These range from single
component interventions such as chest wall vibration and walking aids to
multi component interventions incorporating that incorporate breathing train-
ing, relaxation and counselling. This educational sessionpresentation will
provide an overview of attempt to review the current evidence for a the array
of non-pharmacologic wide range of interventions for dyspnoea treatment
trailed in thein populations with malignant and non-malignant patient pop-
ulations ranging fromdisease.
References
Twycross, RG, Lack, SA. Therapeutics in terminal cancer, Edinburgh:
Churchill livingstone; 1986.
Disclosure: The author has declared no conflicts of interest.
PSYCHO-SOCIAL AND COMMUNITY SUPPORT
L. Mileshkin, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA
Many people with lung cancer have a heavy burden of physical illness due
to their disease, co morbidities and age-related concerns. This may be
associated with multiple symptoms such as fatigue, breathlessness, cough,
anorexia and pain. In addition, psychological, practical, and social concerns
may cause additional distress. If these needs are not recognized or treated
they may contribute to poor quality of life and treatment outcomes. It has
been reported that patients with lung cancer may have more unmet needs
than those with other cancer types, but be less likely to access available
support resources. Screening for supportive care needs within the clinic
increases recognition of unmet needs and allows appropriate referrals to be
made. In particular, our group has identified that patients would like addi-
tional information to be provided about lung cancer management and
supportive care strategies. Given the large burden of lung cancer in our
community, novel ways of providing information and support need to be
explored. Strategies that are being pursued include the development of
audiovisual and internet resources, further training and support for dedicated
lung cancer nurses, and a range of options for peer-support programs
including telephone and internet support groups. Much work remains to be
done to improve the support for carers. Promotion of the message to our
community that lung cancer now most frequently occurs in ex-smokers and
non-smokers will be an important means of reducing stigma and increasing
awareness and funding opportunities to further improve the support of people
affected by lung cancer.
Disclosure: The author has declared no conflicts of interest.
A TALE OF TWO CITIES: CANCER NURSE COORDINA-
TORS BRIDGING THE GAP
K. Mooney1, C. Henneker2 1Western Australian Cancer and Palliative Care
Network (WACPCN), Western Australia/AUSTRALIA; 2Western Australian
Country Health Service – Goldfields & WACPCN, Western Australia/
AUSTRALIA
Introduction: Lung cancer is biggest cause of cancer related death in Western
Australia. Recent figures from the WA Cancer Registry show that there were one
hundred and eighty three incidences and one hundred and seventy deaths from lung
cancer in rural Western Australia. A diagnosis of lung cancer can have a profound
impact on both patient and family members. During this time of heightened anxiety
many rural patients face a complex journey often receiving multiple interventions
from different health service providers.
Method: The WA Cancer and Palliative Care Network (WACPCN), in collabo-
ration with WA Country Health Service (WACHS), introduced a team of specialist
regional Cancer Nurse Coordinators (CNCs) and nine tumor specific metro based
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CNCs responsible for ensuring appropriate, timely and equal access to diagnostic
treatment and supportive care for Western Australians.
Results: This two-speaker presentation will discuss the challenges that lung cancer
patients in theWACHSGoldfields region encounter and show how the coordination
of care between the regional unit and themetropolitan centers enhances outcomes for
rural lung cancer patients.
Conclusion: TheCancerNurseCoordinators are a primary point of contact for lung
cancer patients and strive to enhance patient-centred and culturally sensitive out-
comes. They play a pivotal role in assessing, planning and coordinating care within
the multidisciplinary team.
Disclosure: K. Mooney: has declared no conflicts of interest. All other
authors have not declared conflicts of interest.
METASTATIC
MANAGEMENT OF LUNG CANCER IN VICTORIA: HAVE
WE MADE PROGRESS?
P. Mitchell1, V. Thursfield2, G. Wright3, D. Ball4, G. Richardson5, L. Irving6
and G. Giles2 1Austin Health, Heidelberg, Victoria/AUSTRALIA; 2The Can-
cer Council Victoria, Melbourne, Victoria/AUSTRALIA; 3St Vincent’s Hos-
pital, Fitzroy, Victoria/AUSTRALIA; 4Peter MacCallum Cancer Centre,
Melbourne, Victoria/AUSTRALIA; 5Cabrini Health, Malvern, Victoria/AUS-
TRALIA; 6Melbourne Health, Parkville, Victoria/AUSTRALIA
Aims and methods: We aimed to document lung cancer management and
compare results to a 1993 survey. Patients (pts) diagnosed during 6 months of 2003
were identified from the Victorian Cancer Registry and data obtained from source
documents.
Results: Data were available for 841 (82% of eligible pts): median age 72 yrs and
63% male. Most were ex-smokers (57%), with 8% never smokers (71% female).
Diagnostic modality was: clinical only 10%; pathological - cytology alone 20%,
histology 70% (NSCLC 86%, small cell (SCLC) 13%). Of NSCLC (n655)
characteristicswere: adenocarcinoma 40%, squamous 23%, large cell 13%; stage I/II
23%, III 26%; PS 0-1 63%; PET scan 43%; specialist referral 99%; discussed at
MDM 33%. With curative intent, 191 pts (29%) received, as single modality or in
combination: surgery 125 pts (65%); radiotherapy 91 pts (48%); chemotherapy 66
pts (35%). 326 pts (50%) had palliative treatment while 138 pts (21%) received no
therapy. Considering all NSCLC pts, 258 (39%) received chemotherapy and 365
(56%) radiotherapy at some time during their illness. Considering the 101 pts with
SCLC, 67% had PS 0-1, 33% limited disease, 99% saw a specialist and 21%
discussed at MDM. 9% received no treatment while 27 pts (27%) were treated with
curative intent, including 16 (20%)with chemoradiation.Median and 5-year survival
were: NSCLC 6.9m (SE 0.42) and 11%; SCLC 7.2m (SE 0.96) and 3%, respec-
tively. Considering all pts, better survival on multivariate analysis was associated
with younger age, good PS, no weight loss, early stage, never smoking and better
socio-economic status. Changes over 1993-2003 were: median 3yrs older; fewer
males; less SCLC;more adenocarcinoma and less squamous.When adjusted for age
and sex, the overall 5yr survival of has not changed in the last decade.
Conclusions: Despite increased use of PET scanning and more multi-modality
therapy, lung cancer survival has not improved over the last 10 years. New strategies
are required to improve patient outcomes.
Disclosure: P. Mitchell: Advisory and/or Speaker Honoraria 2009-2010: Roche,
Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Specialised Therapeutics. All other
authors have declared no direct conflict of interest.
DURATION AND MAINTENANCE
M. Boyer, Sydney Cancer Centre, Camperdown, New South Wales/AUSTRALIA
The optimal duration of first line treatment for advanced non-small cell lung
cancer (NSCLC) has been the subject of significant interest over the past
decade. Early studies focused on continuing initial chemotherapy either up to
a defined number of cycles of therapy, or until disease progression. This
approach, often referred to as “continuation maintenance”, was assessed in
randomised trials, the results of which were generally negative for effects on
overall survival (OS), whilst showing improvements in progression free
survival (PFS). No patient selection was used in these trials with randomi-
sation occurring prior to commencement of therapy. More recently, an
approach referred to as “switch maintenance” has been evaluated in a series
of randomised trials using both cytotoxic chemotherapy as well as molecu-
larly targeted agents. In these trials, patients who have not progressed after
several (usually 4) cycles of chemotherapy have been randomised to obser-
vation or continuation of therapy with another agent. These studies have
demonstrated improvements in PFS, with some also showing improvements
in OS. Interpretation of these studies has been made more difficult by
imbalances in the use of second and subsequent lines of therapy in the
different treatment arms. In particular, for those patients in the observation
arms of these studies who actually receive second and subsequent lines of
therapy, survival may be similar to those receiving a maintenance approach.
However, for reasons that are unclear, many patients being observed are
unable to ever receive further therapy, even with the close follow up
mandated in these studies. A meta-analysis1 using published data from both
types of study confirms the effect of extended duration of therapy on PFS,
with a hazard ratio of 0.75 (P  0.0001). The effect on OS was smaller with
a hazard ratio of 0.92 (P  0.03). It has proven difficult to pool toxicity and
quality of life (QOL) data. However, qualitatively toxicity seems to be
slightly increased with extended durations of therapy, but with little differ-
ence in QOL. Extended durations of initial treatment for advanced NSCLC
modestly improve OS and have a larger effect on PFS. Other than non-
progression in response to first line therapy, factors that identify the ideal
patient for this approach to therapy have not been clearly defined. If
maintenance therapy is not used, patients must be followed carefully to
ensure that disease progression and deterioration of performance status do
not prevent access to second and subsequent lines of treatment.
Reference
1. Soon YY, Stockler MR, Askie L, Boyer MJ. Duration of chemotherapy
for advanced non-small cell lung cancer: a systematic review and meta-
analysis of randomized trials. J Clin Oncol 2009; 27: 3277 – 33
Disclosure: M. Boyer: Sponsored attendance at international meeting:
Boehringer Ingelhiem.
OLDER PERSONS
M. Michael,, Lung Service, Peter MacCallum Cancer Centre, Melbourne,
Victoria/AUSTRALIA
The elderly represent a significant proportion of patients with NSCLC. Close
to 50% of NSCLC patients are greater than 70 years of age, with the
incidence of NSCLC in this age group expected to increase in the future.
Despite this, the elderly population are under-represented in NSCLC clinical
trials. This appears to be, in part, due to the study design restricting
participation based on co-morbidities and/or reduced organ function, as well
as an apparent exclusion bias perception that anti-cancer treatments may be
too toxic for elderly patients. Subset analyses of elderly patients included in
randomised phase III trials reveal an overall clinical benefit with single-agent
chemotherapy, chemotherapy doublets and with biological agents, albeit in
some cases increased toxicity. Phase III trials have demonstrated the benefit
of platinum-based combination regimens in these elderly patients but with
toxicity concerns.While some elderly patients are less fit than younger
patients and may have co-morbid conditions, a differentiation between
“biologic” versus “chronologic” age may enable more elderly patients to
access active treatment for NSCLC. Similarly the distinction between the fit
and the frail elderly needs to be considered. Patients selection based on
co-morbidities is now being evaluated in NSCLC clincial trials. However,
co-morbidity scales need to be validated in the oncology setting and designed
for use in the general clinical setting. Hence the treatment of the elderly with
advanced NSCLC represents an ongoing area of research.
Disclosure: M. Michael: Advisory Board: Roche Tarceva, Eli Lilly Thoracic.
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POOR PERFORMANCE STATUS
K. Pittman, The Queen Elizabeth Hospital, Woodville, South Australia/
AUSTRALIA
Patients with poor performance status (PS) represent over 40% of all patients
with the diagnosis of advanced non-small cell lung cancer (NSCLC) seen in
clinical practice. Management of these patients remains controversial, par-
ticularly because of a paucity of randomised trial evidence. Historically these
patients, along with the elderly, have usually been excluded from the major
clinical trials that have been pivotal in formulating our current treatment
guidelines. Some more recent studies specifically addressing the issue of
NSCLC patients with PS 2, as well as some subset analysis of broader
NSCLC trials have suggested a more prominent role for cytotoxic chemo-
therapy. Additionally, new data relating to some of the newer targeted
therapies including epidermal growth factor receptor tyrosine kinase inhib-
itors (EGFR-TKI) has suggested a possible role for these agents in selected
cases. It must always be remembered that with our current therapeutic
armamentarium, the primary goal of management for PS 2 patients with
NSCLC is to maximise quality of life. As such, the expert use of supportive
therapies including radiotherapy, bisphosphonates and early introduction of
palliative care services may help achieve this goal. Future trials more
specifically incorporating poor PS patients with advanced NSCLC may help
more clearly define optimal management.




DETECTION OF STK l l MUTATIONS IN EARLY STAGE
NSCLC PATIENTS USING HIGH RESOLUTION MELTING
ANALYSIS
H. Do1, G. Levallet2, M. Antoine2, B.Solomon1, S. Fox1, G.Zalcman2, A.
Dobrovic1 1Peter MacCallum Cancer Centre, Melbourne, Victoria/AUS-
TRALIA; 2Intergroupe Francophone de Cance´rologie Thoracique, Paris/
FRANCE
Aims: Germline mutations in the tumour suppressor gene STK11 (also
known as LKB1) cause Peutz–Jeghers syndrome which is characterised by
mucocutaneous pigmentation, intestinal hamartomas and increased risk of
developing cancers. In non-small cell lung cancer (NSCLC), STK11 plays a
crucial role in pulmonary tumorigenesis, controlling initiation, differentia-
tion, and metastasis. In contrast to other cancers, the STK11 gene is
frequently inactivated by somatic mutations in NSCLC. The aim of this study
is to establish HRM-based assays to efficiently screen for STK11 mutations
in NSCLC.
Methods: A total of 14 HRM assays were developed covering and flanking
the entire coding region. The mutation status of STK11 was assessed in 195
stage I and II NSCLC samples. All HRM positive samples were then
characterised by Sanger sequencing.
Results: A total of 30 STK11 mutations, comprising 27 non-synonymous
mutations and 3 synonymous changes were detected, giving a mutation
frequency of 15%. The non-synonymous mutations consisted of 9 nonsense,
5 frameshift, 6 missense, and 7 splice site variants. STK11 mutations were
detected in all coding exons except for exon 7 and were not recurrent except
with the exceptions of a nonsense mutation (K191X) and a splice site variant
(c.291-1GT), which were each found in two tumours. Single base substi-
tutions (25/30, 83%) were more common than small insertions/deletions
(5/30, 17%) and the size of insertions/deletions were less than 20 base pairs.
Conclusions: These results demonstrate the utility of HRM analysis as a
pre-sequencing step for the cost efficient detection of somatic STK11 muta-
tions in clinical NSCLC samples.
Disclosure: H Do: The author has declared no conflict of interest. A.
Dobrovic: Advisory Board: Kras; Merck; Research funding: Pfizer; Spon-
sored attendance (accommodation) at national conference: Novartis, Roche.
All other authors have not declared conflict of interest.
FACTORS INFLUENCING SURVIVAL IN PATIENTS WITH
SYNCHRONOUS SOLITARY CEREBRAL METASTATIC
FROM NON-SMALL CELL CANCER OF THE LUNG
D. Lunn1, J. Stroud2, L. Tripcony4, M. Dauth2, M. Lehman3 1Mater Radia-
tion Oncology, South Brisbane, Queensland/AUSTRALIA; 2Respiratory De-
partment, 3Radiation Oncology, Princess Alexandra Hospital, Woollong-
abba, Queensland/AUSTRALIA; 4Cancer Care Services, The Royal Brisbane
and Women’s Hospital, Herston, Queensland/AUSTRALIA
Introduction: Patients with non-small cell lung cancer (NSCLC) presenting
with cerebral metastases have a poor prognosis. Those with isolated, solitary
cerebral metastases at diagnosis may have an improved survival. Following
treatment of the cerebral disease, optimal management of the primary lung
tumour is controversial. This study aimed to validate an institutional approach of
deferred treatment for asymptomatic lung primaries, and to identify prognostic
factors affecting survival.
Methods: Cases of metastatic NSCLC presented at the multidisciplinary
lung cancer clinic of the Princess Alexandra Hospital (PAH), Brisbane,
between 1998 and 2007 were retrospectively reviewed. Thirty-three patients
presenting with isolated, solitary cerebral metastases were identified. Of
these, 27 were deemed to have had optimal management of their cerebral
disease and were further analysed.
Results: Twenty of 27 patients had resection of their cerebral metastasis and
subsequent WBRT. Seven patients had WBRT alone. One patient received
definitive thoracic surgery, 5 patients received palliative thoracic radiother-
apy and 2 patients received systemic chemotherapy. The median overall
survival time was 11 months (range 3-33). Three of 27 patients were alive at
2 years. Neurological death was seen in 59% of patients, pulmonary death in
29% and 12% died from other causes. The significant favourable prognostic
factors identified on multivariate analysis were adenocarcinoma (P  0.006)
and cerebral resection (P  0.03).
Conclusions: With a policy of observation for asymptomatic lung primaries
in NSCLC patients with solitary cerebral metastases the median survival was
11 months and neurological death predominated, suggesting that this is a
reasonable approach. Adenocarcinoma and craniotomy conferred a survival
benefit. Aggressive thoracic management in early-stage patients with this
histology and a good performance status may be appropriate and warrants
ongoing investigation.
Disclosure: All authors have declared no conflicts of interest.
RELATIONSHIPS BETWEEN PLEURAL PLAQUES, LUNG
ASBESTOS CONTENT AND ASBESTOS EXPOSURE IN
AUSTRALIANS WITH OR AT RISK OF LUNG CANCER
J.D. Thomas1, O. Mohammed3, R.E. Slaughter3, M. Fuentes3, J. Crossin3, H.
Marshall2, C.M. Wright1,2, M.U. Martins2, M.E. Tan2, I.A. Yang1,2, K.M.
Fong1,2, R.V. Bowman1 1School of Medicine, The University of Queensland,
St Lucia, Queensland/AUSTRALIA; 2Thoracic Medicine, 3Radiology, The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA
Introduction: Pleural plaques are the most common pathological manifes-
tation of asbestos exposure. The relationship between plaques and other
markers of exposure has been described overseas, but may differ in Austra-
lians exposed to secondary product rather than mining or milling. To
determine whether CT-detected pleural plaques could serve as a non-invasive
indicator of asbestos exposure and a surrogate marker for asbestos-related
disease risk, we examined two cohorts for relationships between pleural
plaques, lung asbestos bodies (AB), and occupational asbestos exposure.
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Methods: 135 patients resected for primary lung cancer with lung asbestos
body counts available (Cohort 1), and 242 people at risk for lung cancer from
smoking (Queensland Lung Cancer Screening Study participants) (Cohort 2)
were studied. Asbestos exposure ascertained from self-report, questionnaire,
or review of medical record was correlated with the presence or absence and
extent of pleural plaques/thickening on pre-operative or screening CT scans
by two independent readers.
Results: In Cohort 1, there was no association between CT-detected pleural
plaques and self-reported asbestos exposure. Cases with plaques had higher
AB counts than cases without (P0.02), and plaques were more extensive in
those reporting prior asbestos exposure (P0.05). In Cohort 2, plaques were
more frequent in those reporting prior asbestos exposure (P0.05).
Conclusions: In these contemporary Australian cohorts, pleural plaques
were more extensive in those reporting past asbestos exposure and more
frequent in those with higher lung asbestos body counts, but the observed
strength of these associations does not support their use as a marker of risk
for asbestos-related disease.
Disclosure: Support: The Australian Lung Foundation Undergraduate Grant-
in-Aid for Lung Cancer Research, DDB NSW, TPCH Foundation, NHMRC
CDA (IY) and PF (KF); Nomination: Australian Lung Cancer Conference/
Cancer Australia Young Investigator Travel Grant. All authors have declared
no further conflicts of interest.
A CASE SERIES OF 100 VIDEO ASSISTED THORACO-
SCOPIC SURGERY FOR CANCER: AN AUSTRALIAN
PERSPECTIVE
J. Hallam1, Z. Wainer2, P. Antippa1 1The Royal Melbourne Hospital; 2The
University of Melbourne, Melbourne, Victoria/AUSTRALIA
Aim: Video-assisted thoracoscopic surgery (VATS) for cancer in the lung is
an increasingly utilised approach. We examined 100 VATS lung resections
by a single surgeon to assess this method of resection.
Methods: Patients who underwent VATS lung resection for cancer were
identified from a prospectively collected surgical database from December
2006 to July 2010. Demographic, operative and postoperative outcomes were
examined. VATS technique used 3 ports including 1 access incision 4-6cm
with no rib spreading. A 30-degree angle scope was used for visualisation.
Results: Between 2006 and 2010, 100 patients underwent VATS lung
resection for cancer. Patient demographics included 39% female and 61%
male, with a mean age of 70.1 years. Diagnoses were 84% primary lung
cancer including 55 adenocarcinomas, 24 squamous cell carcinomas, 4 large
cell carcinomas and 1 small cell lung cancer. Remaining diagnoses were
pulmonary metastases (13%), carcinoid lesions (2%) and a mucoepidermoid
lesion (1%). Surgical procedures consisted: 88 lobectomies; 5 complex
wedge resections; 4 pneumonectomies; and 3 segmentectomies. Four cases
were converted to thoracotomy, three for pulmonary artery tears and one due
to poor vision. There were no intraoperative or in-hospital deaths with
median length of stay 6-days. Complications included: 1 return to theatre for
bleeding; 1 division of right phrenic nerve; and 1 postoperative stroke.
Conclusion: This series shows that VATS can be performed on patients with
lung disease with low mortality and morbidity rates when performed by an
experienced surgeon.
Disclosure: Z. Wainer: Recipient of the Royal Australasian College of
Surgeons 2010 Raelene Boyle Scholarship. All other authors have declared
no conflicts of interest.
MAPPING THE LUNG CANCER METHYLOME
C.M Wright1,2, S.M. Savarimuthu Francis1,2, K.B. Sriram1,2, K.R. Quinn1,
M.S Stark3, N.K Hayward3, I.A Yang1,2, R.V Bowman1,2, K.M. Fong1,2
1Department of Thoracic Medicine, The Prince Charles Hospital, Cherm-
side, Queensland/AUSTRALIA; 2School of Medicine, The University of
Queensland, St Lucia, Queensland/AUSTRALIA; 3Queensland Institute of
Medical Research, Herston, Queensland/AUSTRALIA
Epigenetic gene inactivation of tumour suppressor genes underlies several
human cancers. The potential to develop targeted therapies is being driven by
the recent development of high-throughput genome-wide approaches includ-
ing methylation-based microarrays. Here we report a large-scale project
aiming to characterize the lung cancer methylome.
Methods: Methylation profiling by Illumina Infinium Methylation27 arrays
was performed on 226 primary lung tumours and 81 normal lung samples
from the TPCH lung tumour bank. Data was feature extracted using propri-
etary software (Genome Studio, Illumina, Hayward, CA). We used two
separate approaches in gene identification: 1) we utilised stringent criteria
employed by the The Cancer Genome Atlas (TCGA) project on Glioblas-
toma performing separate analyses for training and test sets and 2) we used
in-house (TPCH) criteria (vis. (1) false discovery rate (FDR) P1x10E-7, (2)
P-value  1x10E-7, (3) frequency of methylation across samples and (4)
magnitude of difference between normal/tumour pairs (at least 2-fold)).
Results: Unsupervised cluster analyses demonstrated distinct clusters for
normal and tumour lung and in primary tumours identified six distinct
tumour clades which could not be explained purely by histology. Differential
methylation analysis identified 171 CpG loci highly methylated in tumours
exhibiting substantially higher methylation levels compared to common lung
cancer methylation markers including P16, MGMT and DAPK1. Next, we
demonstrate samples frequently methylated across multiple genes demon-
strate a survival advantage. Finally, we report methylation signatures capable
of distinguishing adenocarcinoma and squamous cell carcinoma histologies.
Discussion: DNA methylation profiles differ between normal and tumour
lung and are predictive of adenocarcinoma and squamous cell carcinoma
histology. Further validation studies are required to confirm involvement of
candidate genes in lung carcinogenesis.
Disclosure: Supported by: The Prince Charles Hospital Foundation, Queens-
land Clinical Research Fellowship, NHMRC Biomedical Scholarship. All
authors have declared no further conflicts of interest.
SYMPTOMS AND SUPPORTIVE CARE
MEDICAL MANAGEMENT OF MALIGNANT PLEURAL
EFFUSIONS
G. Lee, University of Western Australia & Sir Charles Gairdner Hospital,
Nedlands, Western Australia/AUSTRALIA
Over 8000 cancer patients each year in Australia suffer from a pleural
effusion. One in three patients with breast cancer, 1:4 with lung cancer and
95% of mesothelioma patients will develop a pleural effusion. In Europe,
over 100,000 lung cancer patients develop a pleural effusion every year.
Management of malignant pleural effusions (MPEs) is a major healthcare
burden. In Western Australia, total inpatient costs for MPE drainage have
doubled from 5.4 to 10.6 million, parallel by a 50% increase in hospital
admissions for MPE management, from 2003 to 2008. Breathlessness from
MPE is often disabling. The goals of management are to relieve symptoms
and improve quality of life. MPEs should be drained with small-bore
catheters, which induce less pain than conventional large-bore tubes. Ther-
apeutic thoracentesis is advisable for those with limited life expectancy.
More definitive treatment, especially talc pleurodesis, is often employed.
Three randomized studies have shown that bedside talc pleurodesis is as
effective as thoracoscopic talc poudrage. A recent multicenter trial reported
suboptimal success rates (75% at 1 month and 50% by 6 months), even
in patients without trapped lungs. The UK Medicines and Healthcare Prod-
ucts Regulatory Authority has removed talc as a licensed medicinal product,
after reports of a 2.3% death rate from talc-induced acute respiratory distress
syndrome. Indwelling tunneled pleural catheters (IPCs) allows ambulatory
effusion drainage without many of the shortcomings of talc pleurodesis. It is
indicated in patients with trapped lungs and in those whose pleurodesis
failed. Use of IPCs as first-line treatment is rapidly gaining popularity.
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Disclosure: G. Lee: Co-Investigator of a British Lung Foundation funded
randomised study on indwelling pleural catheters. The catheters were pro-
vided without charge by Rocket Ltd. None of the investigators received any
personal benefits.
SURGICAL MANAGEMENT OF MALIGNANT PLEURAL
EFFUSIONS
G. Wright, St Vincent’s Hospital, Fitzroy, Victoria/AUSTRALIA
Background: Malignant pleural effusion is a major cause of cancer mor-
bidity and indirect mortality. Despite being a common problem for many
disseminated cancers, the solutions are not always straight forward, and
certainly not “one size fits all”.
Aim: The aim of this paper is to describe the various modes of effusion,
based on exudation, impaired drainage, lung entrapment and proximal
obstruction. Surgical management based on these principles will be also
described and supported by my clinical results. When to intervene and, just
as importantly, when not to intervene for a radiological effusion, will be
highlighted.
Methods: Review of a prospective surgical database was undertaken with
respect to the outcomes of treatment of pleural effusions by various means
over the last 10 years. Examples were selected of the various clinical
presentations and how to avoid pitfalls in their management.
Conclusions: Surgical management of malignant pleural effusions should be
based on a thorough knowledge and appropriate investigation of the aetiol-
ogy and mode of effusion. To effectively manage the malignant effusion, one
must pay attention to why the effusion is present and therefore treat the
patient, not the radiograph.
Disclosure: The author has declared no conflicts of interest.
OPTIMISING PATIENTS FUNCTION AND QUALITY OF
LIFE
K. White, Prince of Wales Hospital, Randwick, New South Wales/AUSTRALIA
Occupational Therapists are specialists in assessing function and intervening
to improve a person’s ability to engage in their occupational roles. People
living with thoracic cancer often experience a change in their function. The
intervention of an Occupational Therapist can have a positive impact on the
function and quality of life for the person living with thoracic cancer and
those they share their life with. There is a role for the Occupational Therapist
from the initial diagnosis of thoracic cancer. Occupational Therapists can
assist individuals prioritise their goals while managing the side effects of
curative treatment, also having a vital role in assisting individuals as their
roles and function change with progressive non-curative disease. The in-
volvement of the Occupational Therapist in the Lung Cancer Multidisci-
plinary Team Meetings at the Prince of Wales Hospital in Randwick NSW
has led to improved referral rates to Occupational Therapy. This has in turn
led to the development of specialist skills in the management of occupational
performance dysfunction with this tumour group at Prince of Wales Hospital.
This presentation will explore the role of the Occupational Therapist in the
specialist setting of thoracic cancer. Through task analysis, task modification,
energy conservation, goal setting and techniques to manage breathlessness,
people living with thoracic cancer can continue to live independently and
safely, while achieving their chosen goals towards the end of life.
Disclosure: The author has declared no conflicts of interest
COORDINATING COMPLEX CARE: PATIENTS WITH
SYMPTOMS PROGRESSION
M. O’Brien,Minnesota Oncology in Edina, Minnesota/UNITED STATES OF
AMERICA
The quality of care and the use of medical services for seriously ill patients
are key elements in the ongoing debate over reform of the US health care
system, and cancer care is central because of the cost of diagnosis and
treatment. In the US there is a movement towards a pro-active approach
aimed to reduce physical and psychological distress. Major care trends in the
US to coordinate complex care especially for patients with symptom pro-
gression include (1) interdisciplinary programs, (2) patient navigation, and
(3) survivorship. The interdisciplinary team approach is well suited for
malignancies like lung cancer which involve a number of sequence-sensitive
care components provided by numerous sub-specialists. The role of the nurse
navigator is to bridge the gaps across the full spectrum of care required for
such complex patient cases. Survivorship support for patients has become a
central theme for advocacy groups and an expectation on the part of the 11
million cancer survivors in the US. In 2005, the Institute of Medicine (IOM)
recognized survivorship as a distinct phase of cancer care. Survivorship
support along with palliative care contributes significantly to quality of life
for patients with recurrent disease. Expanding the understanding of quality of
life and the factors that contribute to it will energize and promote the
integration of the three major care trends listed above resulting in optimal
care for patients with complex and/or recurrent disease.
Disclosure: M. O’Brien: Speaker: Genentech Bayer.
PERSONALISING TREATMENT IN
THE REAL WORLD SCLC/MESOTHELIOMA
NEW DEVELOPMENTS IN MESOTHELIOMA
N. Pavlakis, Department of Medical Oncology, Royal North Shore Hospital,
Sydney, New South Wales/AUSTRALIA; Faculty of Medicine, The University
of Sydney, Sydney, New South Wales/AUSTRALIA
For a disease whose asbestos associated was reported in the 1960s, the
timeline for evidence of efficacy from drug therapy for MPM has been very
short and mainly in the last 10 years. Since the publication of the pivotal
pemetrexed (2003) and later raltitrexed (2005) based phase III trials in
confirming an anti-folate and platinum as the treatment of choice first line in
advanced MPM, no additional therapeutic improvement has been made.
However several key trials have either recently completed or are in progress
and some exciting developments with new therapeutic areas have been made.
The UK Meso-1 trial of Active symptom control (ASC) v chemotherapy
(MVP v vinorelbine) was important in highlighting the importance of
standardizing ASC in the clinic. Although no difference was observed for
survival, a trend to improved survival was observed in favour of vinorelbine.
The early closure and reduced sample size limited the statistical power of the
study to demonstrate survival benefit. Subsequent Phase II studies have
confirmed activity of vinorelbine in MPM. Pemetrexed maintenance therapy
is now also being evaluated in the randomized Phase II setting by the
CALGB. An area of great interest for therapies in MPM has been the area of
anti-angiogenic drug therapy. Thalidomide was the first such agent reported
to have some activity in MPM. Recently, the open label NVALT5 Phase III
study evaluating maintenance thalidomide or observation in non-progressive
patient after first line was completed. Interim safety data was reported at the
International Mesothelioma Interest Group Meeting in Kyoto 2010 (#S102).
Bevacizumab (bev), the anti-VEGF monoclonal antibody (Mab) has been
investigated in two randomised PII trials. The first, evaluating bev or placebo
in addition to platinum/gemcitabine chemotherapy was negative. The second,
evaluating first line pemetrexed/platinum /- bev met its primary endpoint
and is now in PIII extension for overall survival analysis (MAPS trial). Novel
vascular targeting agents, such as the tubulin binding agent BNC105P are in
Phase II development. The ongoing committed effort into the biology of
MPM has led to a variety of new strategies in drug development. This
includes the histone deacetylase inhibitor - Suberoylanilide Hydroxamic
Acid (SAHA) Vorinostat. A placebo controlled second line PIII trial met its
final interim analysis boundary and will proceed to completion. Novel
concepts in Phase I/II development include studies evaluating mTOR inhi-
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bition (everolimus), an anti-TGF Mab (GC1008), an anti-IGF1R Mab, a G2
cell cycle checkpoint inhibitor (CBP501), and anti-mesothelin chemother-
apy strategies: Mab (MORAb-009 Amatuximab), immunotoxin SS1P. Fi-
nally, following the successful completion of the initial feasibility study, the
role of radical surgery will be evaluated in the UK led PIII trial - MARS2
(Mesothelioma and Radical Surgery Trial). With all this ongoing clinical
research activity, the time is right for another positive Phase III trial or two!
Disclosure:
SCREENING OF ASBESTOS EXPOSED INDIVIDUALS
N. van Zandwijk Asbestos Disease Research Institute - Bernie Banton
Centre, The University of Sydney, Sydney, New South Wales/AUSTRALIA
Asbestos, a group of naturally occurring mineral silicates, was introduced
into our environment approximately a century ago. Specific properties such
as resistance to corrosive and thermal effects and increased tensile strength
have resulted in its introduction into over 3000 products. Asbestos readily
breaks into small, easily inhaled fibers that may elicit asbestosis, lung cancer
and malignant mesothelioma. In most industrialized countries asbestos has
been banned from work and home environments but current widespread use
of asbestos in developing countries indicates that the epidemic of asbestos-
related disease will continue to grow in the decades to come. In Australia
asbestos is abundantly present in the built environment and may also be
found in natural rock formations. Asbestos-exposed individuals have justi-
fiable anxiety about their future. In some countries monitoring of individuals
with occupations involving asbestos exposure has been effectuated. Unfor-
tunately surveillance with radiographic examinations and pulmonary func-
tion tests has been shown of little value. Studies attempting to define
biomarkers for early detection have shown that Soluble Mesothelin-related
Protein, Osteopontin and Megakaryocyte-Potentiating Factor aren’t sensitive
enough to be introduced in the clinic (1). At the same time it has become
clear that even in high-risk populations significant variations in cancer risk
exist. More accurate risk predication is expected to assist in balancing
potential risks and benefits of screening. For lung cancer risk models have
been developed and easily obtained clinical information can be used to
identify individuals, who may benefit from increased surveillance (2). Thus,
future screening studies in asbestos-exposed individuals are expected to
concentrate on subgroups with very high risk. A better definition of high risk
in combination of sophisticated radiographic and biomarker techniques are
new tools to be tested and may assist in preventing the lethal consequences
of asbestos exposure in the future.
Reference 1. Pass HI. Semin Thorac Cardiovasc Surg 2009. 2. Spitz MR, et
al. J Natl Cancer Inst 2007.
Disclosure: N. Van Zandwijk: Advisory Board: Merck Serono, Eli Lilly,
Pfzier, Boehringer Ingelheim; Speaker’s Bureau: Eli Lilly.
RADIOTHERAPY FOR MESOTHELIOMA
M. Feigen, Radiation Oncology Centre, Austin Hospital, Heidelberg, Victo-
ria/AUSTRALIA
Radiotherapy has been an underutilised treatment option in the management
of mesothelioma, based on old data showing it to be radioresistant, and the
high risk of serious toxicity to normal tissues within the thorax. There have
been major technological advances in radiotherapy over the past decade and
recent series that use three-dimensional techniques with CT and PET scans
for accurate tumour delineation have found that high dose radiotherapy with
intensity-modulated radiotherapy (IMRT) is safe and reduces locoregional
relapse after extrapleural pneumonectomy (EPP). Findings from our radio-
therapy program in Melbourne will be discussed, using data from 35
mesothelioma patients with incompletely resected mesothelioma given ra-
diotherapy since 2003. Most received doses of 50-60 Gy over six weeks to
part or all of one hemithorax including the unresected lung. All patients had
unilateral disease and good performance status, and only two were irradiated
post-EPP. 29 had advanced clinical stage III or IV disease. Most had a prior
pleurectomy/decortication or pleurodesis, and the 19 with prior chemother-
apy had progressed pre-radiotherapy. High dose hemithoracic radiotherapy is
well tolerated with no cases of acute grade 4 or 5 toxicity, and no late side
effects. IMRT has been given to 17 patients and allows better dose homo-
geneity and sparing of normal tissue damage compared to earlier techniques.
Total glycolytic volumes assessed on pre- and post-radiotherapy PET scans
showed 67% reduction in 18FDG activity. Relapses were frequent, with the
majority occurring in areas outside the high dose radiotherapy field, but
durable locoregional control was established in most cases.
Disclosure: The author has declared no conflicts of interest.
FINAL RESULTS OF A PHASE II STUDY OF SUNITINIB AS
SECOND LINE THERAPY OFMALIGNANT PLEURALME-
SOTHELIOMA (MPM)
A.K Nowak1,2, R.J Francis1,3, M.J Millward1,2, A. van der Schaaf3,
T. Seguard3, J. Creaney1, A. Hasani1,2, A.W Musk4, M.J Byrne2 1School of
Medicine and Pharmacology, The University of Western Australia, Crawley,
Western Australia/AUSTRALIA; 2Department of Medical Oncology; 3De-
partment of Nuclear Medicine and WA PET Service; 4Department of Respi-
ratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Austra-
lia/AUSTRALIA
Aims: To test the multi-targeted tyrosine kinase inhibitor sunitinib as
second-line therapy in MPM.
Methods: Eligible consenting patients had progressive MPM during/after
first-line platinum/antimetabolite, ECOG PS 0-1, adequate organ function,
and measurable disease. Treatment: sunitinib 50 mg/day 28d q6 weeks.
Primary endpoint: objective response (OR) defined by either a). Modified
RECIST Criteria (MRC) or b) metabolic response on FDG-PET in pts
without prior talc pleurodesis. Simon’s 2 stage design: 2 responses in first 23
pts and 5 responses in 51 assessable pts gave   0.05,   0.1 assuming
OR of 20% of interest.
Results: 53 eligible patients were accrued: 51 assessable for CT response; 20
without pleurodesis assessable on FDG-PET. Demographics: M/F (44/9);
median age 64 (range 45 - 81); histology epithelial/sarcomatoid/mixed/
unknown (37:1:9:6). ECOG PS 0/1 (15:38). Best MRC response: PR 6
(12%); SD 33 (65%); PD 12 (23%). Metabolic response: 6/20 assessable
(30%), 1 also with CT PR; 4 with CT minor response. Protocol-defined
responses 11/51 (22%, 95% CI 13%-36%). Median OS was 6.1 months.
Median TTP was 3.5 months. Adverse events were similar to previously
reported but 40% required dose reduction, mostly for fatigue. There was one
possible treatment-related death from pneumonitis and a second grade 4
pneumonitis. Four patients developed increasing pleural effusions or ascites
without other radiologic evidence of PD. Baseline serum VEGF-A, VEGF-C,
VEGF-R2 and VEGF-R3 did not correlate with outcomes.
Conclusions: Sunitinib has modest activity in previously treated MPM;
testing at a continuous lower dose may be warranted to ameliorate toxicity.
Disclosure: This study was partially funded by an investigator initiated
clinical trial grant from Pfizer Australia. All authors have declared no other
conflicts of interest.
NEW TECHNOLOGIES
PRENEOPLASIA AFB AND NBI
P. Nguyen1, F. Bashirzadeh1, I.B. Masters2, D. Fielding1 1The Department of
Thoracic Medicine, The Royal Brisbane and Women’s Hospital, Herston,
Queensland/AUSTRALIA; 2The Department of Respiratory Medicine, The
Royal Children’s Hospital, Herston, Queensland/AUSTRALIA
Autofluorescence (AF) has been used to improve the detection of preneo-
plastic lesions of the bronchus as well as the head and neck (H&N). It is
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known to have a high false positive rate. Narrow band imaging (NBI) has
better specificity but poorer sensitivity compared to AF. We hypothesised
that combined AF and NBI inspection would improve overall specificity
without impacting sensitivity.
Methods: H&N cancer patients had white light (WL), AF and NBI inspec-
tion of the oral cavity and tracheobronchial tree at panendoscopy. The aim
was to detect lesions additional to the known primary tumour. In the H&N
region, AF and NBI inspection was unblinded. AF and NBI bronchoscopy of
the tracheobronchial tree were done by two different bronchoscopists who
reported their findings independently as per established scoring systems.
Lesions detected by any imaging modality were biopsied. Lesions of mod-
erate dysplasia or worse were considered significant. Results are reported on
a per lesion basis.
Results: There were 77 H&N cancer patients. In the H&N region there were
27 known primary squamous cell carcinomas detected and these were
excluded from final analysis. In the H&N 19/29 lesions were significant. The
sensitivities and specificities respectively were: WL 0.38 & 0.91; AF 0.95 &
0.09; NBI 1.00 & 0.73. In the tracheobronchial tree 18/59 lesions were
significant. The sensitivities and specificities respectively were: WL 0.17 &
0.97; AF 0.72 & 0.51; NBI: 0.83 & 0.85.
Conclusions: AF and NBI inspection adds to WL evaluation in these
patients. NBI improves specificity in both regions.
Disclosure: Olympus Australia have supplied a loan ENF-VQ nasendoscope
to The Department of Thoracic Medicine, The Royal Brisbane and Women’s
Hospital. Funding: The Royal Brisbane and Women’s Hospital Foundation,
The Australian Lung Foundation, The Cancer Council of Queensland.
MICROWAVE ABLATION (MWA) VS RADIOFREQUENCY
ABLATION (RFA) IN LUNG CANCER
K. Steinke, The Royal Brisbane & Women’s Hospital, Herston, Queensland/
AUSTRALIA
Lung cancer is the number one cancer killer worldwide accounting for more
cancer deaths than colorectal cancer, breast cancer and prostate cancer com-
bined. As many as 15% of patients with early stage NSCLC are not eligible for
surgery due to comorbidities, usually poor cardio-respiratory reserve. Approxi-
mately 30% of patients dying of malignancy have pulmonary metastases at
autopsy with some primary cancers metastasising exclusively to the lungs.
Thermal ablation has been applied to lung tumours for a decade and has
managed to become an established minimally invasive therapy option for a
selected patient population. It is used as a therapeutic means in primary and
secondary lung cancer, both with a curative and palliative intent. Combination of
thermal ablation with radiotherapy for NSCLC should be a viable consideration
in the therapy planning pathway, with available RFA/XRT data showing con-
vincing 5y cumulative survival rates of 39% and no additional toxicity. The role
of palliative thoracic thermal ablation should not be underestimated, indications
being pain, cough and hemoptysis not otherwise controllable. Cyto-reduction
through thermal ablation prior to chemo-/radiotherapy is also worth considering,
bearing in mind that the centre of a large tumour, often hypoxic, is more resistant
to ionizing radiation and chemotherapeutic drugs and prone to recur locally after
treatment. This talk will focus on the indications for pulmonary thermal ablation,
the limitations of the procedure and the advantages of MWA over RFA.
Disclosure: The author has declared no conflicts of interest.
NEW PET AGENTS/STRATEGIES FOR LUNG CANCER
R. Francis, Sir Charles Gairdner Hospital, Nedlands; The University of
Western Australia, Crawley, Western Australia/AUSTRALIA
18F Fluorodeoxyglucose positron emission tomography (FDG PET) has an
established role in staging of NSCLC, and emerging roles in prognosis,
response assessment and in radiotherapy planning. FDG PET is also showing
utility in small cell lung cancer, in confirming limited vs extensive stage
disease. Novel PET tracers which have shown potential utility in lung cancer
include proliferation imaging with 18F-Fluorothymidine (FLT) and hypoxia
imaging with 18F-fluoromisonidazole (FMISO) and 18F-fluoroazomycin
arabinoside (FAZA). The detection of apoptosis 48-72hrs after commencing
chemotherapy in NSCLC using a SPECT Nuclear Medicine tracer, Tc-99m
annexin, has been shown to be predictive of response to chemotherapy. PET
apoptosis tracers are in development. Standardisation of PET imaging
procedures and reporting may facilitate multicentre clinical trials to further
assess the clinical impact of FDG PET imaging in lung cancer, particularly
in response assessment. As new therapies emerge in lung cancer, functional
PET imaging with novel tracers is of increasing value as a non-invasive tool
for assessing tumour physiology and drug effects.
Disclosure: The author has declared no conflicts of interest.
ABSTRACT ORALS
MAPPING THE PATIENT PATHWAY IN THE EVALUATION
PATIENTS WITH NON SMALL CELL LUNG CANCER
P. Forgarty1,3, V. Malipatil1,2, A. Wirth4, D. Costantin3, M. Byrne3,
K. Byrne3, S. Seevanayagam1,2, S. White2,5 1Eastern Health, Box Hill,
Victoria/AUSTRALIA; 2Austin Health, Heidelberg, Victoria/AUSTRALIA;
3North Eastern Metropolitan Integrated Cancer Service (NEMICS), Heidel-
berg, Victoria/AUSTRALIA; 4Peter MacCallum Cancer Centre, Melbourne,
Victoria/AUSTRALIA; 5Northern Health, Epping, Victoria/AUSTRALIA
Introduction: Timely assessment and management of patients with lung
cancer may improve treatment outcomes and diminish psychological stress.
An efficient pathway may also reduce resource utilisation.
Aims: To describe the evaluation pathway of patients with potentially
curable Non Small Cell Lung Cancer (NSCLC) within NEMICS and to
identify potentially avoidable causes of delay in management.
Methods: Retrospective audit of records of 90 consecutive patients treated with
curative intent (surgery or radical (chemo) radiotherapy) within NEMICS after
1st January 2006. Data collected included time from referral to first hospital
review, time from review to tissue diagnosis and time from diagnosis to initiation
of treatment. Details of relevant investigations and evidence to suggest multi-
disciplinary team involvement were also documented.
Results: Substantial variation in the pathway prior to establishing a tissue
diagnosis and commencing treatment was noted. Median time from referral
to first hospital review was 8 days (range 3 to 15 days). Median times from
review to definitive diagnosis and subsequently to initiation of treatment
(unless diagnosed at surgery) were 21 days (range 6 to 53 days) and 31 days
(range 15 to 52 days) respectively. Numerous factors potentially contributing
to delay were identified, in particular the need for patients to undergo more
than one investigation to achieve histological confirmation.
Conclusions: The journey taken by patients prior to initiating treatment for
NSCLC is highly variable. Numerous factors contribute to this. Minimising
referral times, standardisation of care and consistent implementation of a
multidisciplinary team based approach may improve timeliness of care.
Disclosure: Funding: North Eastern Metropolitan Integrated Cancer Services.
LUNG CANCER ADVOCACY
J. Gowing, Cancer Advocacy Coalition of Canada; Global Lung Cancer
Coalition, Glasgow/SCOTLAND; Cambridge Memorial Hospital, Ontario/
CANADA
The funding of lung cancer around the world is less than many other cancers
and does not reflect the incidence or mortality associated with lung cancer.
The Cancer Advocacy Coalition of Canada has been publishing on the
funding and access to cancer drugs, demonstrating the variations across
Canada and the “postal code lottery” that it produces. Newsprint, radio
interviews, and television appearances bring the message to the public.
Meetings with Ministers of Health in the provinces and the Government of
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Canada have brought about real changes in the approach to cancer control in
Canada. The Global Lung Cancer Coalition survey carried out by Ipsos
MORI in 16 countries with regard to attitudes to lung cancer victims has
given valuable access to media in many countries to expand exposure to lung
cancer funding deficiencies. Media opportunities, support statistics, and
outcomes demonstrate that change can happen.
Disclosure: The author has declared no conflicts of interest.
TRIAL OF A LUNG CANCER SURVIVORSHIP CARE PLAN
WITHIN A MULTIDISCIPLINARY TEAM – A CANCER
CARE COORDINATION INITATIVE
J. Elks, Sunshine Coast Cancer Care, Nambour, Queensland/AUSTRALIA
The Sunshine Coast Cancer Service offers a comprehensive multidisciplinary
approach to the care of patients with lung cancer, facilitated by a lung cancer
care coordinator. The multidisciplinary team incorporates medical, nursing
and allied health professionals. The team collaborated on the development of
a Lung Cancer Survivorship Care Plan, and the cancer care coordinator
managed a trial of the document. The Care Plan was designed for patients
treated with curative intent only. Main components of the Care Plan include
a treatment summary, identification of a lead clinician and recommended
follow up pathway as developed by consensus of the MDT. Components of
the follow up pathway included recommended appointment and medical
imaging schedule, possible effects of treatment, fatigue management, spe-
cific recommendations for healthy behaviours and healthy lifestyle choices.
Members of the multidisciplinary team, general practitioners and the patients
themselves were surveyed. Feedback from the treating team was predomi-
nantly positive, with some discord on elements of the plan. General practi-
tioners and patients were extremely supportive of the initiative. One of the
major difficulties encountered with the Care Plans was the length of time
taken to accurately record a comprehensive treatment summary, due to the
fractured nature of multimodality care in a regional setting. The implemen-
tation of the plan across the entire cohort will be predicated on the ability to
generate an electronic treatment summary. The trial of a survivorship care
plan in lung cancer patients treated with curative intent was well received,
but at this point in time, full implementation is unsustainable.
Disclosure: The author has declared no conflicts of interest.
FAMILIAL ASSOCIATIONS FOR MALIGNANT ME-
SOTHELIOMA AFTER EXPOSURE TO BLUE ASBESTOS
N. de Klerk1, H. Alfonso2, N. Olsen3,4, A. Reid3, J. Sleith3, J. Hansen1,
L. Palmer5, G. Berry6, B. Musk3,4. 1Centre for Child Health Research, West
Perth, Western Australia/AUSTRALIA; 2Western Australian Centre for
Health and Ageing, Perth, Western Australia/AUSTRALIA; 3School of Pop-
ulation Health, University of Western Australia, Crawley, Western Australia/
AUSTRALIA; 4Department of Respiratory Medicine, Sir Charles Gairdner
Hospital, Nedlands, Western Australia/AUSTRALIA; 5Ontario Institute for
Cancer Research, Toronto/CANADA; 6School of Public Health, The Univer-
sity of Sydney, Sydney, New South Wales/AUSTRALIA
Background: Clustering of cases of malignant mesothelioma within families
has often been reported, but disentangling effects of common exposure to
asbestos from common genetic associations has rarely been possible.
Aims: To quantify familial risk of mesothelioma after allowance for asbestos
exposure.
Methods: Relationships between family members among 11,500 former
residents and workers from Wittenoom were obtained from questionnaires,
birth and death certificates, and sibsets were formed. Expected numbers of
mesothelioma cases were estimated by fitting a Weibull survival model to all
data based on time from first exposure to asbestos, and duration and intensity
of exposure. A predicted risk at end of follow-up was then estimated for each
subject from the time of diagnosis of the first (index) case in each sibset.
Familial risk ratios for different degree relatives were estimated by dividing
observed familial cases by those expected based on the sum of the risks of
all same degree relatives of the index cases.
Results: There were a total of 384 cases of mesothelioma of which 27 were
familial, with 16.3 expected. The familial risk ratio was 1.8 (95% CI 1.3-2.4,
P0.001), similar to that found with other more common cancers.
Conclusion: This is the first study that has been able to adjust for common
asbestos exposure when evaluating genetic risk of mesothelioma. These
findings suggest that there is an important, but not crucial, genetic component
in mesothelioma.
Disclosure: Funding: NHMRC. All authors have declared no further con-
flicts of interest.
CONTEMPORARY RESULTS OF SURGICAL RESECTION
OF NON-SMALL CELL CANCER (NSCLC) FOLLOWING
NEOADJUVANT THERAPY: A REVIEW OF 549 CONSEC-
UTIVE CASES
S.Barnett1,2, B. Park3, G. Plourde3, J. Zheng3, R. Downey3, R. Flores3,
N.Rizk3, R. Shen3, M.Kris3, M. Bains3, V.Rusch3 1Austin Hospital, Heidel-
berg, Victoria/AUSTRALIA; 2St Vincent’s Hospital, Fitzroy, Victoria/AUS-
TRALIA; 3Memorial Sloan Kettering Cancer Centre, New York/UNITED
STATES OF AMERICA.
Aims: Previous studies have reported high rates of morbidity and mortality
after surgical resection of NSCLC following neoadjuvant therapy, particu-
larly after right pneumonectomy. We reviewed our recent experience to
assess rates of and factors associated with postoperative complications.
Methods: An IRB-approved review of a prospectively-maintained database
identified patients undergoing attempted curative resection of NSCLC fol-
lowing neoadjuvant therapy. Complications were graded according to the
NCI CTCAE Ver3.0. DLCO%predicted (DLCO) and FeV1%predicted
(FeV1) were each multiplied by the number of bronchopulmonary segments
remaining post operatively and divided by 18 to arrive at the predicted post
operative (PPO) DLCO and PPOFeV1 respectively. Uni and multivariate
logistic regression models were used to assess the association of pre-
operative tests and clinical characteristics with peri-operative outcome. ROC
curves and AUC statistics were calculated to evaluate the predictive value of
various models.
Results: From Jan 2000 to Dec 2006, 549 patients were identified. All
received chemotherapy, 17% had radiation in addition. Lobectomy (388/549,
71%) and pneumonectomy (70/549, 13%) were most commonly performed.
R0 resection rate was 83%. Overall complication and major complication
(grades 4-5) rates were 48% (265/549), and 5% (25/549) respectively.
Mortality rate was 2% (10/549), only one death followed right pneumonec-
tomy (1/30, 3%). On multivariate analysis decreasing PPO pulmonary
function was associated with postoperative morbidity. ROC curves revealed
PPOP (AUC0.75, p0.001), PPODLCO (AUC  0.70, p0.001) and
baseline DLCO% (AUC0.66, p0.001) to be predictors of mortality.
Conclusions: Compared to earlier reports, mortality and morbidity have
dramatically decreased, especially after right pneumonectomy. PPOP is the
best predictor of mortality.
Disclosure: S. Barnett: has declared no conflicts of interest. All other authors
have not declared conflicts of interest.
EFFICACY OF EBUS-TBNA UNDER CONSCIOUS SEDA-
TION IN SUSPECTED THORACIC MALIGNANCY
C. Lewis, S. De Boer, TI. Christmas, M.R. O’Carroll, Auckland District
Health Board, Auckland/NEW ZEALAND
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) has become established as a highly sensitive diagnostic and staging
method in thoracic malignancy. Many prior reported series have performed
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EBUS-TBNA under general anaesthesia (GA) with prior CT-PET. We report
data from our new EBUS service in Auckland, NZ, where conscious sedation
is utilized and CT PET has very limited availability. Cases referred for EBUS
for diagnosis and/or staging of suspected intrathoracic malignancy were
included, performed between November 2007 and June 2010. EBUS-TBNA
results were compared with further diagnostic and staging investigations,and
resection specimens where available; if not, the clinical course over the
following 6 months was used to assign EBUS result accuracy. In total, 127
cases were performed. Mean (sd) sedation doses used were fentanyl 101.8
(23.1) mcg and midazolam 2.1 (0.7) mg. Number of passes for the first and
second nodes sampled (if applicable) were 3.1 (1.2) and 1.8 (1.0) respec-
tively. In total, 14 cases were classified as false-negative (FN), 31 as true
negative (TN), 74 as true positive (TP); 1 was not able to be classified (U)
and in 7, no TBNA was performed. In 3 of 14 FN cases, intolerance was
reported. The sensitivity of EBUS-TBNA for malignancy was thus 84.1%.
Sensitivity for procedures performed in the last 12 months of the period was
88.6%. EBUS-TBNA under conscious sedation yields comparable results
with reported series carried out under GA. The diagnostic accuracy of the
procedure appears to improve with experience.
Disclosure: C. Lewis: Travel Support: Olympus Australia for EBUS train-
ing; M.R.O’Carroll: Travel Support: Olympus Australia for EBUS training.
RADICAL EXTRA PLEUROPNEUMONECTOMY: A MEA-
SURE OF THE QUALITY OF LIFE OF ONE GROUP OF
PATIENTS
J. McLean1, B. McCaughan2 1Case Manager Thoracic Surgery; 2Cardiotho-
racic Surgeon, SSWAHS, Liverpool, New South Wales/AUSTRALIA
Little is known about the quality of life (QOL) of patients who are living with
or without disease after radical extra pleuropneumonectomy for Mesotheli-
oma. To address this issue a two part study is currently being conducted. Part
1 is a study to measure the QOL of patients who have had this surgery. Part
2 uses in-depth interviews of patients and carers to explore their lived
experience of recovery following this surgery. The results of the overall
study will be used to produce an information booklet that could be given to
new patients who are making a decision about whether or not to undergo
radical surgery. Two QOL questionnaires were used: The European Orga-
nization of Research and Treatment of Cancer (EORTC) QLQ-C30 and
LC13 as well as the McGill Quality of Life Questionnaire. Twenty one (21)
patients known to be living with or without disease were mailed an invitation
to participate. Seventeen patients consented to complete the questionnaires
and 14 returned the completed questionnaires. Data was analyzed using
SPSS Graduate Pack 13.0 in accordance with the scoring manuals from
EORTC and McGill Quality of Life Questionnaire. Results show that the
QOL of this group of patients was comparable to other patients in three
studies: a pre surgery setting of primary lung cancer, a group of mesotheli-
oma patients not having any treatment and another group who were having
chemotherapy. Part 2 of the study is in progress.
Disclosure: All authors have declared no conflict of interests.
TESTING FOR BIOMARKERS – SESSION 3
GENETIC SUSCEPTIBILITY TO LUNG CANCER
P. James, Monash Medical Centre, Clayton; Peter MacCallum Cancer
Centre, Melbourne, Victoria/AUSTRALIA
Although lung cancer is considered to be one of the most environmental of all
malignancies both lung cancer and smoking behaviour show high levels of
heritability. The 15% of affected individuals who have a family history of lung
cancer is similar to more established ‘familial’ cancers such as breast or colon
but with the absence of the major high penetrance genes seen in those conditions.
The genetic understanding of lung cancer has evolved from identification of rare
syndromic cases such as those associated with Li Fraumeni syndrome and DNA
mismatch repair deficiency, to the search for genes involved in the specific
familial clustering of different sub-types of lung cancer and the entity Multiple
Primary Malignancies Associated with Lung Cancer (MPMLC). Descriptions of
germline mutations remain rare and even the genes most commonly affected by
somatic mutations, including EGFR appear to make only minor contributions in
the familial setting. More recently whole genome approaches have yielded new
insights, although current findings from the 10 published GWAS explain only a
small fraction of the heritability of lung cancer and replication of results is
limited. Despite this a small number of highly reliable associations have been
described with ORs from 1.12 to 1.38. At least one of the significant associa-
tions, a SNP in the CHRNA3 neural nicotinic receptor (15q25.1), appears to
provide a biological link between environmental and genetic eitiologies.
Disclosure: The author has declared no conflicts of interest.
CLINICAL RELEVANCE OF PRIMARY TUMOUR XENO-
GRAFT MODELS OF NSCLC
T. John1, D. Kohler, N. Yanagawa, M. Pintilie, M. Li, D. Panchal, N. Pham,
F.A. Shepherd, M. Tsao 1Ludwig Institute for Cancer Research, Parkville
and Austin Health, Heidelberg, Victoria/AUSTRALIA
Primary tumor xenografts (PTXGs) established directly from patients’ pri-
mary tumors in immunosuppressed animals may represent the spectrum of
histological complexity of lung cancers better than xenograftsderived from
established cell lines. These models are increasingly employed to study
aberrant biological pathways in cancers and as preclinical models for testing
new therapeutic agents. To form PTXGs, tumor fragments from patients
undergoing curative surgery were implanted into NOD-SCID mice within 24
hours of surgery. Using this approach, xenograftswere established and
passaged successfully from 63/157 (40%) implanted NSCLCs. To investi-
gate factors associated with engraftment we explored clinicopathological and
mutational features of the patient’s primary tumor. DNA was profiled for the
presence of 238 known mutations in 19 cancer associated genes using the
MassARRAY platform. Tumor factors associated with engraftment included
squamous histology, poor differentiation and larger tumor size. Significantly
fewer EGFR mutated tumors engrafted (P0.03); conversely, more KRAS
mutated tumors engrafted (P0.05). In multivariate analysis including age,
sex, stage and mutation, patients with XG tumors had significantly shorter
disease-free survival compared to no-XG patients (HR7.0, 95%CI: 3.1-
15.81; P0.000003). Tumors that engraft are biologically more aggressive
and may be more representative of cancers with a higher propensity to
relapse after surgery.
Disclosure: T. John: declared no conflict of interest. All other authors have
not declared conflicts of interest.
ABSENCE OF A RELATIONSHIP BETWEEN 18F-FLUORO-
DEOXGLUCOSE (FDG) UPTAKE AND SURVIVAL IN NON-
SMALL CELL LUNG CANCER PATIENTS TREATED
WITH RADICAL RADIOTHERAPY OR CONCOMITATNT
CHEMORADIOTHERAPY
D.L. Ball1, M.Y. Lin1, M. Wu1, R. Fisher1, S. Brennan1, M-P. Campeau1,
D. Binns1, M.P. MacManus1, B. Solomon1, R.J. Hicks1 1Peter MacCallum
Cancer Centre, Melbourne, Victoria/AUSTRALIA
Background: A recent meta-analysis suggested that patients with non-small
cell lung cancer (NSCLC) whose tumours have a higher standardized uptake
value (SUV) derived from F-2-deoxy-D-glucose (FDG) positron emission
tomography (PET) scans have a worse prognosis than tumours with lower
values (Paesmans et al JTO 2010). However, it is not known if the relation-
ship is consistent over the full range of SUV values. The aim of this
retrospective study was to investigate the potential of maximum SUV
(SUVmax), analysed as a continuous variable, to predict outcome in patients
treated with radical radiotherapy (RT).
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Methods: Patients were eligible if they: had pathologic diagnosis of NSCLC;
were treated with radical RT with or without chemotherapy as their primary
treatment; and had pre-treatment staging PET-CT scans. The maximum SUV
(SUVmax) was defined as the maximum pixel SUV value retrieved from the
primary tumor. SUV max was analyzed as a dichotomous and continuous
variable for overall survival.
Results: 88 patients met the eligibility criteria for the study, including 19
stage I patients, 10 stage II, 59 stage III. Higher stage was associated with
higher values of SUVmax (P0.048). In univariate analysis, using a median
cutpoint of SUVmax 15.0, the hazard ratio (HR) for risk of death was 0.71
(high:low; 95% CI 0.44 to 1.15; P0.18). The effect of SUVmax as a
continuous variable on risk of death was also not statistically significant (HR
0.83 per doubling, 95% CI 0.62 to 1.11, P0.22).
Conclusion: In this cohort of patients, higher levels of FDG uptake were not
associated with worse outcomes.
Disclosure: All authors have declared no conflicts of interest.
A GENOME WIDE ASSOCIATION SCAN FOR MALIG-
NANT MESOTHELIOMA
S. Mukherjee1, G. Cadby2, A. Reid2, M. Garlepp2,3, B.W.S. Robinson2, N. de
Klerk2,3, A.W.M. Musk1, L.J Palmer2,4 1Sir Charles Gairdner Hospital,
Nedlands, Western Australia/AUSTRALIA; 2The University of Western Aus-
tralia, Crawley, Western Australia/AUSTRALIA; 3Telethon Institute for
Child Health Research, West Perth, Western Australia/AUSTRALIA; 4On-
tario Institute for Cancer Research, Toronto/CANADA
Background: Although it is known that malignant mesothelioma (MM) is
caused by exposure to asbestos, not all individuals with documented asbestos
exposure develop MM. There is a demonstrated familial predisposition with
an approximate doubling of risk in 1st degree relatives. It is likely that genes
and gene: environment interactions are important factors involved in the
development of this uniformly fatal cancer.
Aim: To perform the first Genome-Wide Association Scan (GWAS) for MM
and compare these results to age and sex matched controls from a general
population sample.
Methods: Clinical data and DNA samples were obtained from patients
diagnosed with MM who attended a tertiary hospital clinic in Perth between
1995 and 2010. Control blood samples were obtained from residents of
Busselton who were part of the 1994/1995 Busselton Health Survey and who
had not been diagnosed with cancer.
Results: GWAS has been performed on 438 MM patients (382 males and 56
females) and 1366 general population controls. The MM genotypes have
been compared to a larger sample of general population European controls
from Busselton, WA.
Conclusions: This is the first GWAS for MM. The results will improve our
understanding of the complex relationships between genes and the known
environmental exposure (asbestos). This is important in identifying under-
lying susceptibility, progression and variable response to therapy in MM.
Disclosure: S. Mukherjee: has declared no conflict of interest. All other
authors have not declared conflicts of interest.
CANCER CONTROL
CANCER AUSTRALIA’S NATIONAL LUNG CANCER PRO-
GRAM INITATIVES
H. Zorbas, Cancer Australia, Strawberry Hills, New South Wales/AUSTRALIA
An estimated 115,000 new cases of cancer will be diagnosed in Australia this
year and more than 43,000 people are expected to die from cancer in 2010.
Lung cancer is the leading cause of cancer death in both men and women.
While the overall 5 year relative survival rates for cancer have improved
from 42% in 1982-86 to more than 60% in 1998-2004, the current 5 year
relative survival of 10.7% of those diagnosed with lung cancer has changed
very little over the past 20 years. The significant impact of cancer on society
is increasingly being realised worldwide. Cancer is the world’s leading cause
of death and has been recently recognised as also having the greatest
economic impact from years of healthy life lost due to premature death and
disability. While the greatest contributor to the burden of cancer is tobacco,
lung cancer is not a cancer limited to the smoking population. A recent
survey has shown that there is a disconnect between the economic cost of
lung cancer and perceptions in Australia of the impact and causes of this
cancer. Australian survey participants perceived lung cancer to be the 3rd
most deadly cancer behind breast cancer and skin cancers. Of further
concern, particularly given the number of ‘never smokers’ that will be
impacted by lung cancer, is that 1 in 3 Australian survey respondents
indicated that they would have less sympathy for lung cancer patients due to
the perceived linkage between smoking and lung cancer than they would
have for people impacted by other cancer. The Australian Government has
recognised that the impact of lung cancer is significant and has committed
$6.83 million until 2013 for Cancer Australia to deliver the National Lung
Cancer Program, with the specific objectives of:
● Building an accessible evidence base through research, clinical guidance
material and improved cancer data; and
● Supporting health professionals to deliver consistent best practice care
through targeted programs. This presentation will provide an overview of
how Cancer Australia is aiming to deliver on the Government’s objectives
for the National Lung Cancer Program.
Disclosure: The author has declared no conflicts of interest.
LUNG CANCER DATA COLLECTION IN AUSTRALIA
D. Roder, Cancer Council South Australia, Eastwood, South Australia/
AUSTRALIA; Cancer Australia, Strawberry Hill; National Breast and Ovar-
ian Cancer Centre, Surrey Hills; and NSW Cancer Institute, Eveleigh, New
South Wales/AUSTRALIA
Service providers, policy makers, researchers and community representatives
show a strong and increasing demand for data on lung cancer incidence,
mortality, stage-specific survival, treatment, and treatment late effects, plus
comparative data for special groups, including low socio-economic, rural and
remote, Aboriginal and Torres Strait Islander, and various ethnic groups.
Data are sought on lung cancer outcomes according to changes in treatment.
Survey data are sought on effects of preventive initiatives directed at tobacco
smoking, asbestos exposure and other risk factors. Increasingly molecular
and genetic markers are being used to explore treatment interactions and
targeted therapies. Population registries are at the centre of our national
cancer data strategy, but they lack data on stage other prognostic character-
istics and treatment. In this presentation, the role of a new lung cancer data
set specification in filling this gap is discussed, together with research and
development directed at adding TNM or equivalent stage, and other prog-
nostic data, to population registries and determining how best to electroni-
cally extract data from structured pathology reports and through text mining,
from imaging and other test reports. Data linkage will play an important role
in combining treatment data from the new lung cancer data set and admin-
istrative data from inpatient statistics, radiation oncology centres and health
insurance sources with population registry data to increase the evidence base
for clinical, population-health and health-services research in Australia.
Disclosure: The author has declared no conflicts of interest.
LUNG CANCER IN NEW ZEALAND
T. Christmas, Auckland City Hospital, Auckland/NEW ZEALAND
Lung cancer is the 5th most common cancer registered in New Zealand and
the leading cause of cancer death accounting for 19% of male and 16.7%
female cancer deaths. Maori have a high lung cancer death rate of 30%
compared with 19% non-Maori. Death rates have however fallen for men
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from 1997 to 2007 whereas rates for women have increased slightly over the
same period consistent with overseas trends. Five year relative survival was
9.5% for males and 11% for females from 1994 to 2003 which is lower than
Australia and Canada but higher than the UK (6 and 7.5%) for a similar time
frame. These low survival figures may be due to several factors including a
nihilistic attitude to cancer treatment reflected in low rates of MDM presen-
tation and low referral rates for appropriate anticancer treatment. The
survival for Maori, is particularly poor (5.4%) compared with non-Maori
(11%) Differences in survival for Maori may include higher rates locally
advanced disease at presentation, less curative treatment offered and longer
waits from diagnosis to treatment. In response to this data the Ministry of
health have established initiatives to improve lung cancer outcomes. These
include regional cancer networks with key goals to improve outcome and
address inequality in lung cancer. Survival data has is not yet available but
results have included improved data collection, treatment timelines and
MDM presentations which should ultimately improve the outcomes of lung
cancer in NZ.
Disclosure: T. Christmas: Sponsorship to attend the lung tissue meeting and
ALCC 2010: Roche.
LUNG CANCER IN RURAL/REMOTE AUSTRALIA
S. Sabesan, Department of Medical Oncology, Townsville Hospital and
School of Medicine and Dentistry, James Cook University, Townsville,
Queensland/AUSTRALIA
People living in rural and remote areas are at greatest risk of being diagnosed
with lung cancer compared to those in urban areas and were likely to be
diagnosed with non-localised lung cancer than people living in highly accessible
areas1. Australian studies have reported significant area variation in lung cancer
survival, with lung cancer survival being lowest among people living in the most
socio-economically disadvantaged areas and rural areas2. Though there are no
prospective studies examining the reason for this disparity, possible reasons
include access to health care, lack of clinical trials, patient choices due to long
travel to major centres for therapy and higher prevalence of socioeconomically
disadvantaged and indigenous population in rural/remote Australia. This calls for
action from primary care providers and specialist service providers in relation to
prevention, early detection, early referrals and management pathways. While
studies are desperately needed to examine this issue, health workers involved in
the care of rural lung cancer patients have the duty of care to enhance easy access
to their services by rural/remote patients. For example, medical oncologists in
Townsville Hospital provide their services to rural areas in their health service
district using videoconference technology for consultations and treatment. In this
way, unnecessary inter hospital transfers are also minimised. Indigenous patients
find this mode of service delivery particularly important since they can be looked
after closer to their homes3. Hopefully with the recent funding for regional
cancer centre expansion, rural access would be improved. This expansion should
also focus on clinical trial participation to provide equity. Rural patients are as
interested in trials as urban patients but cost of travel and inconvenience of travel
may be barriers4. Studies are currently being conducted to examine the patterns
of care in lung cancer in Queensland by groups from North Queensland and
South East Queensland.
References
1. Youlden DR, Cramb SM, Baade PD, Current status of lung cancer in
Queensland 1982 to 2004. Viertel Centre for Research in Cancer Control,
Cancer Council Queensland, 2007.
2. Jong KE, Smith DP, Yu XQ, O’Connell DL, Goldstein D, Armstrong BK.
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Disclosure: The author has declared no conflicts of interest.
IDENTIFICATION OF HIGH RISK INDIVIDUALS FOR
CHEMOPREVENTATIVE MEASURES
N. van Zandwijk, Asbestos Disease Research Institute - Bernie Banton
Centre and TheUniversity of Sydney, Sydney, New South Wales/AUSTRALIA
Lung cancer is the leading cause of cancer-related mortality and around 3000
people are dying every day as a consequence of this disease. Around 85% of
this enormous toll is due to cigarette smoking. Although the prevalence of
smoking is declining, the risk of lung cancer after smoking cessation persists
and remains elevated compared with never-smokers (1). It has been esti-
mated that 42% of the adult population in the USA has an increased risk of
lung cancer because of current or former smoking practice (2) and this
percentage is expected to be higher in several other countries. In addition it
has been noted that despite the initial success of smoking cessation programs
there seems to remain a population of hardcore smokers that are either
unwilling or unable to quit (3). Thus, the addicted smoker and the ex-
smokers are at high risk for lung cancer and we must elaborate a cost-
effective strategy to prevent this devastating disease in those individuals,
who are at greatest risk. Chemoprevention of lung carcinogenesis is one way
forward. So far the efforts to prevent lung cancer by natural or synthetic
agents have not been successful. A part of the lack of success is attributed to
the fact that several large chemoprevention studies were focussed on current
smokers. A number of groups have explored models for more accurate risk
prediction of lung cancer using both epidemiologic and clinical data (4).
These studies have confirmed that there is a very large variation of lung
cancer risk among smokers and non-smokers. Unsatisfactory outcomes of
large chemoprevention studies have formed a stimulus for a structured
stepwise approach to test new preventive agents (5). This approach is still
valid and can now be enriched by a more accurate definition of high-risk
populations. The introduction of risk stratification is expected to translate
into more effective chemoprevention strategies.
Reference
1. Peto R, et al. BMJ 2000.
2. Mariolis P, et al. Morb Mortal Wkly Rep 2006.
3. Warner KE, et al. Nicotine Tob Res 2003.
4. Spitz M, et al. J Natl Cancer Inst 2007.
5. Lippman SM. J Clin Oncol 2001.
Disclosure: N. Van Zandwijk: Advisory Board: Merck Serono, Eli Lilly,
Pfzier, Boehringer Ingelheim. Speaker’s Bureau: Eli Lilly.
SUPPORTIVE INTERVENTIONS FOR FAMILY MEMBERS
S. Moore, Royal Marsden NHS Foundation Trust, Surrey/UNITED KINGDOM
The need to better support family members of people living with cancer, and
in particular lung cancer, is well recognised. This presentation describes a
feasibility study, conducted in a single UK institution, of a supportive
intervention for family members of people with lung cancer. This study
aimed to:
● Develop and test a supportive nursing intervention
● Determine the feasibility, acceptability and efficacy
● Provide a better understanding of the experience of delivering the inter-
vention
● Determine how best to offer support to those close to the patient with lung
cancer and factors that impede that impede or enhance this
The design and main findings of the study are briefly presented. The main
focus of the presentation describes the experience of the three nurses who
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delivered the intervention. Their experience is discussed under three main
themes:
● Meeting diverse need: the content of the intervention
● Differing models of delivery
● Dilemma and emotion.
Finally, implications for practice are discussed.
Disclosure: The author has declared no conflicts of interest.
EMGERING TECHNOLOGIES
SUB-TYPES PATHOLOGY – CHANGES IN THEWIND FOR
LUNG CANCER
B. Clarke, Pathology Queensland, The Prince Charles Hospital, Chermside,
Queensland/AUSTRALIA
Pulmonary pathologists are increasingly being asked to do more with less in
their attempts to diagnose and classify lung cancer. Gone are the days of an
adequate diagnosis being benign v. malignant or small cell v. non-small cell
carcinoma, although these decisions can still be a challenge in the era of less
invasive, more limited sampling techniques. The heterogeneity of lung
cancers, particularly adenocarcinomas, contributes to diagnostic uncertainty
in small specimens. The development of targeted therapies is driving the
requirement for pathologists to differentiate between subtypes of non-small
cell lung carcinoma (NSCLC), exemplified by the ineligibility of patients
with squamous cell carcinoma to receive the antimetabolite drug pemetrexed
or the anti-vascular endothelial growth factor agent bevacizumab. Response
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs)
is also predicted by histology, notably the predominant adenocarcinoma
pattern as well as TTF-1 status. Although mutational analysis is required to
qualify for treatment with EGFR TKIs, accurate typing on biopsy material is
necessary to determine which cases should be tested. The WHO criteria for
subtyping NSCLC are based on the histological examination of surgically
resected tumours, available in less than 20% of cases. These criteria are not
necessarily applicable to the majority of lung cancers which are diagnosed on
small biopsies or cytology specimens. Mucin histochemistry and immuno-
histochemistry can assist in pushing a diagnosis towards either squamous cell
carcinoma or adenocarcinoma in some cases which are equivocal on routine
H&E morphology, but are not absolute. Until robust prognostic biomarkers
are identified and shown to be applicable to very limited specimens, the
pathological diagnosis of lung cancer will remain a challenging art form.
Disclosure: B. Clarke: Sponsored speaker in November 2009 and March
2010: Roche.
PRELIMIARY EXPERIENCES WITH HELICAL FAN
BEAM IMRT (TOMOTHERPAY) – POTENTIAL
THORACIC APPLICATIONS FOR THE NON-RADIA-
TION ONCOLOGIST
G. Pratt, Radiation Oncology, The Royal Brisbane & Women’s Hospital,
Herston, Queensland/AUSTRALIA
In July 2010 Australia’s first Tomotherapy facility commenced at RBH. An
overview of the technology, benefits, limitations and potential thoracic applica-
tions will be discussed. Potential applications which will be discussed include
mesothelioma, stereotactic body radiotherapy for NSCLC, limited volume me-
tastases in Stage IV NSCLC, and thymoma.
Disclosure: Dr Pratt’s only involvement has been attendance at educational
lectures sponsored by pharmaceutical companies from time to time. No
employment, stock holdings, or research funding or other remunerations
from any pharmaceutical or medical company.
ELECTRONIC NOSE DISTINGUISHES LUNG CANCER
FROM HEALTHLY SMOKING CONTROLS
A. Dent, R. Bowman, P. Zimmerman, I. Yang, K. Fong Department of
Thoracic Medicine, The Prince Charles Hospital, Chermside and University
of Queensland, St Lucia, Queensland/AUSTRALIA
Introduction: The measurement of volatile organic compounds (VOCs) in
exhaled breath using an electronic nose may prove to be a novel, effective
and simple technique for screening and diagnosing lung disease.
Aim: To determine whether VOC profile in individuals with lung cancer can
be differentiated from that of healthy subjects who have at least a 30 pack
year smoking history.
Method: Subjects performed two exhaled vital capacities (10 min apart) into
a Tedlar sample bag after breathing tidally through an inspiratory port filter
for 5 minutes. Samples were analysed using a Cyranose 320. Means of the
two tests for each of the 32 sensors were reduced to principal components
and canonical discrimination analyses were performed to determine signifi-
cance of difference between subject groups and cross validated accuracy
(CVV) of the groups using the leave one out classification method (SPSS
V17.0). Spirometry and gas transfer measurements were also performed.
Results: The VOC profiles of lung cancer subjects (n15) were correctly
differentiated from healthy subjects with a smoking history (n28) with
CVV accuracy of 93% (P0.0001).
Conclusion: Significant differences in exhaled breath VOC profiles between
subjects with lung cancer and healthy subjects with a smoking history
indicate that the eNose (Cyranose 320) does have the potential to be a
clinically useful diagnostic and screening tool for lung cancer. Supported by
The Prince Charles Hospital Foundation, The Prince Charles Hospital Private
Practice Trust Fund, NHMRC Career Development Award (IY), NHMRC
Practitioner Fellowship (KF).
Disclosure: All authors have declared no conflict of interest.
NON EGFR TARGETED THERAPIES
EML4 – ALK
B. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA
A subgroup of non-small cell lung cancer patients (NSCLC) patients have
tumours with transforming rearrangements of the ALK (Anaplastic Lym-
phoma Kinase) gene. The most common rearrangement arises from an
inversion in the short arm of chromosome 2 that creates a fusion between the
5’ portion of the EML4 (echinoderm microtubule-associated protein-like 4)
gene and the 3’ portion of the ALK gene (EML4-ALK). Although ALK gene
rearrangements affect only about 3-5% of all NSCLCs, they are more
frequent in adenocarcinomas, in never or light smokers, in younger patients
and are almost mutually exclusive with activating EGFR or KRAS mutations.
Promising results seen in patients with NSCLC containing ALK rearrange-
ments treated on a phase I study with Crizotinib (PF02341066), an orally
available small molecule inhibitor of the ALK tyrosine kinase, indicate that
ALK represents a new therapeutic target in this molecularly defined subset of
NSCLC and have led to the initiation of a phase III study in this patient
population.
Disclosure:
OTHER TARGETS IN LUNG CANCER
R. de Boer, Royal Melbourne and Western Hospital, Melbourne, Victoria/
AUSTRALIA
Results of treatment in patients with advanced non-small-cell lung cancer
(NSCLC) remains poor with low long-term survival rates. Palliative chemo-
therapy is the standard of care, but offers a median survival of approximately
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a year. Studies suggest that we have reached a plateau with standard
cytotoxic combinations. These agents have little specificity for lung cancer
cells. We have learned much about the molecular and cellular biology of lung
cancer over the past 2 decades, and the differences between lung cancer cells
and normal bronchial epithelial cells provide new targets for therapeutic
interventions. Molecularly targeted drugs may block and control important
pathways that drive cancer progression and in doing so achieve long-term
disease control. EGFR inhibitors are increasingly utilised and anti-EGFR
monoclonal antibodies have been tested. Antiangiogenic therapy with bev-
acuzimab in combintaion with chemotherapy has become a common treat-
ment in patients with non-squamous NSCLC in North America, although is
yet to be widely adopted elsewhere. This presentation will focus on the
evidence supporting the efficacy and safety of the anti-angiogenic agents as
well as novel targeted therapies such as vaccines, gene therapies and agents
that interfere with insulin-like growth factor 1 receptor. Aberrations in other
key signaling pathways such as PI3K/AKT/mTOR and RAS/RAF/MEK
have also been identified as being important targets in patients with NSCLC,
and therapeutic agents aimed at these paths are being trialled and will be
discussed.
Disclosure: R. De Boer: Roche: Member of Roche Australian Lung cancer
Advisory Board and Sponsorship to WCLC 2011, AstraZeneca: Member of
AZ Australian Lung Cancer Advisory Board and Eli Lilly: Member of Lung
cancer Advisory board and attendance at WCLC 2009.
DESIGNING TARGETED THERAPY TRIALS IN AUSTRALIA–
ISSUES
M. Stockler, NHMRC Clinical Trials Centre, Sydney, New South Wales/
AUSTRALIA
Traditional strategies for developing anticancer drugs were designed to
screen cytotoxic agents in poorly-understood diseases with few effective
therapies. Current anticancer drug development is based on rationally de-
signed interventions targeting aberrant molecular pathways amidst a plethora
of moderately active agents. These differences have major implications for
all phases of targeted drug development. This presentation will describe
features, strengths, and limitations of new and emerging approaches, and
reflect on how the Australian lung cancer clinical research community can
best contribute.
Disclosure: Our groups are currently doing trials partly supported by AZ,
Bionomics, Bayer, Roche, Pfizer, Novartis, MSD I have received honoraria
for educational presentations from Novartis, Pfizer, MSD, Roche.
MOUSE LUNG CANCERMODELS: THE NEXT GENERATION
N. Watkins, Monash Institute of Medical Research, Clayton, Victoria/
AUSTRALIA
In the last decade, genetically engineered mouse models of cancer have dramat-
ically enhanced our understanding of tumour biology, and have provided a
unique platform for more accurate preclinical assessment of new therapies.
Recent work has further revealed the potential for this approach in lung cancer.
Using primary xenografting techniques, it is now possible to maintain tumours
in immunodeficient mice indefinitely. Not only are these lines more represen-
tative of the primary tumour than conventional cell lines, they serve as an
excellent therapeutic model when derived from chemo-naive patients. Using
genetic targeting technologies, it is also possible to specifically knock-in or
knock-out genes in the airway epithelium of adult mice. This approach has
generated mouse models of adenocarcinoma and small cell lung cancer that are
remarkably similar to their human counterparts. Moreover, crossing these mod-
els with other knockout models can reveal a genetic requirement for a candidate
therapeutic target in vivo. These new experimental platforms will hopefully
improve our ability to translate new discoveries to the clinic.
Disclosure: The author has declares no conflict of interest.
EARLY DETECTION
BREATH TESTING FOR THORACICMALIGNANCY: VOL-
ATILE ORGANIC COMPOUND (VOC) MEASUREMENT
USING AN ELETRONIC NOSE
D. Yates, Thoracic Medicine, St Vincent’s Hospital, Fitzroy and The Uni-
versity of New South Wales, Sydney, New South Wales/AUSTRALIA
Most lung cancers are detected at a stage when cure is not possible. However,
if detected early enough, surgery and multimodality treatment offer signifi-
cant potential for cure. Screening of those at high risk (e.g. smokers, asbestos
exposed workers) has not yet been shown to have a survival advantage. CT
scanning is currently being prospectively examined in several large studies,
but involves exposure to radiation, is expensive, and has a significant false
positive rate. Thus, there is a need for a simple, non-invasive method which
can be used for screening. Recently, technological developments have
allowed rapid and sensitive detection of exhaled breath biomarkers using
non-invasive methods. A wide variety of cytokines, chemokines and proteins
can be sampled from exhaled breath and novel sophisticated techniques can
be applied particularly to collected proteins. Over 4,000 volatile organic
compounds (VOCs) are present in the breath and produce an individual
breath pattern or “smellprint”. Recently there has been great interest in VOC
measurement worldwide, and several studies from different centres have
demonstrated that this technique can accurately distinguish patients with lung
cancer from those without. VOC breath profiling has been reported to show
sensitivities and specificities of approximately 85% for the detection of lung
cancer and if anything a higher negative predictive value. This talk will
summarise developments in this field and present recent results from NSW,
which confirm international experience. VOC breath testing presents a highly
promising area for early detection of lung cancer and thus for possible cure.
Disclosure: D. Yates: Consultant: Patrys Ltd.
ADDRESSING VARIATIONS IN LUNG CANCER TREAT-
MENT AND OUTCOMES ACROSS AUSTRALIA
R. Hiam1, M. Jiwa2 1Clinical and Primary Care Advisor, Cancer Australia,
Dickson, Australia Capital Territory /AUSTRALIA; 2Professor of Health
Innovation, Curtin University, Perth, Western Australia/AUSTRALIA
Aim: To provide the background to research commissioned and funded by
Cancer Australia on variations in lung cancer management and outcomes and
to present the results of this research undertaken by Curtin University.
Background: In 2006 there were 9563 cases and 7397 deaths from lung
cancer in Australia, making it the commonest cause of cancer deaths in both
males and females. Australian and overseas studies show that many people,
both those with potentially curable disease and those with more advanced
lung cancer, do not receive any cancer specific treatment despite evidence
that treatment is beneficial. Cancer Australia commissioned this research to
investigate the factors which impact on treatment decisions and outcomes.
Method: Review of national and international lung cancer literature from Jan
1995-June 2010 and consultation with experts identified through clinical
networks. The consultation was undertaken via telephone interview (34) and
two online modified Delphi surveys (137 and 150 participants). The research
sought the opinions of experts to identify variations in treatment and
outcomes and the best ways to minimize these.
Results: The following initiatives were recommended: education for general
practitioners on recognition of symptoms and timely investigation; increased
public awareness of the benefits of treatment; monitoring of people with
ongoing symptoms and non –specific test results; improved access to MDTs;
a lung cancer specialist directory of services and enhanced collaboration
between public and private sectors.
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Conclusions: The results and recommendations provide Cancer Australia
with information on where the development of guidance material is likely to
provide the most benefit.
Disclosure: All authors have declared no conflicts of interest.
SYMPTOMS AND SUPPORTIVE CARE
GERIATRIC ASSESSMENT OF OLDER LUNG CANCER
PATIENTS
N. Singhal, H. Cheng, T.H.M. To The Royal Adelaide Hospital Cancer
Centre, Adelaide, South Australia/AUSTRALIA
Background:With the ageing population, there are increased numbers of the
elderly referred to medical oncologists for management of their cancer.
Studies have shown that geriatric assessment and intervention may improve
outcomes of the elderly with cancer. Studies are emerging that are guiding
treatment decisions in older patients with lung cancer. Therefore understand-
ing the profile of elderly patients with lung cancer is important to guide
application of these studies
Aim: To describe the characteristics of elderly patients with lung cancer
referred to the geriatric oncology program at the Royal Adelaide Hospital
(RAH).
Methods: Patients aged  70 years with lung cancer treated by RAH cancer
centre during the period between Jun 2008 and Jun 2010 were asked to
complete a self-reported questionnaire covering co-morbidities, medications,
physical function, social supports, exhaustion, nutrition, cognition and psy-
chological well being. Based on this questionnaire, patients were classified as
fit, vulnerable or frail.
Results: One hundred and twenty-two patients were seen in this period. The
average age was 75.6 and 64% were male. One hundred and five patients
(86%) were diagnosed with NSCLC (18 early stage, 25 locally advanced, 62
metastatic), and 17 (14%) with SCLC. Seventy-three patients (60%) lived
with partners, 26% lived alone, 11% lived with children and 2% lived in
other accommodation. Charlson co-morbidity score shows 80% with score
2 and 20% scoring  2. Patients were categorised into three groups: fit 30
(25%), vulnerable 76 (62%) and frail 16 (13%). As a result of the assessment,
91 (75%) patients had referrals made, including 24 to dietetics, 18 to social
work, 17 to palliative care team, 13 to geriatrics, 10 to occupational therapy,
8 to the geriatric oncology nurse, 8 to clinical psychology, and 3 to the
clinical pharmacist.
Conclusion: Elderly patients with lung cancer presenting to a medical
oncology department were predominantly male, community-living, and pre-
sented with advanced disease. At geriatric oncology review, a large propor-
tion had referrals indicated to support their oncological management.
Disclosure: The author has declared no conflicts of interest.
LIVER TOXICITY FOLLOWING ADJUVANT RADIO-
THERAPY FOR MALIGNANT MESOTHELIOMA
M. Tin1, R. Lin1, R. Tse1, J. Chen1 and B. McCaughan2 1Department of
Radiation Oncology, Sydney Cancer Centre, New South Wales/AUSTRALIA;
2Department of Cardiac Thoracic Surgery, Royal Prince Alfred Hospital,
Camperdown, New South Wales/AUSTRALIA
Purpose: To assess liver biochemical toxicities following Extra-Pleural
Pneumonectomy (EPP) and Adjuvant Three-Dimensional Conformal Radio-
therapy (3DCRT).
Methods and Materials: Since 2004, 33 patients with Malignant Pleural
Mesothelioma (MPM) underwent EPP and adjuvant 3DCRT to the hemitho-
rax. 17 patients also received chemotherapy prior to surgery. Serial Liver
Function Tests (LFTs), Mean Liver Dose (MLD) and liver Dose-Volume
Histogram (DVH) were analysed in 17 patients with right-sided disease.
Changes in LFTs were graded using CTCAE v4.02. Patients (n12) with
left-sided disease and patients (n4) who failed to complete the intended
treatment were excluded from the analysis due to low liver dose. The mean
radiation dose was 46.52Gy (range 41.4Gy - 55Gy).
Result: Total of 108 LFTs from 17 patients were analysed, from start of
radiotherapy (RT) and followed for a median of 18 months (range 1 - 63)
post-treatment. All patients except 2 demonstrated liver biochemical dys-
function, following RT. Grade two or above liver biochemical toxicities were
observed in 10 of 17 patients (59%). There was no grade 4 or 5 toxicity. 6
patients had pre-existing abnormalities at baseline. Only 2 patients had
deterioration in LFT during RT. 11 of 17 patients had deterioration post RT.
The LFT abnormalities generally peaked at 3-6 months post-RT, at 5-14
times the upper level of normal. In all patients LFT returned to normal range
within 2 to 3 years following RT. Alkaline Phosphatase (ALP) and Gamma-
Glutamyl Transferase (GGT) were most affected. The most severe toxicity
was observed in a patient who had abnormal LFTs prior to radiotherapy.
There appeared to be association between liver dose parameters and the
severity of the toxicity.
Conclusion: Liver biochemical dysfunction is common following EPP and
Adjuvant 3DCRT for MPM but LFTs returned to normal in all patients. ALP
and GGT during and post-treatment are more sensitive than the transami-
nases in monitoring liver toxicity.
Disclosure: M. Tin: The author has declared no conflicts of interest. All
other authors have not declared conflicts of interest.
ACCESSING PALLIATIVE CARE INFORMATION AND EV-
IDENCE – AN UPDATE ON RESOURCES
J. Ingham, Cunningham Centre for Palliative Care, Darlinghurst, New South
Wales/AUSTRALIA; St Vincent’s Clinical School, Darlinghurst, New South
Wales/AUSTRALIA, The University of New South Wales, Sydney, New South
Wales/AUSTRALIA
The palliative care needs of individuals with lung cancer, their family
members and carers can be diverse - spanning a myriad of problems through
the illness trajectory. Among other palliative care needs are those related to
symptom management, psychosocial interventions and support, and patient
and carer education and support. As the field of palliative care has evolved
so too has the evidence-base for identifying, evaluating and managing
palliative care needs. The delivery of optimal care in the lung cancer setting
hinges upon health professionals in oncology ensuring that patients and
carers have access to the most current therapies in relation to both oncology
and palliative care. In the setting of an evolving palliative care evidence-
base, a number of on-line resources have been developed that aim to assist
patients, carers and health professionals and, in particular, to link oncology
service providers with state-of the art information in a user-friendly manner
accessible at the point of service. Some of these resources have been
developed specifically for the Australian clinical environment. This educa-
tion session will provide participants with an overview of resources available
to oncology health professionals in Australian clinical settings for accessing
current palliative care information and evidence.
Disclosure:
LUNG CANCER AND/OR MESOTHELIOMA
SUPPORT GROUPS – WHAT WORKS, WHAT
DOESN’T
TELEPHONE SUPPORT GROUPS
F. Ratcliffe1, A. Boyes2, A. Zucca2, P. Vallentine1, J. Friedsam1 1Cancer
Information and Support Service Division, Cancer Council NSW, Wool-
loomooloo, New South Wales/AUSTRALIA; 2The Centre for Health Research
and Psychology, Newcastle, New South Wales/AUSTRALIA
Background: The Telephone Support Group (TSG) Program is a social support
intervention specifically designed to deliver psychosocial care to ‘special needs
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groups’; cancer patients, carers and bereaved carers who have no or limited
access to more conventional forms of support. Cancer Council NSW commis-
sioned the Centre for Health Research and Psycho-oncology to undertake a
formal evaluation of the program – data is across 10 different group types
including a Lung Cancer specific TSG.
Method: A total of 136 TSG members (14 former, 82 current, 39 new)
completed a study-specific Computer Assisted Telephone Interview assessing
utility and acceptability of the groups. New members also completed a pen-and
paper survey assessing their psychosocial wellbeing before participating in their
first group session and again 12 weeks later.
Results: Lack of access to face-to-face support groups was the main reason
members gave for participating in TSG. Most reported a preference for a
moderately structured group with new members able to join at any time. There
was a significant reduction in members’ levels of depression and improvement
in emotional wellbeing from pre-group to post-group assessment. Members
identified facilitator characteristics as the most important feature to ensuring
group success. 96% of participants indicated they would recommend it to others.
Conclusion: TSGs are highly acceptable to people affected by cancer and can
improve their emotional wellbeing. Although some areas for improvement were
identified, these findings highlight the value of telephone-support based support
groups as part of the suite of supportive care services available to people affected
by cancer.
Disclosure: F. Ratcliffe: has declared no conflicts of interest. All other
authors have not declared conflicts of interest.
FACE TO FACE SUPPORT GROUPS
C. Southerton, Cancer Support Centre, Sydney Adventist Hospital, Pymble,
New South Wales/AUSTRALIA
Research has shown that attending a cancer support group has multiple benefits. The
Cancer Support Centre at the Sydney Adventist Hospital runs a fortnightly open
support group for people with lung cancer. The group is open to patients regardless
of which hospital they are receiving treatment. Some patients come to meetings on
their own while others are accompanied by family or carers. The group has two
facilitators and occasionally divides into patients and carers groups. Facilitators give
additional support to groupmembers too unwell to attend through phone calls, emails
and home and hospital visits. The facilitators encourage the group process wherein
the group members support each other through information sharing, meeting emo-
tional needs and by talking to someone in the ‘same boat’. The group often acts like
an anchor and members attend with they need to. By its very nature a lung cancer
support group needs the support of oncology health professional to provide referrals
to the group. While running a lung cancer support group presents unique challenges
and at times is incredibly sad it is also greatly rewarding. To be able to assist patients
and their families through their cancer journey by replacing their feelings of
helplessness with a sense of control and giving them the opportunity to make
informed decisions to achieve the best quality of life that is possible.
Disclosure: The author has declared no conflicts of interest.
UNITED KINGDOM – SUPPORT GROUP MODELS
S. Moore, Royal Marsden NHS Foundation Trust, Surrey/UNITED KINGDOM
A support group is a structured group composed of members who offer mutual
support through interpersonal interactions (Katz & Bender 1976). Support group
involvement has been shown to lead to positive benefits for patients with cancer
including improvements in emotional and physical functioning, relationships and
quality of life (Docherty 2004). However, few studies have evaluated the role of
support groups in specific lung cancer and mesothelioma populations. This presen-
tation describes the various models of support groups that currently exist in the UK
for patients with lung cancer or mesothelioma and their family members. It then
offers a personal reflection of my experience of facilitating separate face-to-face
support groups for these two populations of patients and their family members
highlighting practical implications for practice.
References
Docherty A. (2004) Experience, functions and benefits of a cancer support
group. Patient Education and Counselling 55(1), 87-93.
Katz A. & Bender E. (1976) Self-help group in western society: history and
prospects. Journal of Behavioural Science 12, 265-285.
Disclosure: The author has declared no conflicts of interest.
LOCALLY ADVANCED/SURVIVAL FACTORS
GEOGRAPHIC VARIATION IN LUNG CANCER SUR-
VIVAL PERSISTS AFTER MULTIVARIATE ADJUSTMENT
D. Zarate1, S. Colquist1, R. Bowman2, K. Fong2 1Queensland Cancer Control
Analysis Team, Queensland Health, Brisbane, Queensland/AUSTRALIA; 2The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA
Lung cancer survival is poorer in rural compared to urban areas of Queens-
land. To determine if this is due to geographic differences in patient
morbidity or treatment, we used multivariable regression to analyse the risk
of dying within 2 years of cancer diagnosis among 13,329 Queensland
residents diagnosed with lung cancer from 2000 to 2007. With the largest
population centre (region A) as the baseline, the crude relative risk (RR) of
2-year mortality outside the capital was lowest in the two regions closest to
it – regions B (RR 1.01, 95% confidence interval [CI] 0.97-1.05) and C (RR
0.97, CI 0.94-1.01) – and higher in all areas more than 100 km away from
the capital, with region F, a centre about 1,000 km from it, having the highest
crude mortality risk ratio of 1.16 (CI 1.09-1.22). Comorbidities, tumour
resection, and acuity of care were all significant predictors of mortality and
their rates varied across regions, but adjustment for them did not alter the
geographic trend in mortality and increased the risk estimate for region F to
1.32 (CI 1.10-1.56). These results indicate that geographic differences in
lung cancer outcomes in Queensland exist even when differences in treat-
ment and morbidity are taken into account. Particular attention should be
given to one region where the mortality may be high even among those with
surgically curable disease.
Disclosure: D. Zarate: has declared no conflicts of interest.
CORRELATION OF A PROPOSED LUNG ADENOCARCI-
NOMA CLASSIFICATION SURVIVAL AFTER SURGERY
P. Russell1, Z. Wainer1, G. Wright1, M. Conron1, M. Daniels2, R. Williams1
1St Vincent’s Hospital, Fitzroy, Victoria/AUSTRALIA; 2Mildura Base Hos-
pital, Mildura, Victoria/AUSTRALIA
Aim: To determine whether accurate histomorphological classification of
lung adenocarcinoma predicts overall survival.
Methods: Two hundred and four patients with surgically resected stages I, II
and III lung adenocarcinoma were identified. Using the proposed multidis-
ciplinary adenocarcinoma classification of the European Respiratory Society,
the American Thoracic Society and the International Association for the
Study of Lung Cancer, comprehensive histologic subtyping was performed.
Two pathologists developed guidelines to apply the proposed classification
system and then independently identified the predominant histologic subtype.
Discordance was resolved by consensus at a double-headed microscope. We
modified the groupings in the proposed classification and assigned patients
into three morphologically related groups. These were Group-1 - “lepidic”
based (adenocarcinoma-in-situ, minimally invasive and lepidic predominant
adenocarcinomas), Group-2 - “glandular” based (papillary predominant and
acinar predominant adenocarcinomas) and Group-3 -“other” (mucinous,
colloid, micropapillary and solid with mucin predominant adenocarcinomas).
Pathologists were blinded to patient outcome. The three groups were then
correlated with survival using the Kaplan-Meier method.
Results: One hundred and sixteen males with age range 30-91 years and 88
females with age range 29-84 years with complete resection of pathologically
confirmed non-small cell lung cancer were followed for a median of 45 months.
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Five-year survivals of the groups were: Group-1 - 93%; Group-2 - 66%; Group-3
- 40%. These differences were statistically significant (P0.00001).
Conclusion: We used the proposed adenocarcinoma classification to stratify
patients into three groups which strongly correlated to 5-year survival. We
believe that this could be used as an additional tool in the decision-making
process for adjuvant therapies.
Disclosures: Z. Wainer: recipient of the Royal Australasian College of
Surgeons 2010 Raelene Boyle Scholarship. All other authors have declared
no conflicts of interest.
YOUNG INVESTIGATOR/FELLOW ABSTRACT
ORALS
THE IMPACT OF PHYSICAL ACTIVITY ON FATIGUE
AND QUALITY OF LIFE IN LUNG CANCER PATIENTS
(PAL STUDY): ONE YEAR SCREENING RESULTS
H. Dhillon1,2, A. Parkes1, M. Boyer4, L. Horvath4, SJ. Clarke3,5,
J.L. Vardy1,3,5 1Centre for Medical Psychology & Evidence-based Decision-
making, Central Clinical School, Sydney Medical School; 2Centre for Med-
ical Psychology & Evidence-based Decision-making, School of Psychology,
Faculty of Science, The University of Sydney, Sydney, New South Wales/
AUSTRALIA; 3Sydney Cancer Centre, Concord Repatriation General Hos-
pital, Concord, New South Wales/AUSTRALIA; 4Sydney Cancer Centre,
Royal Prince Alfred Hospital, Camperdown, New South Wales/AUSTRALIA;
5Concord Clinical School, Sydney Medical School, The University of Sydney,
Sydney, New South Wales/AUSTRALIA
Background: The impact of physical activity on function, quality of life and
progression free survival of people with incurable lung cancer is unknown.
PAL is a randomised controlled trial of a 2-month physical activity inter-
vention in this population.
Aim: To determine the proportion of lung cancer patients suitable for the
PAL study, and reasons for non-participation.
Methods: Summary details of thoracic cancer patients seen at participating
hospitals, reasons for ineligibility or non-participation are presented.
Results: Two hundred and seventy-one people with thoracic malignancies
were screened June 2009 - July 2010. Histological types were: non-small cell
201 (74%), small cell 21 (8%), mesothelioma 11 (4%), not recorded at
screening 38 (14%). Ninety-four percent of patients screened have not
entered the study. Of 256 non-participants, the main reasons for ineligibility
were: 46 (18%) were receiving potentially curative treatment, 34 (13%)
unable to exercise, 27 (11%) life expectancy 6 months, 23 (9%) non-
English speaking and 17 (7%) exercising 9 metabolic equivalent hours
weekly. Of the 113 (44%) potentially eligible patients 15 (13%) have been
randomised; reasons for non-participation were: 25 (22%) logistics, 22
(19%) patient choice, 10 (9%) clinician choice, 8 (7%) other or 5 (4%) no
reason recorded. For 28 (25%) the final decision regarding participation had
not been made until anti-cancer treatment was established.
Conclusions: The main reasons for ineligibility were early stage/potentially
curative disease or inability to exercise. As a high proportion of patients were
identified at the beginning of treatment, introducing the trial early and
following patients during treatment will help identify the optimal time to
offer study.
Disclosure: M. Boyer: Sponsored attendance at international meeting: Boehringer
Ingelhiem; All other authors have not declared conflicts of interest.
LUNG CANCER CLINICIAN’ PREFERENCES FOR ADJU-
VANT CHEMOTHERAPY IN NON-SMALL-CELL LUNG
CANCER (NSCLC): WHAT MAKES IT WORTHWHILE
P. Blinman1, S. McLachlan2, A. Nowak3, V. Duric1, G.Wright2,
M. Millward3, C. Brown1, X. Coskinas1, K. Fong4, and M.Stockler1 on
behalf of the Australasian Lung Cancer Trials Group 1NHMRC Clinical
Trials Centre, Sydney, New South Wales/AUSTRALIA; 2St Vincent’s Hospi-
tal, Fitzroy, Victoria/AUSTRALIA; 3The University of Western Australia,
Crawley, Western Australia/AUSTRALIA; 4The Prince Charles Hospital,
Chermside, Queensland/AUSTRALIA
Aims: We sought (i) lung cancer clinicians’ judgements about the smallest
benefits in survival that would make adjuvant chemotherapy for NSCLC
worthwhile, (ii) factors associated with their judgements, and (iii) compari-
sons with breast and colon cancer clinicians surveyed similarly in 2002-3.
Methods: Delegates at the 2008 Australian Lung Cancer Conference were
invited to complete a validated, self-administered questionnaire. Preferences
for adjuvant chemotherapy (4 cycles cisplatin/vinorelbine) were elicited in 4
hypothetical scenarios with baseline survival times of 3 & 5 years and
baseline 5-year survival rates of 50% & 65%. All tests are two-sided and
non-parametric.
Results: Characteristics of the 156 respondents were: median age 41
years(range 23-62), female(55%), married(83%), with dependent children(62%),
respiratory physician(28%), nurse(24%), medical oncologist(14%), radiation
oncologist(12%), trial nurse/coordinator(12%), thoracic surgeon(4%). Most cli-
nicians judged an extra 9 months in survival time sufficient, whether the baseline
was 3 years or 5 years (P0.8). More clinicians judged an extra 5% sufficient
when the baseline survival rate was 65%, than when it was 50% (P0.001).
Smaller benefits were judged sufficient by clinicians who were married (P .01)
or had dependants (P 0.04). The benefits judged sufficient by these lung cancer
clinicians were significantly smaller than those judged sufficient by breast
cancer(n89) and colon cancer(n72) clinicians(e.g 9 months sufficient for
60% v 42%, P 0.002).
Conclusion: The survival benefits judged sufficient by lung cancer clinicians
were moderate, smaller for clinicians who were married or had dependents,
and smaller than benefits judged sufficient by breast and colon cancer
clinicians 5-6 years earlier. Clinicians should be aware of their own prefer-
ences when discussing adjuvant chemotherapy for NSCLC.
Disclosure: P. Blinman: has declared no conflict of interest. M. Millward:
Advisory Board Member: Roche, Eli-Lilly, Boehringer Ingelheim, Travel
support: Roche; M. Stockler: Our groups are currently doing trials partly
supported by AZ, Bionomics, Bayer, Roche, Pfizer, Novartis, MSD. I have
received honoraria for educational presentations from Novartis, Pfizer, MSD,
Roche. All other authors have not declared conflict of interest.
THE PROGNOSTIC SIGNIFICANCE OF HIGH RISK FEA-
TURES IN RESECTED NSCLC: A SINGLE INSTITUTION
RETROSPECTIVE REVIEW
A. Hansen1, M. Colosimo2, K. Fong1, IA. Yang1, RV. Bowman1, BE.
Clarke1, EE. Duhig1, K. Matar1, M. Windsor1 1The Prince Charles Hospital,
Chermside, Queensland/AUSTRALIA; 2The Holy Spirit Hospital Northside,
Chermside, Queensland/AUSTRALIA
Background: In 2010 the IASLC released the seventh edition of the TNM
staging for NSCLC. There was no comment about the relevance or effect that
particular high risk features like vascular invasion, lymphatic permeation and
perineural invasion have on prognosis for resected NSCLC.
Method and Patients: This is a retrospective review of 965 patients (627 M,
338 F) who underwent surgical resection for NSCLC from 1997 to 2009 at
the Prince Charles Hospital (TPCH). The pathology reports were reviewed
for the presence of the following variables: vascular invasion, lymphatic
permeation and perineural invasion. Patients were then stratified by these
variables and analysed according to their stage in terms of overall survival by
the Kaplan-Meier method.
Results: Of the 965 patients who were reviewed 22.2% and 33.2% were
stages 1A and 1B respectively while 19.1% were stage 2. There were 384
(39.1%) patients with vascular invasion, 232 (23.6%) with lymphatic
permeation and 89 (9.1%) with perineural invasion. For each of the
previously mentioned high risk variables a univariate analysis revealed
that the median overall survival was significantly worse for the cohort of
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patients whose resected specimens contained any of these factors. The
multivariate Cox regression analysis and stage specific survival data is
currently being undertaken.
Conclusion: This large single institution review reveals that patients with
resected NSCLC who have any of the high risk features have a significantly
worse prognosis in terms of overall survival, in comparison with patients
who lack these variables. While this is a preliminary statistical analysis these
results suggest that Stage I patients with high risk features should be
evaluated prospectively, in the clinical trial setting, for the potential benefit
of adjuvant treatment.
Disclosure: All authors have declared no conflicts of interest.
DOES SUVmax PREDICT SURVIVAL IN NON-SMALL
CELL LUNG CANCER
M. Daniels1, Z. Wainer2, J. Callahan3, B. Solomon3, D. Binns3, R. Hicks3, P.
Russell4, M. Conron4, N. Alam4, P. Antippa5, G. Wright2 1Alfred Health,
Melbourne, Victoria/AUSTRALIA; 2The University of Melbourne, Depart-
ment of Surgery, St Vincent’s Hospital, Fitzroy, Victoria/AUSTRALIA; 3Pe-
ter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 4St Vin-
cent’s Hospital, Fitzroy, Victoria/AUSTRALIA; 5The Royal Melbourne
Hospital, Parkville, Victoria/AUSTRALIA
Background: The prognostic role of SUVmax in lung cancer has been
extensively investigated. We examined the potential prognostic role of
SUVmax in the multi-disciplinary team meeting setting.
Methods: Patients who underwent surgical resection of pathologically
proven non-small cell lung cancer with curative intent were identified from
a prospectively maintained surgical database. SUVmax was calculated by a
single operator using a purpose designed software program. Receiver oper-
ator curve analysis was used to determine the optimal SUVmax cutoff to
predict all-cause mortality. Kaplan-Meier survival analysis, log rank test and
Cox regression were used to examination the correlation between SUVmax
and survival in patient subgroups based on characteristics available in the
multi-disciplinary team meeting context; age, sex, smoking status, Eastern
Cooperative Oncology Group (ECOG) performance status, tumour size,
nodal status and tumour histopathologic subtype.
Results: Appropriately formatted PET scans were available for 218 patients
who met inclusion criteria. An optimal SUVmax cutoff of 8.06 to predict
mortality was selected. Univariate analysis demonstrated this cutoff pre-
dicted prognosis for males (P0.001), ECOG 0 (P0.007), ever smokers
(P0.002), never smokers (P0.006), those without nodal metastases
(P0.001), adenocarcinoma (P0.001) or squamous cell carcinoma
(P0.008). Multivariate analysis demonstrated SUVmax provided prognos-
tic information after correcting for each examined patient and tumour factor.
This cut off did not predict prognosis for females.
Conclusions: SUVmax provides prognostic information that could contrib-
ute to the decision making algorithm in the multi-disciplinary setting;
prospective validation is required. However, there are important differences
between males and females in the behaviour of disease and usefulness of
SUVmax.
Disclosure: Z. Wainer: Recipient of the Royal Australasian College of
Surgeons 2010 Raelene Boyle Scholarship. All other authors have declared
no conflicts of interest.
THE RELATIVE UTILITY OF CYTOLOGY AND HISTOL-
OGY SPECIMENS IN ASSIGNING NSCLC PATHOLOGI-
CAL SUBTYPES
A. Campbell1, T. John1, M. Newman1, S. White1, P. Mitchell1 1Austin
Health, Heidelberg, Victoria/AUSTRALIA
Aims: Pathological subtypes of non-small cell lung cancer (NSCLC) have
important implications for prognosis and treatment. Subtyping may prove
difficult with cytology specimens, but may be the only tumour tissue
available. We reviewed NSCLC cases to determine the rate of histological
versus cytological diagnoses and the ability to determine a subtype.
Methods: Records of patients newly diagnosed with NSCLC during 2007-
2009 were reviewed. Cases were identified as having definitive versus
suspected histological or cytological subtypes or NSCLC not otherwise
specified.
Results: Of 129 cases, 83 (64.3%) had histology compared to 41 cases
(31.7%) who had cytology only. Five patients were treated expectantly
without definitive histology. Immunohistochemistry was available for some
cases to support the diagnosis. Patients with cytology only tended to be older
(median age 70 years, range 52- 94) compared to patients who had histology
(median age 68 years, range 38-87; P0.09), had poorer performance status
and more comorbidities. There were no significant differences in clinical
stage between the groups. The majority were stage IV. A subtype was more
likely to be assigned in patients who had histology compared to cytology
only (46.9% vs 24.3%; P0.012). In 45 cases both histology and cytology
was available. In 20 cases histology provided additional diagnostic informa-
tion, whilst in 7 cases cytology was superior to histology. In 6 cases cytology
was diagnostic despite negative histology. There was a trend toward worse
median overall survival in the cytology only group (6.18 months vs 7.6
months; P0.18).
Conclusions: Cytology is a useful adjunct to the diagnosis of NSCLC, however
histology more commonly provides definitive subtyping and every effort should
be made to obtain histological samples where clinically appropriate.
Disclosure: All authors have declared no conflicts of interest.
DEVELOPMENT AND EVALUATION OF DVD TITLED
“LUNGCANCER, UNDERSTANDING, MANAGING, LIVING”
L. Mileshkin1, A. Hatton1, J. Rice1, M. Duffy1, M. Jefford1, 2, A. Spillare2,
D. Wenzel1, K. Callaghan3 1Department of Nursing and Supportive Care
Research, Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRA-
LIA; 2Cancer Information and Support Service, Cancer Council Victoria,
Carlton, Victoria/AUSTRALIA; 3The Australian Lung Foundation, Brisbane,
Queensland/AUSTRALIA
Aim: To evaluate the acceptability and usefulness of a 69-minute audiovisual
resource in which health-professionals present evidence-based information
about lung cancer, available treatments and available support resources.
Patients and carers also share their stories. It is available free of charge as a
DVD, as well as on-line at http://www.kjlcn.org.au/pages/resources.php
Methods: Members of the Peter MacCallum lung multi-disciplinary team
and 2 community support groups were invited to complete an evaluation
form which asked questions about the acceptability, comprehensiveness and
usefulness of the DVD. A link to the evaluation form was also placed on the
web-site and the number of downloads of the DVD from the web-site was
monitored post-release.
Results: From 01/03/2010 to 30/06/2010, there were 1062 ‘hits’ on the
website to download DVD chapters and 2000 DVDs ordered. Fifty-five
evaluations were received; 36 health-professionals and 19 people affected by
lung cancer (including 10 patients). Fifty of 55 respondents (91%) found the
DVD an appropriate length and 100% liked the format. Twelve respondents
(22%) would have preferred additional information, particularly about man-
aging weight loss and accessing support groups. Fourteen respondents (25%)
thought some content maybe distressing, particularly prognostic information.
Sixteen respondents (29%) reported they learnt new information, particularly
about lung cancer and available treatments. Responses from people affected
by lung cancer and health-professionals were similar although fewer health-
professionals learnt new information (19% vs 47%: p  0.06).
Conclusion: An audio-visual resource about lung cancer has been a popular
and well-received source of additional information for people affected by
lung cancer.
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Disclosure: The project was been funded through a Cancer Australia grant,
as well as additional funding provided by The Australian Lung Foundation,
The Calvert-Jones Foundation and The Toccolan Club. All authors have
declared no further conflicts of interest.
CANCER CONTROL
DO MULTIDISCIPLINARY TEAMS IMPROVE LUNG CAN-
CER OUTCOMES
S. Vinod1, 2, M. Boxer1, J. Shafig1, 2, K. Duggan3 1Collaboration for Cancer
Outcomes, Research & Evaluation, Liverpool Hospital, Liverpool, NSW/
Australia, 2South Western Sydney Clinical School, The University of NSW,
Sydney, New South Wales/Australia, 3Sydney South West Area Health Ser-
vice Clinical Cancer Registry, Liverpool Hospital, Liverpool, New South
Wales/Australia
Background: There is limited research on the impact of multidisciplinary
team meetings in lung cancer. This study aimed to compare patterns of care
of new lung cancer patients presented at a lung cancer multidisciplinary team
(MDT) meeting with those not presented during the same time period.
Methods: All new lung cancer patients diagnosed in South West Sydney
(SWS) between 1st December 2005 and 31st December 2008 were identified
from the local Clinical Cancer Registry (CCR). Patient and tumour charac-
teristics and treatment utilisation were compared between patients presented
at the MDT meeting and those not presented. A logistic regression model
was constructed to determine predictors for receiving treatment.
Results: 504 patients had MDT discussion and 484 patients had none. The
median age was 69 and 73 years respectively (P0.01). There was no
pathological diagnosis for 12% of non-MDT patients compared with 4% of
MDT patients (P0.01). Treatment utilisation for MDT vs non-MDT pa-
tients was 12% vs 13% for surgery (PNS), 66% vs 33% for radiotherapy
(P0.001), 46% vs 29% for chemotherapy (P0.001), and 66% vs 53% for
palliative care (P0.001). In patients with good performance status, the
MDT group had significantly better radiotherapy utilisation in Stage I-IV
NSCLC and chemotherapy utilisation in Stage IV NSCLC. MDT discussion
was an independent predictor for receiving radiotherapy, chemotherapy and
for referral to palliative care.
Conclusions: MDT discussion of lung cancer patients was an independent
predictor of radiotherapy utilisation, chemotherapy utilisation and palliative
care referrals. This could potentially improve outcomes of lung cancer
patients.
Disclosure: S. Vinod and K. Duggan have declared no conflicts of interest.
All other authors have not declared conflicts of interest.
ROUTINE DATA FOR MEASURING
M. Coory, Cancer Council Victoria, Carlton, Victoria/AUSTRALIA
Background: Not all lung cancer patients receive state-of-the-art care and
providing regular feedback to clinicians might reduce this problem. The
purpose of this study was to assess the utility of various data sources in
providing feedback on the quality of care for lung cancer.
Methods: Published clinical practice guidelines were used to obtain a list of
processes-of-care of interest to clinicians. These were assigned to one of four
data categories according to their availability and the marginal cost of using
them for feedback.
Results: Only 5 (6%) of 83 processes-of-care could be measured using
population-based registry or administrative inpatient data (lowest cost). A
further 41 (49%) could be measured using a core clinical registry, which
contains information on important prognostic factors (e.g., clinical stage,
physiological reserve). Another 32 (39%) required an expanded clinical
registry or medical record review; mainly because they concerned long-term
management of disease progression (recurrences and metastases) and 5 (6%)
required patient interview or audio-taping of consultations because they
involved information sharing between clinician and patient.
Conclusions: The advantages of population-based cancer registries and
administrative inpatient data are wide coverage and low cost. The disadvan-
tage is that they currently contain information on only a few processes-of-
care. In most jurisdictions, clinical cancer registries, which can be used to
report on many more processes-of-care, do not cover smaller hospitals. If we
are to provide feedback about all patients, not just those in larger academic
hospitals with the most developed data systems, then we need to develop
sustainable population-based data systems that capture information on prog-
nostic factors at the time of initial diagnosis and information on management
of disease progression.
Disclosure: The author has declared no conflicts of interest.
AUSTRALIA LEADS THE WORLD IN LUNG CANCER IG-
NORANCE AND STIGMATIZATION
M. Peters, Department of Thoracic Medicine, Concord Repatriation General
Hospital, Concord, New South Wales/AUSTRALIA
All genuine attempts to reduce the mortality and morbidity associated with
lung cancer are admirable. However, to introduce molecular testing without
definition of the limits of what that testing should be and the certainty of
actions that should follow a positive or negative test results is premature.
Whilst the paradigm of EGFR might seem superficially fairly simple, there
is no consensus on whether resistance as well as sensitising mutations should
be tested. Further, we are not yet certain what form of language we should
use to describe results, the impact of this knowledge on individuals, whether
results reported should include resistance or the adverse consequence of
EGFR-negative status. In other areas, markers thought to indicate only
treatment responsiveness, may also predict increased adverse experiences
during treatment. If we test for this, why are we testing and how do we factor
it into clinical care? Finally, testing at the cost of the community must return
a health economic benefit that meets the reasonable standard. This requires
the clinical discipline not to use treatments, cheap or expensive, when effect
is below the agreed efficiency threshold – no matter what. We have not as a
cancer care community demonstrated that discipline but it is an essential
precondition before rational investment should take place in this area of
health care.
Disclosure: M. Peters: Advisory Board Member: GlaxoSmithKline, Ny-
comed, Novartis, AstraZeneca; Honoraria for CME: Pfizer; ERS Travel
Support: Nycomed.
TOBACCO CONTROL
F. Sharkie, Quit Victoria, Melbourne, Victoria/AUSTRALIA
The past ten years in Australia have seen significant declines in smoking
rates across adult males and females, as well as youth. Much of the success
of tobacco control can be attributed to the effective use of strategies, that
when used in combination, generate significant declines in smoking. The
Australian government recently announced their intent to legislate the pack-
aging of cigarettes in generic or ‘plain’ packs; a reform not seen anywhere
else in the world. By July 2012, Quit’s aspiration will be to see all cigarette
packets sold in generic cardboard packs with larger graphic health warnings.
The announcement of plain packaging is the realisation of a goal of tobacco
control organisations to eliminate the last remaining form of advertising
space for the tobacco industry – the cigarette pack. Research conducted with
smokers indicates that smokers associate certain positive attributes with
current cigarette packaging, whereas plain packaging was found to elicit less
of a positive association. The implementation of plain packaging is thereby
critical to eliminate the appeal or enticement associated with smoking
(particularly for young people). The campaign for plain packaging will not
be without its threats; the tobacco funded Alliance of Australian Retailers
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launched a $5mill television, print and radio campaign in an attempt to
discredit plain packaging. The challenge for tobacco control advocates is to
continue to present the evidence & case for plain packaging and mobilise
support within the public and government to implement this landmark
reform.
Disclosure: The author has declared no conflicts of interest.
CLOSING CEREMONY – THE FUTURE
ELETROMAGNETIC NAVIGATION BRONCHOSCOPY
M. Phillips, Sir Charles Gairdner Hospital, Nedlands, Western Australia/
AUSTRALIA
The prevalent use of CT imaging of the thorax has led to increased
identification of patients with pulmonary nodules and masses that are
referred for further evaluation and diagnosis. These lesions are frequently
beyond the range of bronchoscopic visualisation. Bronchoscopy with
washings and brushings in these circumstances is often non-diagnostic.
The use of fluoroscopy may improve yields but still has a low success rate
as it is hard to determine if the biopsy forceps are truly within the lesion,
rather than in front or behind. Percutaneous fine needle aspiration biopsy
(FNA) under CT guidance remains an important diagnostic tool but is
associated with a high incidence of pneumothorax (20–35%) especially if
emphysematous changes are present in the lung. In recent years other
diagnostic bronchoscopic techniques have become available. One such
technique utilises an endobronchial ultrasound probe passed through a
guide sheath via a bronchoscope (EBUS-GS) to confirm, by the ultra-
sound image, that the end of the guide sheath is within the lesion. This
approach has proved valuable and has a yield often equivalent to
percutaneous FNA, but with a significantly reduced rate of pneumotho-
rax. The success of EBUS-GS depends on the bronchoscopist’s ability to
pass the probe and guide sheath into the correct part of the lung by
selecting the appropriate segmental and sub-segmental airways. This is
facilitated by a greater knowledge of airway and lung anatomy than has
been traditionally required or taught. Currently a number of software
programmes are being developed to assist this process by selecting an
appropriate bronchoscopic tract in conjunction with virtual bronchoscopy
images created from the CT images of the thorax. Electromagnetic
navigation is a system that employs a steerable catheter that is passed
through a bronchoscope and is guided to the target lesion within the lung
by its location within a low-frequency electromagnetic field that is
generated by a location board placed under the patient. The position of
the sensor at the end of the steerable catheter is referenced to the CT
images of the thorax displayed on a monitor, to virtual bronchoscopy
images also seen on the monitor and to the real time bronchoscopy
images. The software provides information as to where to steer the
catheter to reach the target and the distance of the sensor from the target.
Once the target is reached the sensor is removed allowing the guide
sheath to act as a conduit for biopsies by brushes, forceps and needles.
The position of the tip of the guided sheath or extended channel can also
be confirmed to be within the target lesion by passage of an ultrasound
probe to demonstrate the characteristic ultrasound pattern. EMN can be
used in this way as a diagnostic tool for peripheral lung nodules or masses
with a success rate of approximately 70% for lesions of about 20mm
diameter, and for sampling of lymph nodes with a yield of approximately
94%. EMN can also be used as a therapeutic instrument for the placement
of fiducial markers for stereotactic radiotherapy with a reported success
rate of 89%.
Disclosure: M. Phillips: Advisory Board Member: GlaxoSmithKline, Astra
Zeneca, Nycomed, Boehringer Ingelheim.
POSTER ABSTRACTS
CLEARING THE MIND: A NURSING ASSESSMENT TOOL
FOR THE RECOGNITION AND MANAGEMENT OF
DELIRIUM
J. Mathieson, Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRA-
LIA
Background: Delirium affects up to 85% of patients with advanced cancer.
The aim of this project was to review the literature and establish which was
the most effective and accurate nursing delirium assessment tool for use in
an inpatient cancer unit.
Methods: Medline, Cinahl, Pubmed and PsycINFO were all searched;
twenty two articles were found and reviewed, thirteen articles were found to
be relevant to the project and critically appraised. Reference lists of key
articles were also hand searched and authors were contacted for clarification
when required.
Results: Seven delirium assessment tools were identified in the literature.
Six tools were not appropriate due to the time they took to complete, they did
not accurately recognise all types of delirium and were more appropriate as
a diagnostic tool rather than a screening tool. The Nu-DESC was found to be
the most accurate, effective nursing assessment tool for diagnosis and for
continuous monitoring of severity of symptoms associated with delirium. An
eight week trial on the Head & Neck and Lung Ward at Peter Mac found the
tool to be effective in recognising and monitoring delirium.
Implications for Practice: This tool will allow delirium to be recognised
early and for interventions to be put in place in a timely fashion, thus
improving the nursing care provided and the patient’s quality of life. Work
is currently been done to update the delirium guidelines at Peter Mac and
include the Nu-DESC tool.
Disclosure:
TREATMENT PATTERNS FOR SMALL CELL LUNG
CANCER IN SOUTH WESTERN SYDNEY RESIDENTS
K. Duggan1, S.K. Vinod2,3 1SSWAHS Clinical Cancer Registry; 2Collabo-
ration for Cancer Outcomes, Research and Evaluation (CCORE), Liverpool
Hospital, Liverpool, New South Wales/AUSTRALIA; 3South Western Sydney
Clinical School, The University of New South Wales, Sydney, New South
Wales/AUSTRALIA
Background: In Sydney South West Area Health Service (SSWAHS), lung
cancer represents 10% of all diagnoses, and 21% of all cancer deaths. Small
Cell Lung Cancer (SCLC) represents 13% of all Lung cancers diagnosed
and/or treated in SSWAHS. SCLC is characterized by rapid growth and
widespread dissemination of disease, meaning that optimal treatment is vital
for quality of care and improved survival. The aim of this study was to
evaluate whether SCLC patients were being treated in accordance with
evidence-based guidelines.
Method: SWS residents who had a new diagnosis of SCLC from 2006-2008
were identified from the SSWAHS Clinical Cancer Registry. Treatment
patterns were compared with NHMRC Clinical Treatment guidelines for
Lung cancer. Guideline treatment for patients with limited stage disease and
ECOG 0-3 is chemotherapy and thoracic radiotherapy. In extensive disease
patients ECOG 0-3, guideline treatment is chemotherapy with radiotherapy
reserved for specific symptomatic sites.
Results: 117 eligible patients were identified of which 61% were male. The
median age was 69 years. The stage was limited in 23%, extensive in 70%
and unknown in 7%. ECOG was documented in 70% of cases. 71% of all
SCLC patients received chemotherapy, 50% received radiotherapy and1%
received surgery. 22% of patients received no active therapy. Of those
patients with documented ECOG and known stage, 76% with limited stage
disease and 73% with extensive stage were treated according to guidelines.
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Conclusion: Most SCLC patients identified received active treatment for
their cancer and the majority of treatment provided was guideline recom-
mended.
Disclosure: All authors have declared no conflicts of interest.
EARLY PREDICTIVE VALUE POST CHEMOTHERAPY OF
METABOLIC RESPONSE ASSESSMENT USING FDG-PET
IN NSCLC
T. Meniawy1, A. Davidson2 1Sir Charles Gairdner Hospital, Nedlands,
Western Australia/AUSTRALIA, 2Royal Perth Hospital, Perth, Western Aus-
tralia/AUSTRALIA
Background: Recently there has been interest in the prognostic value of
baseline FDG-PET standardised uptake value (SUV) measured in primary
tumours as well as the predictive value of PET metabolic response criteria.
Objectives: To assess the predictive value on survival of early metabolic
response assessment by FDG-PET before and after treatment of NSCLC.
Methods: We searched MEDLINE and EMBASE, as well as reference lists
for relevant trials, and included studies evaluating FDG-PET metabolic
response assessment, and reporting survival data.
Data Collection and Analysis: Two authors assessed trial quality and
extracted data. We performed a meta-analysis of the difference in median
overall survival between metabolic-responders and non-responders as de-
fined by individual studies. A subgroup analysis of patients treated with
radical or palliative interventions was performed.
Results: Nine studies involving 426 patients were included. Metabolic
responders had an overall survival significantly longer than non-responders
by 13.34 months. Subgroup analysis demonstrated a survival 19.05 months
longer in metabolic responders than in non-responders in patients treated
radically, and 5 months longer in those treated with palliative intent.
Conclusions: Early metabolic response assessment is predictive of survival
in NSLC. Early identification of response to treatment may have clinical
implications for trial design and personalised patient management. Limita-
tions included small numbers, heterogeneity in PET raw data analyses,
metabolic response criteria and therapeutic interventions.
Disclosure: T. Meniawy & A.Davidson: has declared no conflict of interest.
All other authors have not declared conflict of interest.
AN IN-VIVO MODEL OF ACQUIRED CHEMORESIS-
TANCE IN SMALL CELL LUNG CANCER
L. Martelotto1, J. Falzon2, S. Bennett2, T. Brown2 and N. Watkins1 1Monash
Institute of Medical Research; 2Department of Biochemistry and Molecular
Biology, Monash University, Melbourne, Victoria/AUSTRALIA
Small cell lung cancer (SCLC) is an aggressive, highly metastatic tumour
with an extremely poor prognosis. Although SCLC is extremely sensitive to
platinum-based chemotherapy, a lethal chemoresistant recurrence occurs in
most cases. The clinical challenge is therefore to prevent recurrence, rather
than improve on already effective chemotherapy regimens. The mechanisms
of this acquired chemo-resistance are not understood. This is due, in part, to
the reliance on conventional cell line models that may not reflect the
responses of these tumours to chemotherapy in vivo. We asked whether the
acquisition of chemo-resistance in SCLC in vivo is associated with a
common set of transcriptional adaptations. To address this question, we used
a novel primary xenograft model of SCLC derived from chemo-naive
patients passaged exclusively in immunodeficient mice. In this model,
repeated cycles of cis-platinum therapy led to the rapid acquisition of
chemoresistance. By serially sampling tumours using fine needle aspiration,
we collected RNA and DNA from three independent SCLC primary xeno-
grafts during the development of chemoresistance. Since Hedgehog (Hh)
signalling has been implicated in the maintenance of self-renewal in SCLC,
we analysed the expression of 84 Hh pathway genes in this model. This
revealed a unique gene expression pattern consistent with a dramatic and
novel mode of Hh pathway activation during the acquisition resistance to
cis-platinum. This gene set may be useful in predicting the response to Hh
pathway antagonists in patients with SCLC.
Disclosure:
A CASE FOR CAUTION: COMPOUNDING FACTORS IN
THE INTERPRETATION OF PET/CT IN LUNG CANCER
K. Bowden1, K. Steinke1, O. Ramuz1 1The Royal Brisbane and Women’s
Hospital, Herston, Queensland/AUSTRALIA
Introduction: We report a case which illustrates the short comings of
Positron Emission Tomography (PET) and Computer Tomography (CT) in
accurately staging squamous cell carcinoma. This case demonstrates the
importance of awareness of the conditions which decrease the specificity of
radiological diagnosis and thus necessitate definitive histological diagnosis.
Case: A sixty eight year old farmer with a strong smoking history presented
to his regional hospital with pneumonic symptoms where a CT chest was
arranged. This revealed a 3.7cm  3.8cm obstructing right upper lobe mass
which biopsy showed to be squamous cell carcinoma. Transfer to a tertiary
hospital was arranged for further staging of a suspicious 17mm subcarinal
node using PET. The high standardised uptake values of both the primary
tumour (12.5) and the subcarinal node (8.7) further increased suspicion for
lymphatic malignant spread. Due to this high suspicion mediastinoscopy of
the subcarinal node was performed despite a negative transbronchial biopsy.
Both biopsies confirmed benign anthracosis.
Conclusion: This case highlights that although the sensitivity of CT-PET is
high (94%) the positive predictive value is low (64%). Interpretation of
results should not be made in isolation, but in conjunction with clinicians
who are aware of any known false positive conditions present in each specific
case. In this case, the complicating factors included smoking, pneumonia and
nodal position all of which lowered the predictive value of the CT-PET
results. Greater knowledge of these compounding factors is an essential
component in interpretation of results and justification for invasive histolog-
ical staging procedures.
Disclosure: All authors have declared no conflicts of interest.
HDA l P-MEDICATED PREVENTION OF RECRUITMENT
OF GCN5P IN THE PROMOTER OF ANAPHASE PROMOT-
ING COMPLEX REGULATORS IN SACCHAROMYCES
CEREVISIAE
A. Islam1, E. Turner1, T. Harkness1 1Department of Anatomy and Cell
Biology, College of Medicine, University of Saskatchewan, Saskatoon, SK,
S7N 5E5/ CANADA
Background: Histone acetyltransferases (HATs) and histone deacetylases
(HDACs) play central roles in chromatin metabolism, yet their in vivo
functions and regulation remain largely unknown. HDAC inhibitors, aberrant
histone acetylation and DNA methylation are under investigation for their
potential as therapeutic agents/diagnostic markers in cancer. HATs and
HDACs are conserved from yeast to humans, thereby making yeast an
attractive model system for clinically relevant research.
Objective: To explore the genetic interactions of HATs and HDACs with
Anaphase Promoting Complex (APC) subunits and their subsequent effects
on chromatin metabolism.
Methods: Spot dilution, Western blotting, Northern blotting, rtPCR and
chromatin immunoprecipitation (ChIP).
Results: Deletion of either the GCN5 or HDA1 gene leads to a similar
temperature sensitive (ts) phenotype of the apc5 CAallele. However, deletion
of both GCN5 and HDA1 nullify each other so that their ts effects disappear
and go back to the apc5CA phenotype. Compared to WT, the mRNA levels
were decreased 20-30% in apc5gcn5, increased 20-30% in apc5hda1 and
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set somewhere in between in apc5gcn5hda1. These transcript level varia-
tions of all APC regulators comply with their promoter H3(K9/K14) acety-
lation. The overexpression of GCN5-HA and HDA1-HA and their subse-
quent promoter binding was followed by ChIP analysis. The Gcn5-HA
binding was 2-3 fold increased in the promoter in gcn5hda1, compared to
gcn5, which indicates that Hda1p prevents the access of Gcn5p in the
promoter of APC regulators.
Conclusion: Collectively, the data indicate that Hda1p prevents the recruit-
ment of Gcn5p in the promoter of APC regulators.
Disclosure: A. Islam: has declared no conflict of interest. All other authors
have not declared conflicts of interest.
PATTERNS OF CARE FOR LIMITED-STAGE SMALL-CELL
LUNG CANCER IN A REGIONAL/RURAL SETTING – A
NORTH QUEENSLAND EXPERIENCE
Z. Otty1, J. Dass2, S. Varma1, S. Sabesan1 1Department of Medical Oncol-
ogy, Townsville Hospital; 2Department of Radiation Oncology, Townsville
hospital, Townsville, Queensland/AUSTRALIA
Aim: For treatment of limited-stage small cell lung cancer (LS-SCLC), Concurrent
chemo radiotherapy (CRT) using accelerated hyper fractionation with cisplatin and
etoposide is recommended during first or second cycle of chemotherapy. Aim is to
look at the pattern of CRT for small-cell lung cancer in Townsville hospital which
caters to a large rural area.
Methods: Review of medical records of all patients with small-cell lung cancer
patients treated from 2006 to 2009.
Results: Of the 19 patients with LS-SCLC, 15were treated with radical intent CRT
during this period. Only 33% received radiotherapy with first 2 cycles of chemo-
therapy, 47% received it in subsequent cycles and 20% received radiation sequen-
tially. The reasons for delay in radiotherapy included difficulty in co-ordinating
chemotherapy in the peripheral centres and radiotherapy at the tertiary centre,
patients’ choice and physicians’ preference. 10 patients had CRT using Turrisi
protocol and 5 using standard fractionation. Mean number of chemotherapy cycles
were 5. In total, 10 patients had complete response and 5 had partial response. On
follow-up, 2 patients each from Turrisi protocol group and standard protocol group
are still alive. CTC grade 3/4 oesophagitis and myelosuppression were more
common in Turrisi group.
Conclusion: Ideal timing and protocols of chemo-radiotherapy is not always
feasible for regional and rural patients for several reasons and whether it impacts on
the outcome would be only possible with larger prospective studies.
Disclosure:
PROFILE OF LUNG CANCERS FROM A TERTIARY CARE
CENTRE IN SOUTH INDIA – AN INCREASING TEND
WITH A PARADIGM SHIFT
V. Thanasekaraan1, A. Rekha1, Safreena Mohamed1, N.S.J. Sundar1,
T. Dhanasekar1, B. Rajagopalan1 1Sri Ramachandra Medical College and
Research institute, Chennai, S INDIA
Aim: To review the types of lung cancers at a tertiary care centre in the past
decade. To study the demographics of these patients and to analyze the
changing trends of presentation.
Patients and Methods: A retrospective analysis, of proven cases of lung
cancer, was carried out from June 2000 to June 2010 at Sri Ramachandra
Medical College and Research Institute, Chennai, S. India. The data obtained
from medical records, pathology files, radiology archives were analyzed.
Results: There was a total of 237 patients with an increasing trend. Eighty
three patients (35%) were in the age group of 51-60 years. The males
accounted for 81% of the tumors. 57% occurred on the right side (upper lobe
50%, middle lobe 8% and lower lobe 42%). Of 43% of cancers on the left
side, 71% were in the upper lobe and 29% were in the lower lobe.
Peripherally located tumors constituted 82% and 18% wer. central lesions.
Poorly differentiated non small cell carcinoma the most common type of
tumor constituted 40%. Adenocarinomas accounted for 24% (including 3%
of bronchioalveolar carcinomas). Squamous cell carcinoma constituted
13%,small cell carcinoma (5%), adenosquamous (2%) and the rest were large
cell carcinomas and pulmonary blastomas. Thirty percent of the tumors in
women were adenocarcinomas.
Conclusions: We observed an increase in the incidence of lung cancers over
the last ten years and a drastic spike over the last three years. The numbers
of males were more as is consistent with the rest of the world. The non small
cell lung cancer-poorly differentiated carcinoma accounted for the largest
faction and there was an increase in adenocarcinomas over squamous cell
carcinoma.
Disclosure: All authors have declared no conflicts of interest. There was no
funding for this study.
SURGERY FOR LUNG CANCER IN VICTORIA: THE CASE
FOR PROSPECTIVE CLINICAL DATA COLLECTION
G.M Wright1, V. Thursfield2, D. Ball3, G. Richardson4, L. Irving5,
Y. Torn-Broers2, P. Mitchell6 1St Vincent’s Health, Fitzroy, Victoria/AUS-
TRALIA; 2Cancer Council Victoria, Carlton, Victoria/AUSTRALIA; 3Peter
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 4Cabrini
Medical Centre, Malvern, Victoria/AUSTRALIA; 5Melbourne Health,
Parkville, Victoria/AUSTRALIA; 6Austin Health, Melbourne, Victoria/
AUSTRALIA
Aim: A management survey of lung cancer in Victoria in 2003 was
commissioned by the Victorian Cooperative Oncology Group to educate and
promote optimal management of this disease. Results from a similar survey
in 1993 were available to identify changes in the disease or its management.
This paper outlines the surgical care of patients diagnosed with non-small
cell lung cancer (NSCLC) in the study period.
Methods: All patients diagnosed with lung cancer in the first 6 months of
2003 were identified from the Victorian Cancer Registry. Registry research
staff completed a detailed questionnaire using primary source documents
from hospitals and consulting rooms. The survey data was then de-identified
with respect to patient and treating clinician prior to statistical analysis.
Results: From 921 eligible cases identified, 841 surveys were completed
(91.3%). NSCLC was confirmed in 655. Thoracotomy was performed in 145
cases (22%), only 130 receiving the intended resection (90%). Compared to
1993, significant differences were increased use of pre-operative PET scan-
ning (79% vs. 0%), fewer resections (20% vs. 25%), lower pneumonectomy
rate (14% vs. 25%) and higher sub-lobar resection rate (22% vs. 11%).
30-day mortality remained below 2%. Positive resection margins were much
higher than expected (21%). There was minimal difference in 5-year survival
between surveys.
Conclusions:We have retrospectively identified problems in surgical cancer
care in 2003. In particular, unacceptably high positive margin rates. Pro-
spective data collection would have allowed earlier intervention. Survival
was unchanged from 1993 despite lower resection rates, suggesting either
lost opportunities to cure or better selection for surgery.
Disclosures: All authors have declared no conflicts of interest.
FUNCTIONAL DECLINE IN PATIENTS WITH ADVANCED
STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
A. Murnane1, M. Krishnasamy1, L. Denehy2, C. Granger2, S. Aranda1 3,
L. Mileshkin1 1Peter Maccallum Cancer Centre, Melbourne, Victoria/AUS-
TRALIA; 2Department of Physiotherapy; 3The School of Nursing, The
University of Melbourne, Melbourne, Victoria/AUSTRALIA
Background: Patients with advanced NSCLC decline physically over time.
This study aimed to quantify the physical function and health-related quality
of life (HRQoL) of patients with advanced NSCLC.
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Methods: A descriptive cohort study was performed. Patients with stage III
and IV NSCLC were recruited within one month of starting treatment and
completed assessments bi-monthly to six months or until they became too
unwell. HRQoL and functional status data were collected using the EORTC
QLQ-C30, the 6-minute walk distance (6MWD) and timed up and go test
(TUG). Preliminary results are presented.
Results: 20 patients with a mean age of 61 years (9 males) had a mean
6MWD at baseline of 407.1m, significantly lower than predicted for age, sex
and height (579.8m). This significantly declined from baseline to 2 months
(n15) by a mean of 29.9m (95%CI:1.8 to 57.9; P0.03), with a non-
significant decline from baseline to 4 months (n11) of 47.2m (95%CI:5.9
to 100.5; P0.76). Time taken to complete the TUG increased (worsened)
significantly from baseline (mean 7.82 seconds) by a mean 0.73 seconds
(95%CI:0.38 to 1.09; P0.001) at 2 months (n15) and a mean of 1.03
seconds (95%CI:0.52 to 1.53; P0.001) at 4 months (n11). Despite the
decline in physical function, self-reported fatigue significantly improved
from baseline to 4 months, and global HRQoL remained stable.
Conclusions: Patients with advanced NSCLC have clinically significant
lowered physical function at commencement of treatment. Function contin-
ues to decline significantly over time, despite improvements in self-reported
fatigue, and interventions to address this are needed.
Disclosure: Funding: NHMRC Palliative Care Grant.
EPIGENETIC INACTIVATION OF SFRP FAMILY BY DNA
METHYLATION IN MALIGNANT MESOTHELIOMA
Y. Cheng1, H.C. Jin, F.K.L. Chan, L. Schedlich1, M. Kirschner1, N. van
Zandwijk1, G. Reid1 1Asbestos Diseases Research Institute, Bernie Banton
Centre, University of Sydney, NSW, AUSTRALIA
Epigenetic inactivation of tumour suppressor genes plays a crucial role in the
progression of cancers including malignant mesothelioma (MM). Inappro-
priate silencing of critical genes can result in the inactivation of tumour
suppressed genes (TSGs). Reactivation of affected TSGs has therapeutic
potential in mesothelioma. DNA hypermethylation is the most well recog-
nized epigenetic change in regulating gene expression. Previous studies
shown that the secreted frizzled related protein (SFRP1), the non-receptor
antagonist of Wnt, is downregulated in a subset of cancers by an undeter-
mined mechanism. Recently, it was shown that the down-regulation of
SFRP2 gene family in gastric cancer, colorectal cancer and mesothelioma
was mediated by methylation silencing. In this study, we aimed to investigate
the relationship between gene silencing and DNA methylation of SFRP gene
family in MM. We first looked at the changes in gene expression of SFRP
MM cell lines upon treatment with the demethylating agent 5’Azacitidine.
The mRNA expression level of SFRP was studied using conventional
RT-PCR, and DNA methylation analysis was examined using COBRA,
methylation specific PCR (MSP) and bisulfite sequencing. Our results
indicated that these genes are reactivated by DNA demethylation, suggesting
that epigenetic inactivation of SFRP gene family could be a common event
in MM which may play a pivotal role on MM development.
Disclosure: Y. Cheng and M. Kirschner: has declared no conflicts of interest.
N. Van Zandwijk: Advisory Board Member: Merck Serono, Pfzier and
Boehringer Ingelheim, Eli Lilly; Speaker’s Bureau: Eli Lilly. All other
authors have not declared conflicts of interest.
KNOCKDOWN OF Y-BOX-BINDING PROTEIN l INDUCES
SUBTYPE-SPECIFIC GROWTH INHIBITION IN MALIG-
NANT MESOTHELIOMA CELLS
M. Kirschner1, L. Schedlich1, Y. Cheng1, N. van Zandwijk1, G. Reid1
1Asbestos Diseases Research Institute, Bernie Banton Centre, The University
of Sydney, Sydney, New South Wales/AUSTRALIA
The overexpression of the DNA-and RNA-binding protein Y-Box-binding
protein 1 (YBX-1) has been shown to be associated with late stages of
disease and a poor prognosis of various cancers. Furthermore, YBX-1 is
associated with the RNA-induced silencing complex which is important for
the biogenesis of microRNAs. As the identification of novel therapeutic
targets for malignant mesothelioma (MM) treatment is an important unmet
need, the aim of our study is to investigate whether targeting YBX-1 in MM
might represent a novel therapeutic option. We have used RNA interference
to investigate the effects of YBX-1 knockdown in established ATCC and
primary MM cell lines. Growth inhibition was measured by SYBR Green
staining of DNA and mRNA expression was quantified by RT-qPCR.
Preliminary results indicate a subtype-specific effect on cell growth. Al-
though in all cell lines transfection with YBX-1 siRNA leads to a reduction
of YBX-1 mRNA expression of 80-90%, the effect on cell growth is variable.
4 days after transfection the growth of the biphasic cell lines MSTO-211H
and MM05 is reduced by 50-80%, but only one of the epithelioid cell lines
used, H2452, showed similar effects, while there was no growth inhibition in
H28 and H2052 or the desmoplastic MM04 cell line. Further experiments
with NCode arrays have identified ncRNAs and miRNAs expressed in MM
lines and preliminary data suggest changes following YBX-1 knockdown.
With subtype-specific effects on cell growth and the development of a
specific inhibitory peptide, YBX-1 represents a potential therapeutic target in
MM.
Disclosure: M. Kirschner: has declared no conflicts of interest. N. van
Zandwijk: Advisory Board Member: MerckSerono, Eli Lilly, Pfizer, Boehr-
inger Ingelheiml Speaker’s Bureau: Eli Lilly. All other authors have not
declared conflicts of interest.
HDA l OCCULSION OF GCN5 RECRUITMENT TO PRO-
MOTERS ALTERS THE GROWTH PROPERTIES OF
ANAPHASE PROMOTING COMPLEX MUTANTS IN
YEAST
A. Islam1, E.L. Turner1, T.A.A. Harkness1 1Department of Anatomy and Cell
Biology, University of Saskatchewan, Saskatoon, SK, S7N 5E5/CANADA
Histone modifications, such as histone acetylation, play major roles in gene
expression. In yeast, many proteins have been characterized that add and
remove acetyl groups from a broad spectrum of histone lysine residues.
Histone acetylation is most often associated with gene transcription, whereas
removal of acetyl groups usually reflects gene silencing. Furthermore, some
histone modifying enzymes have global functions while others act at specific
genes. Nonetheless, the regulation of these enzymes remains relatively
uncharacterized. In a recent study we demonstrated that mutations to the
histone acetyltransferase (HAT) Gcn5 and to the histone deacetyltransferase
(HDAC) Hda1 each worsen growth phenotypes observed in an Anaphase
Promoting Complex (APC) subunit mutation apc5CA. Here we show that
deletion of both HDA1 and GCN5 in apc5CA cells cancel each other out,
resulting in the normal apc5CA phenotype. In otherwise WT cells, the gcn5‚
hda1‚ growth phenotype is unimpaired. Using Northerns, reverse transcrip-
tase PCR (rtPCR), chromatin immunoprecipitation (ChIP) and mutant phe-
notype suppression analysis, we observed that Hda1 and Gcn5 functionally
interact at similar promoters. The presence of Hda1 at promoters partially
occludes the binding of Gcn5 to these promoters. Occlusion of Gcn5
recruitment to these promoters required Hda1, Tup1 and Ssn6. We showed
using sequential ChIP that Hda1 and Tup1 form complexes at these promot-
ers, and in some cases, complex formation is reduced in a Gcn5-dependent
manner. We conclude that a complex pattern of interactions at promoters
regulates Gcn5 recruitment and activity. It is most likely the altered tran-
scriptional program established in these mutant cells that apc5CA cells are
particularly sensitive to.
Disclosure: A. Islam: has declared no conflicts of interest. All other authors
did not declare conflicts of interest.
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EPIDERMAL GROWTH FACTOR EXPRESSION IN NON
SMALL CELL CARCINOMA – PAVING THE WAY FOR
TARGETED THERAPY
R. Arcot1, D. Prathiba1, P.S. Shanmuga1, V.Thanasekaraan1 1Sri Ramachan-
dra Medical College and Research institute, Sri Ramachandra University,
Chennai116/INDIA
Introduction: Epidermal growth factor receptor (EGFR) is expressed in
40-80% of lung cancers which makes this an attractive target for molecular
interventions. Gefitinib, erlotinib and cetuximab are some of the agents
currently used to target EGFR.
Aim of the Study: To study and compare the EGFR expression in the sub
types of non small cell lung cancers (NSCLC).
Materials and Methods: This was a retrospective study done on the paraffin
sections of NSCLCs from the archives of the pathology department at
SRMC.38 cases of NSCLCs were included in the study. After initial
screening of the histopathology slides, immunohistochemical staining was
done for thyroid transcription factor1 (TTF1) and p63.The tumors were sub
typed based on the findings. EGFR immunostain was performed on all the
tumors and the results were analyzed.
Results: 69.6% of primary adenocarcinomas expressed EGFR. 80% of
squamous cell carcinomas expressed EGFR. 40% of secondary adenocarci-
nomas expressed EGFR.
Conclusions: Multiple studies support the fact that EGFR tyrosine kinase
inhibitors are effective in the treatment of adenocarcinomas of the lung.
Several randomized trials with small molecules that inhibit multiple tyrosine
kinases are underway. It may be worthwhile trying these molecules consid-
ering the high EGFR expression pattern noted in our patients.
Disclosure: All authors declared no conflict of interest.
DILEMMAS IN POORLY DIFFERENTIATED NON SMALL
CELL LUNG CANCERS – DOES IMMUNO HISTOCHEMIS-
TRY OFFER DIRECTION FOR DIAGNOSIS
R. Arcot1, D. Prathiba1, P.S. Shanmuga1, V. Thanasekaraan1 1Sri Ramachan-
dra Medical College and Research Institute, Sri Ramachandra University,
Chennai 116/INDIA
Introduction: Non small cell lung cancers (NSCLCs) predominantly include
adenocarcinomas and squamous cell carcinomas(SCC) ,which are difficult to iden-
tify when they are poorly differentiated. Precise sub typing of NSCLCs is important
as the treatment modalities and response to therapy vary. Immunostaining often
offers a direction to diagnosis.
Aim of the Study: To sub type the NSCLCs reported at our centre andnalyse
the relative proportions of these sub types.
Materials and Methods: The paraffin blocks of poorly differentiated NSCLCs
reported from the department of pathology, SRMC and RI were retrieved.
Sections from these blocks were subject to thyroid transcription factor 1(TTF 1)
immunostain. The TTF 1 negative blocks were stained with p 63(TTF 1
positivity in squamous cell carcinomas is rare) and the results were analyzed.
Results: Of the 38 samples, 23 were TTF1 positive(60.5%). Among the TTF1
negative samples, 10were p63 positive (26.3%). Five caseswere both TTF1 and p63
negative(13.2%). The samples that were only TTF1 positive were categorized as
primary adenocarcinomas. p63 positive but TTF1 negative sampleswere categorized
as squamous cell carcinomas. Secondary adenocarcinomas were negative for both.
Conclusions: A combination of TTF 1 and p63 immunostain can be a useful
tool in the diagnosis of poorly differentiated NSCLC.
Disclosure: All authors declared no conflict of interest.
AUSTRALIAN MESOTHELIOMA REGISTRY
L. Huang1, A. Burnham1, N. Grayson1, M.R. Sim2, B. Musk3, A. Anderson4, J.
Hill4, B. Armstrong5, N. van Zandwijk6 1Cancer Institute NSW, Eveleigh, New
South Wales/AUSTRALIA; 2Monash University Centre for Occupational and
Environmental Health, Melbourne, Victoria/AUSTRALIA; 3Western Australian
Mesothelioma Registry; 4Safe Work Australia, Braddon, Australia Capital
Territory/AUSTRALIA; 5Cancer Epidemiology and Health Services Research
Group, Sydney School of Public Health, The University of Sydney, Sydney, New
South Wales/AUSTRALIA; 6Asbestos Diseases Research Institute – Bernie
Banton Centre, Sydney, New South Wales/AUSTRALIA
Background: Australia was a producer and one of the biggest users of asbestos in
the world. It has a legacy of a large amount of asbestos in buildings and other
infrastructure and a high incidence of malignant mesothelioma. Due to the long
latency between exposure to asbestos and the onset of the disease, the incidence of
mesothelioma in Australia is probably yet to peak. While Australia has collected
national mesothelioma incidence data for many years, their ability to estimate
patterns of exposure in at risk populations has been limited. Overseas studies indicate
a change in the pattern of at risk occupations: such as an increase in the risk among
occupational groupswhowork on structures containing asbestosmaterials, including
carpenters, plumbers and electricians. Further, little is known about the risk among
workers in the asbestos removal industry and there is uncertainty about the level of
risk from domestic and environmental exposures to asbestos.
Aim: The AMR will monitor the national incidence of mesothelioma, recruit new
cases and collect detailed information from them on their occupational and environ-
mental asbestos exposure.
Methods: The AMR is funded by SafeWork Australia. The Cancer Institute NSW
is developing and will manage the AMR, including the coordination of mesotheli-
oma notifications from State and Territory Cancer Registries. Cases will be assessed
for their past asbestos exposure using tools developed by The Monash Centre for
Occupational and Environmental Health. Hunter Valley Research Foundation will
conduct computer assisted telephone interviews with the cases. Clinician’s involve-
ment will be important for the recruitment of cases for participation in the interviews.
An expert and representative management committee will provide oversight.
Implications: AMR information will aid federal and state governments to develop
policies to deal with the legacy of asbestos in buildings and other infrastructure. It
will provide a national resource for researchers to identify preventable risk factors to
assist in reducing mesothelioma in the future.
Disclosure: This abstract has also been submitted to COSA (Clinical Oncolog-
ical Society of Australia) Annual Scientific Meeting.
UPTAKE OF ADJUVANT CHEMOTHERAPY FOR NSCLC
INTO ROUTINE CLINICAL PRACTICE AT THE LIVER-
POOL AND MACARTHUR CANCER THERAPY CENTRES
M. Hui1, M. Boxer1, S. Vinod1, S.A. Della-Fiorentina1, P. Blinman1 1Liver-
pool and Macarthur Cancer Therapy Centres, Liverpool, New South Wales/
AUSTRALIA
Background: Adjuvant chemotherapy for NSCLC improves overall survival, but
its reported uptake into clinical practice is low. We sought to determine the uptake
of adjuvant chemotherapy at the Liverpool and Macarthur Cancer Therapy Centres.
Methods: Patients with resected stage I to III NSCLC who were discussed at the
lung cancer multidisciplinary meeting (MDT) between 1 December 2005 and 30
December 2009 were identified by retrospective review of the prospectively main-
tained MDT database. Outcomes included the proportion of patients who: were
recommended chemotherapy, received any chemotherapy and completed 4 cycles of
treatment.
Results: Of 322 patients with stage I to III NSCLC, 72 had curative-intent surgery.
28/72 (39%) patients were recommended adjuvant chemotherapy: their median age
was 66 years, half (14/28, 50%) were male and most had adenocarcinoma (14/28,
50%) or squamous cell carcinoma (10/28, 36%). Adjuvant chemotherapy was not
recommended due to stage I disease (18/44, 41%), neoadjuvant chemotherapy (7/44,
16%), and poor performance status (5/44, 11%). 9/28 (32%) patients did not receive
any chemotherapy due to patient refusal (4/28, 14%), poor performance status (3/28,
11%), and transfer to another centre (2/28, 7%). Chemotherapywasmost commonly
cisplatin/vinorelbine (13/19, 68%) or a carboplatin-doublet (4/19, 21%). 8/19 (42%)
patients completed 4 cycles of chemotherapy,with 10/19 (53%) patients received4
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cycles due to chemotherapy-related toxicity. 8/28 (29%) patients died from recurrent
NSCLC over the study period.
Conclusion: Adjuvant chemotherapy uptake and completion rates were low.
Further research to develop strategies to improve its use in routine clinical practice is
warranted.
Disclosure: All authors have declared no conflicts of interest.
LUNG CANCER: THE PATIENT’S JOURNEY
K. Mooney1, A. King1, C. Cameron1, B. McBride1, L. Knight1, J. Stiberc1
1Western Australia Cancer and Palliative Care Network, Perth, Western
Australia/AUSTRALIA
Introduction: A diagnosis of cancer can have a profound emotional impact on
patients and their significant others. Along with anxiety patients face a complex
journey with numerous investigations and intervention from a number of health
professionals. It is well documented that informed patients have more positive
outcomes. The role of the Cancer Nurse Coordinator in WA is to provide
information and education to patients diagnosed with cancer, provide a point of
contact and coordinate their care. The volume of cases is high and not all patients
can to be seen. There are nine tumour specific cancer streams in WA and
although staging investigations differ between them, the processes are journey
similar.
Method: A working party was convened to discuss how information could be
disseminated to a wider group than those referred thus providing patients with
knowledge about their cancer journey. This would also provide a point of contact
to assist with coordination of their care.
Aim: To provide an adaptable educational resource for the Cancer Nurse
Coordinators in Western Australia. To educate a wide audience regarding the
cancer journey of patients with lung cancer. To increase awareness of the role of
the Cancer Nurse Coordinator.
Results: A poster was developed to provide simple information outlining the
process from referral through staging, treatment and follow-up.
Disclosure: K. Mooney: has declared no conflict of interest. All other
authors have not declared conflicts of interest.
SITUATION AND PROBLEMSOF LUNGCANCER IN NEPAL
P. Pant1, B. Kayastha1, S. Kunwar1, P. Khatiwada1, R. Koju1, R. Gurung1,
B. Pokharel1, T.R.S. Bedi1 1Department of Internal Medicine, Kathmandu
University School of Medical Sciences, NEPAL
Aims of the Study: Lung cancer is the most frequently diagnosed cancer in
the world and accounts for more deaths than any other cancer. There is no
reliable information about the situation of lung cancer in Nepal. This study
has been done to assess the situation and problem associated with lung
cancer.
Methods: A prospective cross sectional study was conducted in a suspected
case of lung cancer from January 2009 - Jun, 2010. The lung cancer was
confirmed by histological and CT-Scan thorax of the patient. The associated
risk factors, demographic pattern, time of presentation and presenting symp-
toms of the lung cancer cases were studied.
Results: Out of 40 suspected cases, 32 (80%) were diagnosed as lung cancer.
Amongst these 32 cases, 18 (56.25%) were male and remaining 14 (43.75)
were female. As per the smoking habit (n 27) 84.4% were smokers and
remaining (n5) 15.6% were nonsmokers. The mean age of presentation was
65.3/-9.3 years. The most common presenting symptoms were cough and
breathlessness 27 (84.3%). Metastasis was present in 9 (50%) males and 2
(4.2%) females.
Conclusions: The most common risk factor of lung cancer is smoking. Lack
of awareness have been found to be most significant determinant. Commu-
nity health awareness program would diminish late presentation and burden
of disease. It is the tip of iceberg for this situation in Nepal. Therefore, a large
community based study is a must which would reveal the true nature of
burden in the country.
Disclosure: P. Pant: has declared no conflict of interest. All other authors
have not declared conflicts of interest.
DIAGNOSIS OF MALIGNANT MESOTHELIOMA USING
AN ELECTRONIC NOSE
E.A. Chapman1, P.S. Thomas1, D.H. Yates2 1Inflammation and Infection Re-
search Centre, School of Medical Sciences, University of New South Wales,
Kensington, New South Wales, AUSTRALIA; 2Department of Thoracic Medi-
cine, St Vincent’s Hospital, Sydney, New South Wales/AUSTRALIA.
Rationale: Malignant mesothelioma (MM) is a rare and aggressive tumour
which develops secondary to asbestos exposure, and is invariably fatal. MM
is commonly diagnosed late in the disease when treatment is palliative only.
Early detection of MM could allow intervention including multimodality
treatment, thereby improving survival. VOC sampling in exhaled breath
using an electronic nose creates a breath profile pattern that may characterise
MM. VOC pattern recognition in breath is a potential tool for non-invasive
diagnosis of MM.
Hypothesis: Breath patterns established by the electronic nose will be able
to discern patients with MM from healthy control subjects.
Methods: Fifty five subjects participated in a cross-sectional study. After 5
minutes of tidal breathing, a single expiratory vital capacity was collected
into a Tedlar bag and sampled by the electronic nose (Cyranose 320) within
5 minutes. Smellprints were analysed via canonical discriminant analysis on
principal component reduction. Repeatability was assessed by evaluating the
samples in duplicate.
Results: Fifteen patients with histologically diagnosed MM, and 40 non-
smoking control subjects were studied. Smellprints from 10 MM patients
were distinguished from 10 non-smoking control subjects with an accuracy
of 95%. Five patients with MM and 30 control subjects were introduced into
this training set, of which 89% were correctly identified. Duplicate samples
replicated these results.
Conclusion:Molecular profiling of biomarkers in exhaled air can distinguish
patients with MM from healthy smoking and non-smoking control subjects.
The electronic nose has promise as a tool for early diagnosis (and possibly
also screening) for MM.
Disclosure: E.A. Chapman: has declared no conflicts of interest. All other
authors have not declared conflicts of interest.
HOW LONG HAVE I GOT? ESTIMATING TYPICAL, BEST
AND WORST CASE SCENARIOS FOR PATIENTS START-
ING FIRST-LINE CHEMOTHERAPY FOR EXTENSIVE
SMALL CELL LUNG CANCER (ES SCLC): A SYSTEMATIC
REVIEW OF CONTEMPORARY RANDOMISED TRIALS
M. Bagia1, B. Houghton1, M. Boyer2, M. Millward3, M. Stockler1 1NHMRC
Clinical Trials Centre, Sydney, New South Wales/AUSTRALIA; 2Sydney
Cancer Centre, Camperdown, New South Wales/AUSTRALIA; 3University of
Western Australia, Crawley, Western Australia/AUSTRALIA
Backgound: Our goal was to provide estimates of typical, best and worst
case scenarios for survival for people starting first line chemotherapy for ES
SCLC.
Methods: We sought randomised trials of first line chemotherapy with 70
subjects per arm and Kaplan Meier survival curves published since 1990. We
extracted the median overall survival (mOS), median progression free
survival (mPFS), median post-progression free survival (mPPFS) and the
following percentiles (represented scenarios) from OS curves: 90th (worst
case), 75th (lower typical), 25th (upper typical), and 10th (best case). Predic-
tions of scenarios for each curve based on multiples of its median were
deemed accurate if within 0.75 to 1.33 times the actual value.
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Results: We analysed 24 trials including 7,175 subjects and 40 OS curves.
The median and interquatile range (IQR) for mPFS was 5.6 months (5.2 to
6.2), for mOS was 9.3 months (8.7 to 10.2), and for the ratio of mOS:mPFS
was 1.66 (1.48 to 1.96). The median (IQR) survival times in months for each
of the scenarios was: worst case 2.3 (1.2 to 3.4), lower typical 5.7 (4.9 to 6.5),
upper typical 15 (13 to 15), and best case 22 (19 to 24). The median (IQR)
of the ratios of median survival to each scenario was: worst case 0.23 (0.16
to 0.34), lower typical 0.62 (0.58 to 0.66), upper typical 1.54 (1.48 to 1.59),
and best case 2.30 (2.12 to 2.54). Predictions based on these median ratios
were accurate for the worst case in 38% of curves, the lower typical in 98%,
the upper typical in 100%, and the best case in 98%.
Conclusions: Scenarios for survival estimated from these trials were remark-
ably consistent. Multiples of the median gave more accurate predictions of
scenarios for the typical and best case than for the worst case.
Disclosure: M. Bagia: has declared no conflicts of interest. M.Boyer:
Sponsored to attend international meeting: Ingelheim; M. Millward: Advi-
sory Board Member: Roche, Eli-Lilly and Boehringer Ingelheim; Travel
support: Roche; M. Stockler: Our groups are currently doing trials partly
supported by AZ, Bionomics, Bayer, Roche, Pfizer, Novartis, MSD. I have
received honoraria for educational presentations from Novartis, Pfizer, MSD,
Roche. All other authors have not declared conflicts of interest.
MULTIMODALITY THERAPY IN MALIGNANT PLEURAL
MESOTHELIOMA (MPM): SINGLE INSTITUTIONAL
EXPERIENCE
Y. Kadota1, D.H. Yates1,2, P. Spratt3, S. Pendlebury4, K. Dhital3, E. Stone1,2
1Lung Cancer Multidisciplinary Team, Departments of 2Thoracic Medicine,
3Cardiothoracic Surgery, 4Radiation Oncology, St Vincent’s Hospital, Dar-
linghurst, New South Wales/AUSTRALIA
Introduction: Multimodality therapy, including chemotherapy, radical sur-
gery, post-operative radiotherapy (PORT) has an emerging role in malignant
pleural mesothelioma but no randomized trial data exist. The international
Mesothelioma and Radical Surgery (MARS) Pilot Study confirmed the
feasibility of randomisation to surgical and non-surgical arms (1) with
extrapleural pneumonectomy (EPP) as the surgical procedure with a planned
multicentre, international study, MARS2, in development. With the start of
MARS1 our institution has intensified its focus on the surgical treatment of
MPM as part of multimodality therapy, using the MARS protocol as a guide.
Aim: To assess the institutional experience of multimodality therapy for
MPM at St Vincent’s Hospital since the commencement of the MARS1 trial.
Methods: Retrospective review of MPM cases screened for multimodality
therapy at St Vincent’s Hospital since 2006.
Results: We identified 7 patients screened for multimodality therapy in the
last 4 years: 3 proceeded to EPP and 1 to pleural decortication (PD). The
remaining three patients were unsuitable for surgery due to co-morbidities or
extent of disease. All 4 surgical patients are alive, two patients at more than
2 years post-EPP, one patient 1 month post-EPP, and one patient 4 months
post-PD (May 2010).
Discussion: Our experience indicates it is feasible to treat patients with
MPM with multimodality therapy including radical surgery. The planned
MARS2 trial may provide randomized data on outcome benefit.
Conclusion: Carefully selected MPM patients may benefit from multimo-
dality therapy incorporating radical surgery.
Disclosure:
LUNG CANCER IS DETECTED EARLIER IN PATIENTS
WITH PRIOR MALIGNANCIES
D. Zarate1, S. Colquist1, K. Fong2, R. Bowman2 1Queensland Cancer Control
Analysis Team, Queensland Health, Brisbane, Queensland/AUSTRALIA, 2The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA
Background: A population-based study has shown that survival is better
in lung cancer patients with prior malignancies compared to patients
where lung cancer was the first or index cancer.
Methods: We analysed the distribution of clinical stage among patients
who were diagnosed with non-small cell lung cancer (NSCLC) between
2000 and 2007 and were managed by multidisciplinary teams participat-
ing in the Queensland Integrated Lung Cancer Outcome Project (QIL-
COP). Prior malignancies included all invasive cancers registered since
1982. The likelihood of presenting with stage I lung cancer was analysed
through multivariate logistic regression controlling for age and sex.
Results: 4,270 NSCLC patients presented to QILCOP in 2000-2007. Of
these, 636 had at least one other primary malignancy before lung cancer.
The proportion with stage I lung cancer was 34% in patients with prior
malignancy and 28% in those with no such history (p0.001). In
multivariate analysis, patients with prior malignancy were 21% more
likely (95% confidence interval [CI] 5%-38%) to be diagnosed with stage
I lung cancer. The trend is most pronounced in women with previous
breast cancer, more than half of whom presented with stage I NSCLC.
Conclusion: Current surveillance and screening for other cancers contribute
significantly to the early detection of lung cancer.
Disclosure: D. Zarate has declared no conflicts of interest. All other authors
have not declared conflicts of interest.
ESTIMATING SURVIVAL AFTER ADJUVANT CHEMO-
THERAPY FOR RESECTED NSCLC
G. McCaughan1, P. Blinman1,2, M. Boyer1, M. Stockler1,2 1Sydney Cancer
Centre, Camperdown, New South Wales/AUSTRALIA; 2NHMRC Clinical
Trials Centre, The University of Sydney, Sydney, New South Wales/
AUSTRALIA
Aim: To help doctors provide better estimates of survival for patients
considering adjuvant chemotherapy after surgery for NSCLC by summa-
rising and describing updated information from randomised trials of
platinum-based chemotherapy.
Methods: We searched MEDLINE and the Cochrane Central Register of
Controlled Trials for unconfounded randomised trials published in En-
glish with overall survival (OS) curves. We digitized the OS curves with
‘Un-Scan-It ®’ and recorded the OS rates at 1, 2, 5, 7 and 10 years and
the following percentiles (scenario): 90th (worst case), 75th (lower typi-
cal), median, 25th (upper typical) and 10th (best case).
Results: We analysed 34 OS curves from 17 trials (6806 patients). The
median patients per arm was 113 (range 33 to 935), median age was 61,
and median proportion male was 75%. With adjuvant chemotherapy the
median OS rate (interquartile range, IQR) at 1y was 91% (84-96), 2y was
79% (69-88), 5y was 62% (47-66), and 7y was 54% (41-57). Survival
rates at 2, 5, and 7y were well-estimated by raising the 1y survival rate
to the power of 2, 5 and 7 respectively (83%, 63%, and 52%). The median
OS time (IQR) for the worst case scenario was 13 months (8-21), for the
lower typical was 35 months (19-41), and for median was 55 months
(35-72). Few trials reported 25th or 10th percentiles, or survival rates
at 10y.
Conclusions: Simple percentages and their powers provide a useful
starting point for estimating and describing survival to patients consid-
ering adjuvant chemotherapy after surgery for NSCLC.
Disclosure: P. Blinman: declared no conflict of interest. M. Boyer: Sponsored
attendance at international meeting: Boehringer Ingelhiem. M. Stockler: Our
groups are currently doing trials partly supported by AZ, Bionomics, Bayer,
Roche, Pfizer, Novartis, MSD. I have received honoraria for educational pre-
sentations from Novartis, Pfizer, MSD, Roche. All other authors have not
declared conflicts of interest.
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ONCOLOGY INPATIENTS: INTERVENTIONS RECIEVED
IN THE LAST THIRY DAYS OF LIFE
L. Robinson1, G. Fairbrother1, M. Reid1 1Prince of Wales Hospital, Rand-
wick, New South Wales/AUSTRALIA
Subjective opinion among oncology nurses suggests that there is wide
variation in approach to treatment and palliation among endstage oncology
patients. A novel retrospective medical record audit was designed and
conducted to explore, quantify and describe the intervention and treatment
profile and trajectory of a consecutive sample of oncology patients (n30)
who died under Prince of Wales Hospital-based care, during their last 30
days of life. Auditing was conducted for each of the 30 days prior to patient
death. Details of all interventions, procedures and tests performed were
recorded. Data descriptive of cognitive state, functional state, represented by
ECOG status, and palliative care service input at the time of the intervention
was also recorded. Reasons and justifications for interventions, procedures
and tests (recorded in the medical record) were collected along with ratings
of the investigators’ opinions as to the appropriateness of each intervention
and its justification. Cross-sectionally analysed results of the audit will be
presented and discussed in the following poster.
Disclosure:
THE USE OF COMPUTER MODELING TO SUPPORT THE
USE OF FDG PET SCANS AS EARLY PREDICTORS OF
RESPONSE TO TREATMENT
A. Davidson1, A. Long1, R Francis2 1Medical Oncology,Royal Perth Hos-
pital, Wellington St Campus, Perth, Western Australia/AUSTRALIA; 2Sir
Charles Gairdner Hospital, Nedlands, Western Australia/AUSTRALIA;
3The University of Western Australia, Crawley, Western Australia/AUSTRA-
LIA
Aim: The role of PET scans in assessing response to therapy is gaining
popularity. Here we aim to highlight the benefit in terms of patient quality of
life years and cost benefit. Our main aim is to argue for the use of FDG PET
scans in a predictive manner in NSCLC, thereby minimising treatment and
quality of life costs in treating non-responders.
Method: Computer modelling techniques have been used to predict possible
outcomes of patients and project costs incurred with the use of FDG PET
scans after 1 cycle of treatment in patients with NSCLC. We estimate that
without PET scans, median survival is 9.8 months and with PET (90%
sensitivity and specificity), 12.9 months. We further estimate that costs can
be minimised in those patients who are non-responders and may even offer
a savings in some cases.
Outcome: These estimations support further work in the implementation of
standardised PET procedures across Australia. We are proposing further
work in this area to be done in ascertaining the necessary modifications to
PET centres and protocols to ensure comparison and collation of data for trial
and research purposes is possible. The use of predictive PET scanning may
have significant implications for the way we treat NSCLC in the future.
Disclosure: A. Davidson: has declared no conflict of interest. All other
authors have not declared conflict of interests.
EFFICACY OF PET STAGING FOR SMALL CELL LUNG
CANCER (SCLC): A SYSTEMATIC REVIEW AND COST
ANALYSIS IN THE AUSTRALIAN SETTING
J. Ruben, William Buckland Radiotherapy Centre, The Alfred Hospital,
Monash University, Victoria/AUSTRALIA
Aims: To establish from the published literature the efficacy of a PET-based
strategy for the staging of SCLC compared to conventional methods, the
potential impact on patient management and outcomes, and cost implications
for the Australian health system.
Methods: The Pubmed database was searched using terms “PET” or
“positron emission tomography” and “small cell lung cancer.” Reference
lists of identified studies were examined for additional pertinent papers. A
literature review identified 17 relevant studies containing data for 561
patients. The efficacy of PET-staging was analysed. The Medicare benefits
schedule was used to compare costs of the two strategies.
Results: Published data confirm that PET staging has a sensitivity approach-
ing 100% and specificity exceeding 90%. Data suggest that compared to
conventional staging, PET can alter management (including radiotherapy
portal changes) in 21% of patients, can result in the addition of life-
prolonging radiotherapy in 6%, and avert unnecessary radiotherapy with
associated toxicity in 9%. PET-based staging costs $1603 and conventional
staging $1610 per patient. An additional $540,354 may be saved annually
through avoidance of unnecessary radiotherapy.
Conclusions: PET-based staging appears superior to conventional staging
and can significantly alter patient management particularly with regard to the
inclusion, omission and portal design of radiotherapy. Initial costs of the two
strategies do not appear significantly different provided no doubling up of
investigations occurs. PET may ultimately reduce healthcare costs through
avoidance of inappropriate thoracic radiotherapy. The major advantages of
PET-staging may however lie in averting unnecessary toxicity and in the
appropriate addition of thoracic radiotherapy with potential survival gains.
Disclosure: The author declared no conflicts of interest.
PATIENTS TREATED WITH PLATINUM DOUBLET CHE-
MOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG
CANCER HAVE INFERIOR OUTCOMES IF PREVIOUSLY
TREATED WITH PLATINUM-BASED CHEMO-RADIATION
L. Mileshkin1, A. Paramanathan2, B. Solomon1, M. Collins1, 2, S. Kofoed1,
H. Francis1, M. Franco1 1Peter MacCallum Cancer Centre, Melbourne,
Victoria, 2The University of Melbourne, Melbourne, Victoria/AUSTRALIA
Background: Patients suitable for radical chemo-radiation for non-small lung
cancer (NSCLC) usually receive concurrent platinum-based chemotherapy. Many
patients relapse and first-line systemic treatment for non-mutation patients involves
chemotherapy with a platinum-based doublet.
Objective: A retrospective study was performed to determine if the outcomes in
these patients are worse when compared to patients without prior platinum exposure.
Methods: Eligible patients had de novo or relapsed metastatic NSCLC and
received treatment with carboplatin and gemcitabine. The primary outcome was
progression-free survival (PFS) and a multifactor analysis of prognostic factors was
performed.
Results: 104 patients treated 01/01/2002 – 31/12/2006 were analyzed (76
males; 38 females). Median age was 63 (range 35-81) with 63 (55.3%)
newly-diagnosed and 41 (36%) previously treated with platinum-based
chemo-radiation. The response rate was significantly lower for the group
previously exposed to platinum (10% vs 29%: p 0.001), as was the median
PFS (3.6 months vs 5.7 months; p  0.002), and median overall survival
(OS) (8.6 months vs 12.1 months; p  0.007). Only the treatment group was
a significant predictor (P0.032) of PFS by univariate analysis. For OS;
gender (male, p  0.04), histology (squamous cell: P0.04), ECOG status
(P0.002), and treatment group (P0.023) were significant adverse prog-
nostic factors. Multivariate analysis showed the ECOG score as the only
significant predictor of inferior OS.
Conclusion: Outcomes are worse in patients previously exposed to platinum
during chemo-radiation. This phenomenon should be further evaluated and alterna-
tive options such as non platinum-based doublets or targeted therapies should be
considered in this group.
Disclosure: All authors declared no conflicts of interest.
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INTERACTIONS BETWEEN HEDGEHOG AND RAS SIG-
NALING IN LUNG ADENOCARCINOMA
A. Szczepny1, S. Jayasekara1, N. Watkins1 1Centre for Cancer Research,
Monash Institute of Medical Research, Monash University, Clayton, Victo-
ria/AUSTRALIA
The Hedgehog (Hh) signaling pathway is essential for growth, patterning
and cell fate specification in development. Uncontrolled activation of Hh
signaling is implicated in the initiation and maintenance of the malignant
phenotype in a subset of adult carcinomas. Although the Hh pathway and
Ras signaling are both commonly activated in lung adenocarcinoma, the
functional significance of this potential interaction is not known. We have
developed a mouse model in which we can conditionally activate expres-
sion of the Hh pathway ligand Sonic Hh (Shh) and/or an oncogenic Ras
mutant (KRasG12D) in the airway epithelium of adult mice. Conditional
activation of both alleles in the airway epithelium is achieved through the
delivery of Cre recombinase using an inhaled adenoviral vector. Histo-
logical analysis of the lungs of KRasG12D animals following treatment
with adenovirus revealed the presence of multiple, small adenomas, in
keeping with the first description of this model. Preliminary results show
that in compound heterozygotes carrying both Shh and KRasG12D
conditional alleles develop larger, more aggressive tumours following
adenovirus treatment than their littermate controls. These data suggest
that expression of Shh can dramatically enhance the oncogenic potential
of cell-autonomous Ras signaling in the airway epithelium.
Disclosure:
GENETIC CHANGES IN TWOCELL LINES FROMHUMAN
MALIGNANT MESOTHELIOMA DURING LONG TERM
CULTURING
V. Relan1,2, K.R.Quinn1, C.M. Wright2, S.M. Savarimuthu2, M.E. Tan1, B.E.
Clarke1, E.E. Duhig1, I.A. Yang1,2, K.M. Fong1,2, R.V. Bowman1,2 1The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA; 2The Uni-
versity of Queensland, St Lucia, Queensland/AUSTRALIA
Aim: This study aimed to assess genetic changes during long term
culturing of two malignant mesothelioma (MM) cell lines (MM04 and
MM05).
Methods: Cell lines were established from fresh resected pleural tumour
tissues. Morphological changes between early passage (10) and late
passage (30) were analyzed using standard light microscopy and
Transmission Electron Microscopy (TEM). Growth characteristics were
determined from growth curves. Gene expression differences between
early and late passages were determined using Illumina’s HumanHT-
12_v3_BeadChip providing coverage of 20,000 genes. Cytogenetic
abnormalities were determined using Spectral karyotyping (SKY).
Results and Discussion: Spindle shaped cells were observed in both early
and late passages of both cell lines. TEM showed similar ultra-structural
features in early and late passages in MM05. Doubling times were also
similar between early (P9, 46hours) and late passage (P47, 43 hours). T
Test (P  0.001) on gene expression profile displayed down regulation of
24 genes (TMEM165, GREB1, HS566426, PRUNE, SLC10A7,
C4ORF38, TBN, USP53 etc) and up regulation of 18 genes (TMEM2,
CDKAL1, TIAM2, RPL23A, STAT3, UPK1B etc) in later passages.
Although morphology and growth of late passage cell lines are similar to
early passages, gene expression and cytogenetetic alterations were
observed possibly reflecting adaptation and seletion pressures in cell
culture.
Disclosure: Support for this study was provided by The Prince Charles
Hospital Foundation, Cure Cancer Australia, Dust Disease Board. All
authors have declared no further conflicts of interest.
SUPPORTING THE DIAGNOSIS AND TREATMENT OF
LUNG CANCER THROUGH DEVELOPING SPECIFIC TU-
MOUR STREAMS ON CANCER LEARNING
A. Munro, T. Shaw Workforce Education and Development Group, The
University of Sydney, Sydney, New South Wales/AUSTRALIA
Cancer Learning is an online knowledge portal developed by Cancer Aus-
tralia to provide access to resources and learning activities for all health care
professionals engaged in the delivery of cancer care. The site has over 1800
registered users and over 800 users a month spending more than 5 minutes
on the site. To enhance access to the resource, a number of tumour streams
are currently being developed to link directly to resources and activities
relevant to those tumours, in alignment with the Cancer Australia developed
and validated “Cancer Professional Development Framework”. In addition,
an innovative online learning program targeting diagnosis and appropriate
referral for General Practitioners around Lung Cancer is under development.
This poster will present the methodology behind the development of the
tumour stream in lung cancer and the development process for the program
targeting diagnosis and referral in lung cancer. The Lung Cancer Tumour
stream resources will be demonstrated during this conference at the Cancer
Australia exhibition booth for comment and review.
Disclosure:
ALGORITHMS FOR THE MANAGEMENT OF LUNG CAN-
CER IN NEW SOUTH WALES
M. Peters1, K. Armstrong2, S. Vinod3, L. Simonella2, R. Thomas4,
D. O’Connell2 1Concord Repatriation General Hospital, Concord, New
South Wales/AUSTRALIA; 2Cancer Council NSW, Woolloomooloo, New
South Wales/AUSTRALIA; 3Liverpool Hospital, Liverpool, New South
Wales/AUSTRALIA; 4Cancer Institute NSW, Eveleigh, New South Wales/
AUSTRALIA
Aims: To develop algorithms and a simple clinical tool for the management
of lung cancer patients.
Methods: Existing algorithms used in NSW cancer centres were identi-
fied and compared with the NHMRC clinical practice guidelines. The
most comprehensive algorithms and the management recommendations in
the guidelines were circulated to members of the NSW Oncology Group-
Lung comprising lung cancer specialists, lung cancer nurses, consumers
and allied health workers. Comments and management preferences were
received and collated. A workshop was conducted with members of the
NSW Oncology Group-Lung to draft the algorithms and the final versions
were circulated for comment. The project was funded by the Cancer
Institute NSW.
Results: In late 2009, four sets of algorithms for the management of lung
cancer were used in NSW. The most comprehensive of these were
compared with the NHMRC clinical practice guidelines and formed the
basis for the final algorithms. Preferred management of non-small cell
(NSCLC) and small cell (SCLC) lung cancer was agreed upon according
to stage of disease and patient’s performance status and symptoms.
Management recommendations were summarised in tabular form. Flow-
charts were developed for ease of use in the clinical setting.
Conclusions: Consensus driven evidence based algorithms for the manage-
ment of lung cancer in NSW have been developed. It is hoped that these will
raise awareness of the treatments available for lung cancer and decrease the
variation in management and outcomes.
Disclosure: The Cancer Council NSW received funding from the Cancer
Institute NSW to conduct the project. The clinicians, lung cancer nurses,
consumers and allied health workers who contributed to the development of
the guidelines did so on a voluntary basis without remuneration.
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MAKING SENSE OF THE T3 POTPOURRI: AN EVAULA-
TION OF THE SEVENTH REVISION OF THE TNM CLAS-
SIFICATION
A. Salipas1, M. Daniels2, Z. Wainer1, M. Conron1, P. Russell1, G. Wright1
1St Vincent’s Hospital, Fitzroy, Victoria/AUSTRALIA; 2Alfred Health, Mel-
bourne, Victoria/AUSTRALIA
Background: The seventh edition of the TNM Classification of Malignant
Tumors for lung cancer altered the T(umour) descriptors based on the work
of the International Association for the Study of Lung Cancer. An interna-
tional cohort of 1941 patients diagnosed between 1990 and 2000 provided
the data for this revision which has increased the heterogeneity of T3; a
minority from Australia. It is yet to be prospectively validated. This project
evaluated the prognostic value of new T3 descriptors in an Australian
surgical practice.
Methods: Patients who underwent surgical resection after January 2000 of
pathologically T3 tumours, based on the seventh revision TNM criteria, were
identified from a prospective surgical database. Survival of patients in the
five T3 descriptor groups was compared using Kaplan-Meier survival anal-
ysis, log rank test and Cox regression.
Results: One hundred and five patients were identified. T3 descriptor groups
demonstrated significantly different actuarial survivals (P0.028); this effect
persisted despite controlling for stage and nodal status. Patients with T3
disease on the basis of invasion of adjacent structures had significantly worse
survival than the whole cohort (P0.016). Five year actuarial survivals (with
95% confidence intervals) were: size70 mm, 42.7% (19.9-65.5); additional
tumour nodules, 37.7% (7.5-68.3); invasion of defined adjacent structures,
28.3% (7.5-49.1); associated obstruction, 40% (0-83.8%) at 51 months;
tumour 2 cm from the carina, 34.1% (4.1-64.1).
Conclusion: T3 can be separated into subgroups with different survivals;
those with invasion of adjacent structures demonstrated significantly poorer
prognosis in this cohort. Further prospective validation is needed in this
heterogeneous group. Words: 248.
Disclosures: Z. Wainer: Recipient of the Royal Australasian College of
Surgeons 2010 Raelene Boyle Scholarship. All other authors have declared
no further conflicts of interest.
ARRAY-COMPARATIVE GENOMIC HYBRIDIZATION
IDENTIFIES NOVEL COPY NUMBER ALTERATIONS IN
RECURRENT SQUAMOUS CELL LUNG CANCER
K.B. Sriram1,2, J.E. Larsen2, S.M. Savarimuthu Francis1,2, C.M. Wright1,
K. Mattar1, M. Windsor1, B.E. Clarke1, E.E. Duhig1, N.K. Hayward3,
R.V.Bowman1,2, I.A. Yang1,2, K.M. Fong1,2 1The Prince Charles Hospital,
Chermside, Queensland/AUSTRALIA; 2The University of Queensland, St
Lucia, Queensland/AUSTRALIA; 3Queensland Institute of Medical Re-
search, Herston, Queensland/AUSTRALIA
Recurrence of the primary cancer after ‘curative’ surgical resection occurs in
30-50% of early stage NSCLC patients. Genomic factors regulating recur-
rence, particularly squamous cell cancer (SCC) are poorly understood.
Consistent and frequent copy number alterations (CNA) are likely to harbor
regulatory cancer genes. We hypothesize that whole genome array compar-
ative genomic hybridization (aCGH) will identify novel CNAs in recurrent
SCCs.
Methods: DNA from frozen tumour tissues was obtained from 58 patients
with stage I-III primary SCC who underwent surgical resection;. 25 patients
had recurrence (3-18 months) and 33 patients were recurrence free at 36
months. Two patients received neo-adjuvant radiotherapy, 1 patient received
adjuvant chemotherapy and another received adjuvant radiotherapy. aCGH
was performed using Agilent CGH 44B microarrays. CNAs were identified
using the Genomic Identification of Significant Targets in Cancer (GISTIC)
algorithm developed at the Broad Institute. Fisher’s exact test was used to
assess the relationship between CNAs and recurrence phenotype.
Results: Regions of amplification occurred in 3q26.33, 8p11.23 and 19q13.2
while deletions occurred in 9p12.3, 3p12.1, 8p23.1, 5q13.3, 4q28.2,
10q23.31, 13q22.1, 1p21.1, 17p12, 16q23.3, 4p15.31 and 18q22.3. Deletions
in 18q22.3 occurred more frequently in recurrence compared to non-recur-
rence samples (52% vs. 24%, P0.001). This region contains 22 RefSeq
genes, among which SOCS6, ZNF236, CD226, GALR1 and CNDP1 have
been reported to function as tumour suppressor genes (TSGs).
Conclusion: We have identified several CNAs in SCC and found 18q22.3
deletions occur more frequently in recurrent SCC. These findings will need
to be validated using independent datasets and methodology.
Disclosure: This study was supported by NHMRC Medical Postgraduate
Scholarship 569762.
RNAi-BASED SCREENINGOF POTENTIAL CHEMOSENSI-
TISING TARGETS FOR MALIGNANT MESOTHELIOMA
L. Schedlich1, M. Kirschner1, V. Relan2, K. Fong2,3, R. Bowman2,3, N. van
Zandwijk1, G. Reid1 1The Asbestos Diseases Research Institute - Bernie Banton
Centre, University of Sydney, Sydney, New South Wales/AUSTRALIA; 2Thoracic
Research Laboratory, The Prince Charles Hospital, Chermside, Queensland/
AUSTRALIA; 3The University of Queensland, St Lucia, Queensland/
AUSTRALIA
Malignant mesothelioma (MM) is an asbestos-related tumour involving the
membrane lining of serosal cavities. Australia suffers the highest incidence
of this almost invariably fatal disease, a legacy of the mining of asbestos and
its widespread use in the construction industry. Despite modest improve-
ments in treatment, the prognosis remains poor, in part because of the genetic
heterogeneity of MM tumours and their intrinsic resistance to chemotherapy.
Therefore, the aim of this study is to identify novel growth inhibitory and
chemosensitising targets using a rational RNAi-based screening approach.
Gene targets (100 in total) were selected on the basis of known overexpres-
sion in MM cells and tumours and known involvement in abnormal tumour
cell metabolism or drug resistance in MM or other tumour types. The
primary readout for the screening process was inhibition of cell growth
determined by quantifying total DNA using a SYBR Green based assay. In
initial screening experiments, we found that silencing the expression of 28 of
the target genes caused greater than 50% inhibition of primary MM cell
growth. These included genes involved in DNA repair and replication, cell
cycle progression and/or apoptosis. Future experiments will screen and
validate potential chemosensitising targets, using synthetic lethal screens
combining gene knockdown with chemotherapeutic agents used to treat MM.
This work has the potential to identify genes that are targets in their own
right, or can enhance the efficacy of currently used chemotherapeutic agents.
Disclosure: Funding: DDB Research Grant.
MITOCHONDRIAL DNA MUTATIONS IN THE EXHALED
BREATH CONDENSATE OF PATIENTS WITH LUNG
CANCER
S. Ai1, Z. Cheng1, J. Hunt1, C. Lewis3, K. Hsu1, C. Herbert1, P.S. Thomas1,2
1Inflammation and Infection Research Centre, School of Medical Sciences,
University of New South Wales, Sydney, New South Wales/AUSTRALIA;
2Department of Respiratory Medicine; 3Department of Oncology, Prince of
Wales Hospital, Randwick, New South Wales/AUSTRALIA
Aim: Non-invasively collected biofluids present a potentially valuable sam-
ple for detecting genomic alterations implicated in tumourigenesis. Due to its
high copy number and greater mutability, mitochondrial DNA is a sensitive
target of oxidative stress, which is implicated in the development of various
cancers. Consequently, the detection and classification of mitochondrial
DNA changes in exhaled breath condensate could be a novel and non-
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invasive biomarker which may expand our understanding of the pathogenesis
of lung cancer.
Methods: 15 newly diagnosed patients with non-small cell lung cancer (LC)
were recruited as was a control group (C) of 15 subjects without lung cancer.
Each subject breathed tidally for 10-15 minutes into a cooled collection
system, yielding 1-2mL of exhaled breath condensate. Genomic DNA was
extracted from the breath condensate, PCR performed to amplify the D-loop
region of the mitochondrial DNA, and direct sequencing performed on the
PCR product. The sequence obtained was compared to the reference Cam-
bridge sequence to identify polymorphisms and mutations.
Results: Sufficient genomic DNA was extracted from all (n30) of the
exhaled breath condensate samples for PCR amplification. Furthermore,
some alterations occurred more frequently in the LC group than the control
group, such as insertion/deletion mutations in the D310 mononucleotide
repeat sequence (P0.05).
Conclusions: Mitochondrial DNA is detectable in the exhaled breath con-
densate of patients with lung cancer and healthy controls. Mitochondrial
DNA mutations may represent a potential biomarker of lung cancer.
Disclosure: All authors have declared no conflicts of interest.
METHYLATION PORTRAITS OF DNA REPAIR GENES IN
NON-SMALL CELL LUNG CARCINOMA REVEALS BOU-
TIQUE TARGETS FOR THERAPY
H. Do1,2, T. John3, P.L. Mitchell3, A. Dobrovic1,2 1The University of
Melbourne, Melbourne, Victoria/AUSTRALIA; 2Peter MacCallum Cancer
Centre, Melbourne, Victoria/AUSTRALIA; 3Ludwig Institute for Medical
Research, Melbourne, Victoria/AUSTRALIA
Aims: Promoter hypermethylation is a common epigenetic mechanism for
gene silencing in non-small cell lung cancer (NSCLC). Methylated DNA
repair genes offer potential therapeutic targets by either targeting the specific
repair deficiency or by synthetic lethal approaches. Identifying methylated
genes is best done by a methodology that is unlikely to give false positives
or negatives. We used methylation sensitive HRM as it can give a methyl-
ation portrait for each assayed region and is less prone to false positives than
other commonly used methodologies.
Methods: 56 N1 NSCLC patients were analysed byMS-HRM for the methylation
of a panel of DNA repair genes that were previously identified as being methylated
in cancer:MGMT,XPC,RAD23B,BRCA1,MLH1 andERCC1. SelectedMS-HRM
positive samples were bisulfite sequenced.
Results: We were able to confirm previous reports of MGMT methylation. We
were unable to replicate previous reports of a high incidence of XPC, BRCA1 and
MLH1methylation inNSCLC aswe saw nomethylation for any of these genes. One
tumour showed RAD23B methylation and one tumour showed significant ERCC1
methylation. These are the first reports of the methylation of RAD23B and ERCC1
in NSCLC.
Conclusions: Methodology is critical in accurately assessing methylation status.
Except for theMGMT gene, detectable methylation of the DNA repair genes in this
study is rare. Nevertheless, these rare exceptions offer intriguing boutique targets for
therapy.
Disclosure: H. Do and T. John: declared no conflict of interest. P.L. Mitchell:
Advisory groups and/or speaker honoraria 2009-2010: Roche, Astra Zeneca, Eli-
Lilly, Boehringer Ingelheim, Specialist Therapeutics; A. Dobrovic: Advisory board:
Merck Kras, Research Funding: Pfizer, Sponsored attendance at national conference
(accommodation): Novartis, Roche.
THE HDA l TUP l SSNP COMPLEX BLOCKS GCN5 PRO-
MOTER RECRUITMENT
A. Islam, E.L. Turner, and Troy A. A. Harkness Department of Anatomy and
Cell Biology, University of Saskatchewan, Saskatoon, SK, S7N 5E5, CANADA
Histone modifications, such as histone acetylation, play major roles in gene expres-
sion. In yeast, many proteins have been characterized that add and remove acetyl
groups from a broad spectrum of histone lysine residues. Histone acetylation is most
often associated with gene transcription, whereas removal of acetyl groups usually
reflects gene silencing. Furthermore, some histone modifying enzymes have global
functions while others act at specific genes. Nonetheless, the regulation of these
enzymes remains relatively uncharacterized. In a recent study we demonstrated that
mutations to the histone acetyltransferase (HAT) Gcn5 and to the histone deacetyl-
transferase (HDAC)Hda1 eachworsen growth phenotypes observed in anAnaphase
Promoting Complex (APC) subunit mutation apc5CA. Here we show that deletion of
bothHDA1 andGCN5 in apc5CA cells cancel each other out, resulting in the normal
apc5CA phenotype. In otherwise WT cells, the gcn5‚ hda1‚ growth phenotype is
unimpaired. Using Northerns, reverse transcriptase PCR (rtPCR), chromatin immu-
noprecipitation (ChIP) andmutant phenotype suppression analysis, we observed that
Hda1 and Gcn5 functionally interact at similar promoters. The presence of Hda1 at
promoters partially occludes the binding of Gcn5 to these promoters. Occlusion of
Gcn5 recruitment to these promoters required Hda1, Tup1 and Ssn6. We showed
using sequential ChIP that Hda1 and Tup1 form complexes at these promoters, and
in some cases, complex formation is reduced in a Gcn5-dependent manner. We
conclude that a complex pattern of interactions at promoters regulates Gcn5 recruit-
ment and activity. It is most likely the altered transcriptional program established in
these mutant cells that apc5CA cells are particularly sensitive to.
Disclosure: A. Islam: has declared no conflict of interest. All other authors
have not declared conflict of interest.
LUNG CANCER MULTIDISCIPLINARY TEAM MEET-
INGS: A SURVEY OF PARTICIPANTS AT A NATIONAL
CONFERENCE
C. Broderick4, S. Bydder1,2, A. Hasani3, J. Semmens5 Departments of
1Radiation Oncology, 3Medical Oncology, Sir Charles Gairdner Hospital,
Nedlands, Western Australia/AUSTRALIA; 2School of Population Health,
University of Western Australia, Crawley, Western Australia/AUSTRALIA;
4WA Cancer and Palliative Care Network, Perth, Western Australia/AUS-
TRALIA; 5Centre for Population Health Research, Curtin Health Innovation
Research Institute, Curtin University, Perth, Western Australia/AUSTRALIA
Aim: The aim of the study was to examine the operation of lung cancer
multidisciplinary meetings (MDMs) across Australia.
Method: Attendees of the 2008 Australian Lung Cancer Conference who
participated at least weekly lung cancer MDMs were surveyed. The survey
addressed attendees perceptions regarding the aims of MDMs, and for their
own institutional MDMs, the importance and need for improvement for each
of: (1) the attendance of nine disciplines, and (2) 15 aspects related to MDM
function derived from the literature. The survey also asked participants if
MDMs met their needs?
Results: There was general agreement on the aims of the meetings, the
importance of various groups’ attendance and each of the examined aspects
of MDM. 20% of respondents indicated a need for moderate to substantial
improvement for either; attendance by one of the following disciplines,
palliative care physicians, pathologists or cardiothoracic surgeons or for 10
out of the 15 aspects of MDM (computerized database 55%, dissent docu-
mented 48% and letter to general practitioner 45%). The MDMmeetings met
the needs of 79% of respondents.
Conclusions: General agreement on the aims of meetings, the importance of
various groups’ attendance at MDMs and each of the examined aspects of
MDMs, however, moderate to substantial improvements were thought to be
required by many respondents. The performance of individual institutions’
MDMs and the resources they have available to achieve their aims should be
assessed and periodically reviewed. The survey applied here may provide a
framework for MDM members to do this.
Disclosure:
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RADIATION DOSE DURING LUNG CANCER SCREENING
WITH LOW-DOSE COMPUTED TOMOGRAPHY: HOW
LOW IS LOW DOSE?
H. Marshall1, I. Smith4, B.J. Keir5, R.V. Bowman1, J. Crossin2, M. Fuentes2,
R. Slaughter2, L. Passmore1, E. McCaul1, D. Courtenay1, M. Webb2,
M. Windsor3, I.A. Yang1, P.V. Zimmerman1, R. Hayes2, S. Redmond2, K.M.
Fong1 1Department of Thoracic Medicine; 2Department of Medical Imaging;
3Department of Thoracic Surgery, The Prince Charles Hospital, Chermside,
Queensland; 4St Andrew’s Medical Institute, St Andrew’s War Memorial
Hospital, Spring Hill, Queensland/AUSTRALIA; 5Biomedical Technology
Services, The Royal Brisbane and Women’s Hospital, Herston, Queensland/
AUSTRALIA
Background: Lung cancer screening using CT is under investigation.
Medical radiation has the potential to cause cancer. Typical Effective dose
(E) using conventional CT chest is 5-8 mSv. Low-dose protocols are used in
lung cancer screening research. We report doses for scans obtained during
the Queensland Lung Cancer Screening Study.
Methods: Volunteers (age 60-74; 30 pack-year smoking) received a
non-contrast, low-dose whole-chest baseline scan. Nodules were monitored
with interval scans (low-dose, limited to nodule whenever possible). We used
a 64-detector helical scanner (Brilliance, Philips) at 120 kVp, reconstructed
at 0.9-mm slice width. Scan parameters (milliamp.seconds, mAs; Dose
Length Product, DLP; CT Dose Index, CTDI) were recorded. E was calcu-
lated (DLP  0.017).
Results: No scan was substandard quality. 160 men and 82 women had 242
baseline scans. 72 men and 34 women had interval scans (mean 185 days
from baseline scan). Radiation dose parameters (median, range):
Baseline scan: Men mAs 40 (25-60), CTDI 2.4 (1.2-3.5) DLP 93.9 (51.4-
151.7) E 1.60 (0.90-2.60); Women mAs 30 (25-67), CTDI 1.6 (1.5-3.9), DLP
65.5 (50.9-148.2) E 1.10 (0.90-2.50).
Interval scan: Men mAs 40 (25-367), CTDI 2.4, (1.5-14.7), DLP 57.75,
(22.2-307.0), E 0.98 (0.38-5.22); Women mAs 30 (25-224), CTDI 1.8
(1.5-13.1), DLP 59.9 (22.2-187.9), E 1.02 (0.38-3.19). Overall median E for
baseline and interval scans was 1.5 and 1.0 mSv respectively.
Conclusions: High quality low-dose CT scans are achievable. Monitoring
nodules for growth using a limited, low-dose approach significantly reduces
radiation exposure.
Disclosure: Supported by a Queensland Smart State Grant, NCARD and
NHMRC.
THE LUNG CANCER JOURNEY – A REVIEW FROM THE
PRINCE CHARLES HOSPITAL PULMONARY MALIG-
NANCY UNIT
L.J. Rassam1, N.P. Sinhal1, H. Mackenzie1, R.V. Bowman1, K.M. Fong1,
I.A. Yang1, 3, G. Pratt2, M. Fay2, B. Hughes1, M.F. Windsor1, K. Matar1 1The
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA; 2Queens-
land Radium Institute, Herston, Queensland/AUSTRALIA; 3The University of
Queensland, St Lucia, Queensland/AUSTRALIA
Introduction: The aim of this study is to identify factors affecting intervals
between critical nodes in the referral and medical assessment pathways up to
the point of initial treatment for patients with suspected lung cancer.
Method: A review of the Pulmonary Malignancy Unit database and medical
records for patients referred between January2010 and June 2010 with
suspicion of lung cancer was conducted.
Results: A total of 138 patients were referred during this interval. Journey
intervals were ascertained for 30 of these patients referred in January/
February and whose records were readily retrieved. The average time from
referral to diagnosis was 30  23.45 days (range 3-64 days). The time
between first medical assessment at the hospital to clinicopathologic diag-
nosis was 16.5 17.3 days. Patients whose diagnostic interval exceeded one
SD above the mean had explanatory factors including need for invasive
diagnostic procedures other than bronchoscopy or fine needle aspiration, and
significant co-morbidities or recent acute illness where an opinion from other
specialists was required. The average time from diagnosis to the commence-
ment of treatment was 36  33 days. Factors shown to influence the
treatment interval were mainly the need for radiotherapy and further staging
imaging e.g. PET scans, both of which are conducted at another health
facility.
Conclusion: On a limited sample from a pulmonary malignancy referral unit
at a major public hospital to date, reasons for longer intervals between
referral and diagnosis, and diagnosis and first treatment, were readily
identifiable.
Disclosure: All authors declared conflict of Interest.
MERKEL CELL POLYOMA VIRUS IN LUNG CANCER
V. Relan1,2, R.V. Bowman1,2, I.A. Yang1,2, K.M. Fong1 1The Prince Charles
Hospital, Chermside, Queensland/AUSTRALIA; 2The University of Queens-
land, St Lucia, Queensland/AUSTRALIA
Polyoma Virus refers to viruses, which have ability to produce multiple
(poly) tumours (oms). They are potentially oncogenic (tumour-causing);
they often persist as latent infections in a host without causing disease,
but may produce tumours in a host of a different species, or a host with
an ineffective immune system. WU (Washington University) virus and KI
(Karolinska Institute) virus are novel virus identified in respiratory
secretions in acute respiratory infections. MC (Merkel cell polyoma
virus) virus was discovered in 2008 in Merkel cell carcinoma (MCC).
MCC is a rare aggressive small cell neuroendocrine carcinoma primarily
derived from the skin, morphologically indistinguishable from small cell
lung carcinoma (SCLC). The study aimed to detect a relationship between
lung cancer and MC polyoma virus.
Methods: High molecular weight genomic DNA from the tissue was
isolated using standard salt extraction method. All DNAs were quantified.
Diagnostic stringency was maintained for this study. We screened 231
lung cancer subjects for Merkel cell polyoma virus using real time PCR.
Results: One out of 231 lung cancer subjects (1/231) found to be positive for
Merkel cell polyoma virus. Sequencing is underway.
Disclosure: Supported by The Prince Charles Hospital Foundation.
PROLONGED PROGRESSION – FREE SURVIVAL OF
OVER 40 MONTHS WITH ERLOTINIB IN A MAORI
FEMALE WITH NSCLC
H.S. Winter1, L. Batten2, C. Hardie1, G. Forgeson1 1Regional Cancer
Treatment service, Palmerston North Hospital, NEW ZEALAND; 2School of
Public Health, Massey University, Palmerston North/NEW ZEALAND
Lung cancer is the leading cause of cancer death in New Zealand.
Compared with non-Maori the hazard ratio for Maori female lung cancer
mortality is 4.0. The median survival following active therapy for stage
IV NSCLC is 8 months. This case represents a prolonged progression free
survival of over 40 months in a 68 year old Maori woman; a mild smoker
with histological adenocarcinoma. Diagnosed in November 2005, she
commenced four cycles of a platinum doublet. Having progressed,
Erlotinib commenced Sept 2006. CT assessment confirmed partial re-
sponse. She had significant rash throughout treatment. Therapy was
stopped March 2010 when she was admitted with worsening renal failure.
EGFR status was unable to be determined. This case highlights the
impressive survival of a TKI responder and supports the need for further
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research with ethnic groups in New Zealand. It is well documented that
specific ethnic groups have higher EGFR mutation status and increased
response rates to targeted therapies. This is pertinent as TKIs having
recently been introduced in New Zealand for second line therapy and
currently there is no EGFR testing in New Zealand. However, funding has
now been secured for an EGFR testing feasibility study in Maori patients
with NSCLC.
Reference
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